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CHAPTER I   
 
INTRODUCTION 
 
 
Methamphetamine (Meth) is a potent, widely-used stimulant and its use is 
met with high rates of relapse without an effective, FDA-approved 
pharmacotherapy (Brecht et al. 2000;Elkashef et al. 2008;United Nations Office 
on Drugs and crime 2009).  One factor that contributes to craving and relapse is 
exposure to environmental or contextual cues associated with previous Meth use 
(Hartz et al. 2001;O'Brien et al. 1992;Tolliver et al. 2010).  With repeated Meth 
use, the rewarding properties of the drug become associated with the 
environmental cues in which they are taken.  These contextual cues then become 
extremely salient to the Meth user.  This associative learning can be studied in 
the laboratory with humans and rodents using conditioned place preference 
(CPP), which employs classical conditioning to measure the rewarding properties 
of abused drugs (Childs and deWit H. 2009;Tzschentke 1998;Tzschentke 2007).  
Another way to assess Meth-induced brain adaptations following repeated Meth 
use is the enhanced motor activity (termed motor sensitization) that is elicited 
with subsequent drug injections.  This behavior endures for long periods of time 
after cessation from drug administration (McDaid et al. 2007).  It is hypothesized 
that the neuronal adaptations associated with this motor sensitization model 
aspects of the brain changes that reflect drug craving (Robinson and Berridge 
1993).   
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The current dissertation project utilizes Meth-induced CPP and motor 
sensitization to elucidate the neuronal underpinnings of addiction. 
Repeated drug stimuli are hypothesized to “hijack” normal neuronal mechanisms 
of learning and memory processes, resulting in abnormal, addictive behaviors 
(Kelley 2004).  The glutamate transmitter system is an important player for 
learning and memory processing as well as stimulant addiction.  Glutamate 
activates both ionotropic and metabotropic receptors.  Ionotropic receptors 
rapidly increase neuronal spiking, whereas metabotropic glutamatergic receptors 
(mGluRs) modulate and fine tune neuronal excitability.  mGluRs are divided into 
three groups based on pharmacology, sequence homology and associated 
signaling mechanisms (Conn and Pin 1997).  The group I subtype 5 receptor 
(mGluR5) is highly expressed in brain regions important for stimulant reward 
(Lu et al. 1999;Testa et al. 1995).  The mGluR5 is important for several phases of 
behaviors induced by amphetamines, including Meth, such as acquisition 
(Miyatake et al. 2005;Osborne and Olive 2008) and expression (Gass et al. 
2009;Herzig et al. 2005) of associative learning.  However, the role of these 
receptors in the maintenance of Meth-induced reward remains unknown.  This is 
an important clinical issue, as treatment strategies need to be effective following 
the molecular adaptations and behavioral changes have occurred.  Withdrawal 
time after the last drug administration influences drug-induced behaviors as well 
as underlying molecular adaptations.  For example, rodent models of addiction 
including opiate-induced conditioned place preference and stimulant- induced 
self-administration demonstrate that cue-induced drug seeking can “incubate” 
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over a time frame of two weeks to three months after the cessation of drug 
treatment (Li et al. 2008;Lu et al. 2004a;Lu et al. 2004b).  Furthermore, the 
glutamate receptor systems, including the mGluR5, also are up-regulated in 
reward-related brain regions following extended (but not short term) withdrawal 
from cocaine administration (Ghasemzadeh et al. 2009a;Ghasemzadeh et al. 
2009b).  Therefore, we sought to determine if the mGluR5 was important for 
long-term maintenance of Meth-induced associative learning.        
Substance use disorders occur with a higher frequency in the 
schizophrenia patient population than in the general United States population 
(Compton et al. 2005).   Moreover, the use of amphetamines exacerbates 
psychosis in schizophrenia patients (Angrist et al. 1980;Janowsky and Davis 
1976).  Developmental rodent models of schizophrenia (e.g., isolation rearing and 
neonatal ventral hippocampal lesions) demonstrate an enhanced sensitivity to 
stimulant-induced motor sensitization (Chambers and Taylor 2004;Dai et al. 
2004) and self-administration (Brady et al. 2008;Chambers and Self 2002), but a 
deficit in stimulant-induced associative learning that are likely due to cognitive 
deficits incurred with this disorder (Le et al. 2002;Wongwitdecha and Marsden 
1995).  These observations likely reflect the fact that the neurocircuitry 
implicated in schizophrenia overlaps with that targeted by stimulants (Pierce and 
Kalivas 1997;Swerdlow et al. 2001).  Therefore, we hypothesized that deficits 
associated with schizophrenia, such as sensorimotor gating, would negatively 
correlate with that of Meth-induced associative learning (i.e., greater deficits in 
sensorimotor gating would correlate with less preference for the context 
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associated with the rewarding properties of Meth).  Thus, we used both 
pharmacological and developmental (i.e. isolation rearing) models of 
schizophrenia in conjunction with Meth-induced CPP to model the co-morbid 
condition of the schizophrenia individual with stimulant use disorder.  We 
further sought to determine the effects of augmenting mGluR5 signaling on the 
different phases of Meth-induced CPP and motor sensitization in isolation reared 
rats (i.e., development and expression). 
The overall goal of this dissertation is to expand our knowledge of the 
role of the mGluR5 system in Meth addiction and in the co-morbidity of 
schizophrenia and Meth substance use disorder.  This project is subdivided into 
two major parts with individual, yet related hypotheses.  Part 1 was designed to 
determine if the mGluR5 is necessary for the maintenance of Meth-induced 
associative learning, and if this was associated with an up-regulation of these 
receptors in reward-related brain regions.  Part 2 was designed to ascertain if 
deficits associated with schizophrenia are directly correlated with Meth-induced 
associative learning and if mGluR5 receptor activation enhances Meth-induced 
CPP in a developmental rodent model of schizophrenia. 
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CHAPTER II 
LITERATURE REVIEW 
 
Methamphetamine substance use disorder and rodent behavioral 
models 
Methamphetamine (Meth) was given the title “America’s most dangerous 
drug” by Newsweek Magazine in August 2005 by David J. Jefferson.  In the same 
year, it was estimated that Meth use resulted in 900 deaths and the loss of 
44,000 quality of life years (Nicosia et al. 2009).  The estimated total cost to the 
United States in 2005, including factors such as drug treatment, criminal justice, 
and child endangerment reached $23.5 billion (Nicosia et al. 2009).  Though 
there has been a decline in prevalence of Meth use since 2005, Meth remains the 
third most widely abused drug in the world (United Nations Office on Drugs and 
crime 2009).  Meth use is a problem of grave concern with high health, social, 
and economic costs that merit scientific investigation.   
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Meth is a powerfully rewarding substance due to its ability to greatly 
increase brain monoamines.   Meth and other amphetamines act as a substrate 
for plasma membrane monoamine transporters including dopamine (DAT), 
serotonin (SERT) and norepinephrine (NET), thereby inhibiting the reuptake of 
these transmitters (Bonisch 1984;Fleckenstein et al. 1999;Han and Gu 
2006;Haughey et al. 2000;Jones et al. 1998;Liang and Rutledge 1982;Zaczek et 
al. 1991).  Amphetamines bind to vesicle monoamine transporters (VMAT) 
located on the monoamine containing synaptic vesicles (Partilla et al. 2006;Peter 
et al. 1994).  VMATs use secondary active transport via a coupled proton pump to 
transport monoamine transmitters into the vesicle (Schuldiner et al. 1998).  
Amphetamines are weak bases, and upon entering the vesicle amphetamines 
increase the vesicular pH and reduce the vesicular/cytoplamic pH gradient, thus 
reducing the energy barrier for sequestered transmitter to be released into the 
cytosol (Sulzer et al. 1993;Sulzer et al. 1995;Sulzer and Rayport 1990).  This 
results in a decrease in monoamine transmitter in the vesicle, an increase in 
transmitter in the cytosol, and, through reverse transport at the monoamine 
transporters, an increase in transmitter release to the extracellular synaptic cleft 
(Sulzer et al. 1995).  Amphetamines also act as competitive monoamine oxidase 
inhibitors, which are yet another means of increasing monoamine concentration 
within the cell by hindering catabolism (Mantle et al. 1976;Scorza et al. 1997).  
Thus, through its action at monoamine transporters, VMATs, and monoamine 
oxidase, Meth acts to increase monoamine neurotransmitters released into the 
synaptic cleft. 
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Meth (international union of pure and applied chemistry (IUPAC) 
nomenclature = N-methyl-1-phenyl-propan-2-amine) differentiates itself from 
amphetamine (Amph, IUPAC nomenclature = (±)-1-phenyl-propan-2-amine) in 
having an additional methyl group that allows for greater brain penetration and 
more persistent effects (NIDA Research Report Methamphetamine Abuse and 
Addiction 2006).  Moreover, the rates of illicit Meth use are reported to be higher 
than that of Amph (Colliver 2006).  In humans, the half life of Meth is 
approximately 10 hr (Cook et al. 1993;Harris et al. 2003;Newton et al. 2005) and 
the subjective “high” occurs rapidly after approximately 10min (Perez-Reyes et al. 
1991).  The subjective effects of Meth in humans include arousal, euphoria, 
relaxation, anxiety, talkativeness, paranoia, and hallucinations (Bell 1973;Martin 
et al. 1971).  Meth is a sympathomimetic that produces physiological effects 
including increases in heart rate, blood pressure, and respiration rate (Ho et al. 
2009;Martin et al. 1971) and a propensity for stroke (Perez, Jr. et al. 
1999;Rothrock et al. 1988).   
The laboratory rat is often used to model human Meth addiction, and the 
pharmacodynamics of Meth in the rat emulates the human; however, the 
pharmacokinetics of Meth is quite different.  In the rat, the half life is of Meth is 
70min after an intravenous administration (Cho et al. 2001;Riviere et al. 1999).  
After intraperitoneal (i.p.) administration, peak locomotor activity following an 
acute, low dose of Meth (1-2mg/kg) occurs at approximately 30min (Shoblock et 
al. 2003).  The Napier laboratory reports similar peak motor effects for an acute 
dose of subcutaneously (s.c.) administered Meth (1mg/kg) and that this motor 
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activity is enhanced following repeated treatment (2.5mg/kg, s.c. per day for 5 
days) (McDaid et al. 2007).  These pharmacokinetic factors must be considered 
in experimental design using rodent models of addiction. 
The rewarding subjective effects of Meth can be associated with the 
context in which they are administered.  Presentation of cues associated with 
drugs, such as pictures of people taking drugs or drug paraphernalia produce an 
enhanced subjective and physiological state similar to that experienced with drug 
taking (Carter and Tiffany 1999;Tolliver et al. 2010).  Moreover, human imaging 
data demonstrate that exposure to drug-related cues can enhance activity in 
reward-related brain regions of stimulant addicts (Breiter et al. 1997;Childress et 
al. 1999;Grant et al. 1996;Kilts et al. 2004;Maas et al. 1998), and lead to craving 
and relapse in the withdrawn addict.  Newton and colleagues recently reported 
that 15% of Meth-dependent individuals surveyed relapse due to cravings and 
44% stated that they relapsed because they wanted “to get high” (Newton et al. 
2009).  Though drug craving may not be the only factor contributing to relapse, 
craving in Meth-dependent individuals has been shown to predict Meth use 
(Hartz et al. 2001).  The presentation of drug cues to stimulant withdrawn 
addicts increases measures of craving and drug-taking behavior in a clinical 
laboratory setting (Hogarth et al. 2010;Mucha et al. 1998;Panlilio et al. 
2005;Tolliver et al. 2010).  Cues associated with stimulant use produce a strong 
psychological and physiological response in stimulant abusers that can lead to 
craving and relapse.  Therefore, uncoupling these contextual drug cues with the 
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rewarding properties of Meth may provide an important means of relapse 
prevention in stimulant use disorders.   
A behavioral model that measures the association between drug-paired 
cues and the rewarding effects of abused drugs is conditioned place preference 
(CPP).  CPP  implements classical or Pavlovian conditioning (Pavlov 1927).   In 
this paradigm, the unconditioned stimulus (UCS; e.g., Meth) is paired with a 
neutral environmental context, termed the conditioned stimulus (CS), during a 
process called conditioning.  After conditioning, the subject demonstrates that 
the enhanced salient properties of the UCS are transferred to the CS, and in CPP 
this process is demonstrated by the subject preferring the drug-paired context in 
the absence of the UCS.  This is termed expression of CPP.  CPP is reliably used to 
measure the rewarding effects of Meth as well as Amph and other abused 
substances in laboratory rodents (Spyraki et al. 1982;Tzschentke 
1998;Tzschentke 2007).  Recently, Childs and deWit report that this behavioral 
paradigm can be directly tested in humans using Amph as the UCS (Childs and 
deWit H. 2009).  Therefore, the CPP behavioral model provides a means for 
assessing the association between rewarding effects of drugs and conditioned 
contextual cues that is relevant in humans. 
Another index of brain plasticity that occurs with repeated drug 
administration, aside from CPP, is the progressive enhancement in motor 
activity, termed motor sensitization.  Neuronal structures upon which 
psychostimulants and other drugs of abuse act adapt to produce an enhanced 
response with repeated exposure to the drug stimulus (Stewart and Badiani 
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1993).  It is hypothesized that the neuronal adaptations associated with motor 
sensitization may model certain aspects of the brain changes that are associated 
with Meth abuse in humans (Robinson and Berridge 1993;Stewart and Badiani 
1993).  The sensitizing effect of Amph, for example, is so powerful that a single 
administration of the drug can enhance responding to subsequent Amph 
administration, and these sensitized behaviors evoked by Amph become more 
pronounced even after long periods of withdrawal from repeated exposure (e.g., 3 
weeks) (Vanderschuren et al. 1999).  Sensitization to the effects of Amph also 
occur in humans after repeated, intermittent administration including 
enhancements in Amph-induced euphoria, energy level, and talkativeness 
(Strakowski et al. 1996;Strakowski et al. 2001;Strakowski and Sax 1998).  
Repeated Amph and Meth induce psychotic effects similar to those reported in 
schizophrenia (Angrist and Gershon 1970;Bell 1973;Griffith et al. 1972) which 
also demonstrates persistent sensitization-like properties (Robinson and Becker 
1986;Schmidt and Beninger 2006;Yui et al. 1999).  Our laboratory and others 
have demonstrated that Meth and Amph can differentially induce CPP and motor 
sensitization behaviors in rodents depending on factors such as drug dosage 
(Itzhak et al. 2002;Shen et al. 2006), rodent age (Belluzzi et al. 2004), and rodent 
strain (Kosten et al. 1994).  These reports suggest that the two behaviors may 
model different aspects of human drug addiction. 
Relapse rates for Meth addicts undergoing behavioral/cognitive recovery 
programs reach approximately 50-60% (Brecht et al. 2000;McLellan et al. 2000), 
and there is currently no FDA-approved pharmacotherapy for Meth use disorders 
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(Elkashef et al. 2008).  Therefore, the treatment of Meth use disorders represents 
an unmet need for which the development of more effective pharmacotherapy 
merits investigation.  The current studies implemented CPP and motor 
sensitization in order to identify potential therapeutic targets for addiction 
therapy.  
 
Dual diagnosis of substance use disorders and schizophrenia: clinical 
scenario and rodent behavioral models  
 
A recent clinical assessment determined that 25% of schizophrenia 
patients also meet criteria for psychostimulant abuse or dependence (Compton et 
al. 2005), a frequency that is considerably higher than the 5% of the general 
United States population reported to have used or abused Meth in 2004 
(http://www.drugabusestatistics.samhsa.gov/2k5/meth/meth.htm).  Dual 
diagnosis schizophrenia patients show an increased incidence of violence 
(Buckley et al. 2004), as well as greater housing, economic, and health care 
access problems (Compton et al. 2005).  Case studies demonstrate that the 
atypical antidepressant, olanzapine, can reduce psychotic symptoms induced by 
Meth abuse, but it remains unclear if this treatment reduces relapse to Meth 
abuse in the stimulant abstinent co-morbid patient (Misra et al. 2000).  Fifty-five 
percent of schizophrenia patients who are medicated with antipsychotics are 
substance abusers (Swofford et al. 2000), indicating that blocking dopamine 
transmission is insufficient to alter stimulant abuse.  There clearly is an unmet 
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need for an effective pharmacotherapy for the dual diagnosis patient.  This 
project is predicated on the concept that a better understanding of the behavioral 
profile of dual diagnosis will shed light on the neurobiological underpinnings that 
overlap between stimulant use disorders and schizophrenia.  
Schizophrenia is described by the Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition (DSM-IV) as a mixture of characteristic positive 
and negative “signs and symptoms associated with marked social or occupational 
dysfunction.”  Positive symptoms include “distortions in thought content 
(delusions), perception (hallucinations), language and thought process 
(disorganized speech), and self-monitoring of behavior (grossly disorganized or 
catatonic behavior)” while negative symptoms include “restrictions in the range 
and intensity of emotional expression (affective flattening), in the fluency and 
productivity of thought and speech (alogia), and in the initiation of goal-directed 
behavior (avolition)” (American Psychiatric Association 2000).  As stated in the 
previous section, repeated use of amphetamines results in psychotic symptoms 
akin to schizophrenia in humans, including cognitive dysfunction, delusions, and 
hallucinations (Harris and Batki 2000;McKetin et al. 2006;Scott et al. 2007).  
Though the DSM-IV classifies substance-induced psychotic disorders separately, 
there is evidence to suggest that use of amphetamines results in an augmentation 
of symptoms in schizophrenia patients (Angrist et al. 1980;Janowsky and Davis 
1976).  The striking similarity between clinical presentations of schizophrenia 
and psychosis induced by amphetamines lends credence to the idea that there is 
an overlapping neurobiological function between the two disorders.  One 
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behavioral feature that occurs with both schizophrenia patients and 
administration of amphetamines is a sensorimotor gating deficit that indicates 
cognitive fragmentation (Braff et al. 1978;Grillon et al. 1992).  This can be 
measured in both humans and rodents with the prepulse inhibition (PPI) deficits 
of the acoustic startle response (Braff et al. 2001;Swerdlow and Geyer 1998).  PPI 
is defined as the natural inhibitory response that occurs when a startling stimulus 
is preceded by a weaker stimulus (Graham 1975;Hoffman and Searle 1968;Ison et 
al. 1973;Swerdlow and Geyer 1998)(Fig. 1).  Recent studies report that sensitizing 
treatment regimens of Amph disrupt PPI and Amph-induced PPI deficits in 
laboratory rats can model of aspects of human schizophrenia (Peleg-Raibstein et 
al. 2008;Tenn et al. 2005).  Assays of brain chemistry and anatomy in Amph-
treated rats demonstrate further similarities to the schizophrenia brain state such 
as a decrease in the enzyme glutamic acid decarboxylase 67 (GAD67) in the 
prefrontal cortex, hippocampus and thalamus (Akbarian et al. 1995;Heckers et al. 
2002;Peleg-Raibstein et al. 2008;Perry et al. 1979;Volk et al. 2000).  Therefore, 
further study into the behavioral outcomes induced by repeated Amph such as 
sensorimotor gating deficits and reward-mediated behaviors will help elucidate 
neurobiological underpennings of, and identify therapeutic targets for, the dually 
diagnosed patient. 
Early stressors in development of laboratory rodents such as maternal and 
social deprivation (termed isolation rearing), produce behavioral, neurochemical, 
and morphological adaptations that result in a phenotype that resembles aspects 
of schizophrenia.  In this model, rats are separated from their mother 
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approximately one day post-weaning (post-natal day 21) and housed individually 
until adulthood with minimal handling by the experimenter (Einon and Morgan 
1977;Varty et al. 1999).  Sensorimotor gating deficits are observed in isolation-
reared rats (Geyer et al. 1993).  Isolation rearing-induced PPI deficits are 
reversed by antipsychotic medications used to treat symptoms in schizophrenia 
patients, giving predictive validity of isolation rearing as a model for 
schizophrenia (Bakshi et al. 1998).  Furthermore, there is evidence of decreases 
in volume of the frontal cortex in both isolation reared rodents (Day-Wilson et al. 
2006) and schizophrenia patients (Benes et al. 1991), which indicates similar 
morphological alterations.  Isolation rearing provides an ideal non-
pharmacological means of assessing sensorimotor gating deficits associated with 
schizophrenia in the adult rat. 
Other rodent models of schizophrenia demonstrate enhanced sensitivity to 
psychostimulants; a phenomenon that is known to occur in humans (Angrist et 
al. 1980;Janowsky and Davis 1976).  The model predominantly used in these 
studies is the neonatal ventral hippocampal lesion (NVHL).  In this model, 
bilateral excitotoxic lesions are produced in the ventral hippocampus on post 
natal day seven which disrupts the hippocampal connection to the prefrontal 
cortex.  This results in behavioral and neurochemical properties in rats that are 
similar to features presented by human patients with schizophrenia (Lipska et al. 
1993;Lipska et al. 1995).  The NVHL rodents show enhanced motor sensitization 
to nicotine and cocaine compared to sham lesioned counterparts.  The acquisition 
of both cocaine (Chambers and Self 2002) and Meth self-administration (Brady 
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et al. 2008) is also enhanced in NVHL rats.  Furthermore, NVHL lesioned 
rodents displayed enhanced motivation to work for Meth administration when 
the schedule of reinforcement was altered to a progressive ratio in the self-
administration paradigm (Brady et al. 2008).  Like the NVHL rats, isolation-
reared rodents also demonstrate enhanced motor sensitization to Meth (Dai et al. 
2004), cocaine and amphetamine (Lipska et al. 1993) as well as enhanced 
responding in a progressive ratio for both cocaine and amphetamine (Smith et al. 
1997).  Taken together, motor sensitization and self-administration studies 
indicate that the NVHL and isolation rearing rodent models of schizophrenia are 
more sensitive to the locomotor stimulating and reinforcing effects of stimulants, 
which may reflect positive symptoms associated with schizophrenia.  However, 
these developmental rodent schizophrenia models demonstrate a diminished 
response to the rewarding properties of stimulant drugs, which could reflect 
negative symptoms associated with schizophrenia such as anhedonia and 
cognitive dysfunction.  For example, in CPP paradigms, isolation reared rats fail 
to demonstrate a significant preference for environmental context associated 
with Amph (Wongwitdecha and Marsden 1995) and the opiate morphine 
(Wongwitdecha and Marsden 1996).  Rats with the NVHL lesion also showed 
blunted CPP induced by Amph or the natural reward saccharin (Le et al. 2002).  
Overall, in developmental rodent models of schizophrenia there is a disparity in 
the rewarding vs. reinforcing properties of stimulants.  Therefore, one objective 
of the current dissertation project was to investigate how sensorimotor gating 
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deficits associated with different rodent models of schizophrenia correlate with 
rewarding and incentive motivational properties of Meth. 
 
Glutamate transmission in addiction and schizophrenia 
 
The reinforcing properties of abused stimulants and the neuropathology of 
schizophrenia are both associated with hyperactivity of the mesolimbic dopamine 
system (see reviews (Carlsson 1988;Wise and Rompre 1989)).  Most abused 
drugs increase extracellular dopamine concentrations in the nucleus accumbens 
(NAc) (Di Chiara and Imperato 1988), which receives dopaminergic input from 
the ventral tegmental area (VTA) (Swanson 1982).  Amphetamines also increase 
extracellular glutamate concentrations in the NAc and other regions where VTA 
dopamine projections terminate such as the mPFC and ventral pallidum (VP) 
(Chen et al. 2001;Shoblock et al. 2003;Xue et al. 1996).    The mPFC provides 
glutamatergic innervations to both the NAc and VP (Christie et al. 1985;Fuller et 
al. 1987;Sesack et al. 1989) as well as the VTA (Sesack and Pickel 1992).  The VP 
and NAc have reciprocal GABAergic connections (Jones and Mogenson 
1980;Mogenson et al. 1983;Walaas and Fonnum 1979;Zahm et al. 1985).  The 
NAc receives glutamatergic projections from the hippocampus and amygdala 
(McDonald 1991;Meredith et al. 1990).  The amygdala also sends a glutamatergic 
projection to the VP (Carnes et al. 1990;Fuller et al. 1987;Russchen and Price 
1984).  The current literature review will focus on the mPFC, NAc and VP as these 
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regions are critical players in stimulant-induced motor sensitization, conditioned 
reward, schizophrenia and sensorimotor gating (see Fig. 2 for circuitry diagram). 
 
Glutamate alterations specific to motor sensitization 
Rodent studies demonstrate that mPFC, NAc and VP brain structures are 
involved in different phases of motor sensitization.  Initial studies revealed that 
lesions of the mPFC reduce induction of Amph-induced motor sensitization 
(Bjijou et al. 2002;Cador et al. 1999;Wolf et al. 1995;Wolf and Xue 1999) but not 
the expression of this behavior (Li and Wolf 1997).  Tzschentke later revealed, 
however, that mPFC lesions do not affect the development of Amph-induced 
motor sensitization (Tzschentke and Schmidt 1999;Tzschentke and Schmidt 
2000).  These disparate findings may be due to differences in environmental 
conditions associated with Amph administration and lesion extent.  However, the 
literature is in agreement that mPFC lesions disrupt both the development and 
expression of cocaine-induced motor sensitization (Li et al. 1999;Pierce et al. 
1998;Tzschentke and Schmidt 1999;Tzschentke and Schmidt 2000).  To date, 
there is no study employing lesions of the mPFC to determine its effects on Meth-
induced motor sensitization.  It is known that extracellular glutamate levels in the 
mPFC are differentially altered by systemic administration of Amph vs. Meth.  
That is, there is an increase in mPFC glutamate levels after Meth (2mg/kg) 
injections peaking approximately 100min post-injection but no changes occur in 
mPFC glutamate levels after Amph (2mg/kg) administration (Shoblock et al. 
2003).  Preliminary work from the Szumlinski laboratory demonstrated a 
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reduction in mPFC extracellular glutamate levels three weeks after repeated Meth 
(Lominac and Szumlinski 2008). However, direct infusion of Amph into the 
mPFC results in a dose-dependent increase in glutamate levels in the same brain 
region (Del Arco et al. 1998).  The neuronal firing response of mPFC neurons to 
local, microiontophoretic application of glutamate is also enhanced in Amph-
sensitized rats (Peterson et al. 2000).  These studies implicate the mPFC as an 
important structure in the development of stimulant-induced motor sensitization 
and that neurons of this region are hyper-responsive to glutamate during 
withdrawal from repeated exposure to stimulants. 
The NAc is a brain region classically considered important for the 
expression of stimulant-induced motor sensitization (see reviews (Pierce and 
Kalivas 1997;Vanderschuren and Kalivas 2000).  Glutamate neurotransmission is 
important in this role, since local injection of NMDA receptor antagonist (AP-5) 
into the core region of the NAc blocks cocaine-induced motor sensitization 
(Pulvirenti et al. 1994).  Furthermore, increases in extracellular glutamate occur 
in the NAc only in rats sensitized to cocaine subsequent to an additional cocaine 
injection, and this effect is specific to the core subregion of the NAc (Pierce et al. 
1996).  Pierce and Kalivas also demonstrated that local injection of AMPA into 
the core but not the shell subregion of the NAc enhanced locomotor effects in 
cocaine-sensitized rats (Pierce et al. 1996).  However, NAc neurons are less 
sensitive to locally applied glutamate three days after administration of a 
sensitizing regimen of cocaine or Amph, perhaps due to a shorter withdrawal 
period (White et al. 1995).  These findings converge to show the importance of 
19 
 
glutamate in the NAc core to the expression of stimulant-induced motor 
sensitization. 
An output structure of the NAc, the VP, may play a role in the development 
and expression of stimulant-induced motor sensitization.  Local injection of 
Amph into the VP increases motor activity but to a lesser extent than local NAc 
application (Fletcher et al. 1998).  Blockade of AMPA/kainate receptors in the VP 
also reduces acute Amph-induced hyperactivity (Willins et al. 1992).  The 
expression, however, of Amph-induced motor sensitization is reduced by intra-
VP administration of NMDA receptor antagonists (Chen et al. 2001).  
Furthermore, a challenge administration of Amph given 10-14 days after repeated 
Amph treatments increases extracellular glutamate levels in the VP (Chen et al. 
2001).  Our lab has demonstrated that the there is an increase in neuronal 
response of VP neurons three days following repeated, sensitizing cocaine 
administration (McDaid et al. 2005).  These studies demonstrate that the VP 
glutamate system is involved in the acute hyper-motoric effects of stimulants as 
well as in the expression of stimulant-induced motor sensitization.   
 
Neuronal activation and glutamatergic alterations following 
stimulant-induced associative learning 
The complex neuronal processes involved with addiction are thought to 
involve hijacking normal components of learning and memory.    The PFC, 
important for executive function and control of memory maintenance (Goldstein 
and Volkow 2002;MacDonald, III et al. 2000), has decreased activation in Meth-
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addicted humans performing cognitive tasks (Paulus et al. 2003;Salo et al. 2009).  
However, the PFC becomes highly activated with the presentation of stimulant-
related cues in subjects with stimulant use disorders (Grant et al. 1996;Hester 
and Garavan 2009;Maas et al. 1998).  Meth conditioned rats given a priming 
injection of Meth and re-exposed to Meth-cues demonstrate enhanced 
extracellular mPFC glutamate levels compared to rats that were not primed with 
Meth (Qi et al. 2009).  These data indicate that the mPFC is sensitive to Meth and 
Meth-related cues.  The mPFC projects to the NAc, and recently both of these 
regions were proven to be critical for cue- and Meth-induced reinstatement of 
drug-seeking behavior in rodents (Rocha and Kalivas 2010).  The NAc is a central 
component of the reinforcing, rewarding and hyper-motoric effects of stimulants 
(Bozarth and Wise 1981;Swerdlow et al. 1986;Wise and Bozarth 1985).  While the 
NAc is a central mediator of the reinforcing effects of stimulants, it may not be as 
critical to the learning or craving associated with the drug and drug cues, since 
cortical regions but not subcortical structures such as the NAc are metabolically 
activated in the presence of cocaine cues (Grant et al. 1996) but also see (Breiter 
et al. 1997).  In rodent studies of cellular activation, there is an increase in fos 
expression after Meth administration in the NAc (Lee et al. 2000).  However, 
there is an increase in fos expression in the mPFC but not in the NAc in rodents 
responding to cocaine cues (Brown et al. 1992;Mattson and Morrell 2005).  
However, Rhodes et al. found an increase in c-Fos expression in the NAc shell as 
well as in the PFC in response to Meth-associated cues (Rhodes et al. 2005).  
Based on behavioral and cellular activity data, the mPFC and NAc play important 
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roles in response to stimulant cues.  While imaging data suggests that the mPFC 
might be more sensitive to drug-related cues, the resolution of these procedures 
may make discerning activation in the NAc or VP more difficult.   
The VP plays a critical role in integration of neuronal signaling to produce 
motivated motor behavior (Mogenson and Yang 1991).   VP neurons encode 
information relevant to incentive properties of cues that predict reward, which is 
enhanced subsequent to Amph sensitization (Tindell et al. 2005).  NMDA 
receptors in the VP are necessary for the development but not expression of 
amphetamine-induced CPP (Hiroi and White 1993).  Work conducted in the 
Napier lab revealed an increase in the stable form of the FosB immediate early 
gene family, ΔFosB, that persists following a sensitizing regimen of Meth in the 
VP (McDaid et al. 2006b).  Biochemical and electrophysiological data suggest 
that VP neurons are activated by stimulants and related cues.   
In summary, the mPFC, NAc, and VP all demonstrate cellular or region 
activation in response to stimulant administration, and these responses are 
enhanced following repeated exposure.  The mPFC is hyper-activated in response 
to the presentation of stimulant-related cues in human addicts.   
 
Glutamate alterations associated with schizophrenia and 
sensorimotor gating deficits 
The glutamate hypothesis of schizophrenia was born out of clinical 
evidence that individuals taking phencyclidine (PCP), the ionotropic glutamate 
NMDA receptor open channel blocker, experienced a psychotic state similar to 
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that of schizophrenia (Allen and Young 1978;Fauman et al. 1976;Rainey, Jr. and 
Crowder 1975), and that PCP exacerbated illness in schizophrenia patients (Itil et 
al. 1967).  PCP can also induce sensorimotor gating deficits in rodents and non-
human primates (Linn and Javitt 2001;Martinez et al. 1999) that are reversed by 
antipsychotic medications (Bakshi et al. 1994;Bakshi and Geyer 1995;Linn et al. 
2003).  Levels of glutamate are lower in the cerebral spinal fluid (CSF) of 
schizophrenia patients than in individuals without the illness (Kim et al. 1980).  
There is pre-clinical and clinical evidence that schizophrenia is not merely a 
disorder of a hyperactive dopamine system but also involves glutamatergic 
dysregulation. 
Limbic circuitry associated with reward innervates the brain stem circuitry 
that mediates the acoustic startle response.    Briefly, auditory stimuli are 
received by the inferior colliculus (IC) via the cochlear nucleus (Coch) and 
relayed to the superior colliculus (SC) and pedunculopontine tegmental nucleus 
(PPTg).  The PPTg sends descending cholinergic projections to the nucleus 
reticularis pontis (PnC) of the primary startle pathway as well as sending 
excitatory ascending projections to the thalamus and dopaminergic nuclei of the 
reward pathway such as the VTA.  The PnC can also be directly activated by 
auditory stimuli and sends projections to spinal motor neurons eliciting a startle 
response (see Fig. 2, and reviews, (Davis et al. 1982;Fendt et al. 2001;Swerdlow et 
al. 1992).  The limbic reward circuitry (discussed above) modulates the PPI 
circuit predominantly at the level of the PPTg via GABAergic projections from the 
VP and NAc (Chivileva and Gorbachevskaya 2008;Haber et al. 1990).  I will limit 
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my review of brain regions involved with the modulation of PPI to those 
discussed previously, the mPFC, NAc and VP (see Fig. 2 for diagram of circuitry). 
Post-mortem morphological studies identify a decreased neuronal density 
in the mPFC of schizophrenia patients (Benes et al. 1986).  It was further 
determined that this lower density was due to a loss of small, likely GABAergic 
interneurons and that levels of larger pyramidal neurons were generally 
unaltered (Benes et al. 1991).  This morphological alteration may contribute to 
the sensorimotor gating deficits in schizophrenia patients since intra-mPFC 
administration of picrotoxin, the GABAA receptor antagonist, disrupts PPI in 
rodents (Japha and Koch 1999).  A reduction in GABAergic inhibition in the 
mPFC would result in an increase in glutamate release in the VTA leading to an 
increase in dopamine release in the NAc (see Fig. 2 for circuitry).  The 
mechanism by which PPI is disrupted in the mPFC is likely associated with a loss 
of dopaminergic inhibition of glutamate neurons since lesions of dopamine 
terminals reduce PPI and this effect is reversed by administration of the 
antipsychotic haloperidol that has a high affinity for dopamine D2 receptors 
(Bubser and Koch 1994;Koch and Bubser 1994).  The deficits in PPI induced by 
local injections of picrotoxin into the mPFC are also reversed by haloperidol, 
further substantiating this claim (Japha and Koch 1999).  Therefore a loss of 
inhibition of in the mPFC via both GABAergic and dopaminergic means may lead 
to an increase in NAc dopamine resulting in PPI deficits associated with 
schizophrenia.  Isolation-reared rodents that displayed PPI deficits have reduced 
mPFC volume (neuronal number was unaltered), which further validates the role 
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of mPFC in sensorimotor gating deficits associated with schizophrenia as well as 
the utility of the isolation-rearing model (Day-Wilson et al. 2006).  Other studies 
reveal a disconnection in PFC neurons (Bagorda et al. 2006;Witte et al. 2007) 
and a reduction in metabotropic glutamate receptors in isolation reared rodents 
(Melendez et al. 2004).  Therefore, the mPFC is key in sensorimotor gating 
deficits associated with schizophrenia.   
The NAc receives glutamatergic projections from the mPFC, hippocampus, 
amygdala, and dopaminergic innervation from the VTA.  The NAc, thus, is an 
important site for glutamate and dopamine transmitter interaction.    Zhang and 
colleagues report a close correlation between Amph-induced deficits in 
sensorimotor gating and increases in extracellular dopamine levels in the NAc 
(Zhang et al. 2000).  Local injection of Amph into the NAc disrupts PPI 
(Swerdlow et al. 2007;Wan and Swerdlow 1996), an effect that is reduced by the 
co-administration of ionotropic AMPA receptor antagonist, CNQX (Wan and 
Swerdlow 1996).  Furthermore, intra-NAc administration of AMPA or NMDA 
alone decreases PPI (Reijmers et al. 1995;Wan et al. 1995).  Lesions of dopamine 
terminals in the NAc and administration of haloperidol reverse AMPA-induced 
disruptions of PPI (Wan et al. 1995).  Clearly, the NAc is a region critical for the 
dopamine-induced effects on sensorimotor gating that are also affected by 
glutamatergic transmission. 
The NAc and VP are connected via reciprocal GABAergic projections and 
both regions innervate the PPTg (Haber et al. 1990;Heimer et al. 1991;Parent et 
al. 1999).    Volume loss in the VP is reported in post-mortem brain tissue from 
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schizophrenia patients (Bogerts et al. 1985).  Lesions of the VP as well as GABA 
agonist application in this region reveal that it is a critical mediator in the 
sensorimotor gating deficits associated with excess dopamine in the NAc 
(Kretschmer and Koch 1998;Swerdlow et al. 1990).   Further evidence for the role 
of VP GABA transmission in regulation of dopamine induced PPI is 
demonstrated by dopamine receptor (D3/D2) agonist quinelorane inducing 
increased extracellular GABA levels in the VP as well as reducing PPI in rodents 
(Qu et al. 2008).  The VP works to integrate dopamine- and GABA-mediated 
signaling to modulate sensorimotor gating behavior. 
 
Involvement of the metabotropic glutamate receptor group I, subtype 
5 (mGluR5) in reward-mediated behaviors 
 
Glutamate activates ionotropic glutamate receptors and metabotropic 
glutamate receptors.  Metabotropic glutamate receptors (mGluRs) are classified 
into three different groups based on sequence homology, pharmacology and 
associated signaling cascades with which they are coupled (Nakanishi 1992).  The 
mGluRs have seven transmembrane domains, a large extracellular amino-
terminus, an intracellular carboxy-terminus, and are members of the family 3/C 
G-protein coupled receptors (GPCRs) (see for review (Conn and Pin 
1997;Hermans and Challiss 2001;Pin et al. 2003)).  The group I subtype 1 
receptor (mGluR1) was the first cloned mGluR (Houamed et al. 1991;Masu et al. 
1991) and subsequent cloning of group I subtype 5 metabotropic glutamate 
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receptor (mGluR5) determined that the two receptors share approximately 87% 
sequence homology (Abe et al. 1992).  The mGluR5 also exists in a covalent, 
disulfide-linked homodimer in non-reducing conditions (Romano et al. 1996) but 
also see evidence for non-covalent dimerization (Romano et al. 2001).  The 
extracellular amino-terminal region of the group I mGluR homodimer forms a 
venus-flytrap-shaped region where agonist binding occurs (Kunishima et al. 
2000).  Also, mGluR5 demonstrates constitutive activity, and both the 
extracellular amino terminal (Muhlemann et al. 2005) and the seven-
transmembrane domain play roles in this receptor behavior (Goudet et al. 2004).  
The mGluR5 are coupled to guanine nucleotide binding Gq proteins and upon 
activation stimulate phosphoinositide (PI) hydrolysis resulting in an increase in 
intracellular calcium concentrations (Abe et al. 1992).  Splice variants of both 
mGluR1 (mGluR1a-c; (Pin et al. 1992;Tanabe et al. 1992) and mGluR5 exist 
(mGluR5a and mGluR5b; (Abe et al. 1992;Joly et al. 1995;Minakami et al. 1993)) 
and mGluR1a, mGluR5a, and mGluR5b all function to induce PI hydrolysis in a 
similar manner (Joly et al. 1995).  The activation of group I mGluRs (mGluR1 and 
mGluR5) modulates neuronal excitability and increases intracellular calcium 
levels, which makes these receptors important modulators of neuronal plasticity.  
The mGlu5 receptor is of special interest since these receptors are located 
within reward-related brain regions.  Studies using in situ hybridization to detect 
mRNA levels of subtype-specific mGluRs have demonstrated that expression 
levels of mGluR5 are high in the rat basal ganglia, including the NAc, 
caudate/putamen, hippocampus and frontal cortex (Kerner et al. 1997;Lu et al. 
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1999;Testa et al. 1994a), and these results were confirmed by receptor protein 
detection (Romano et al. 1995).  Deposition of Fluoro-Gold retrograde dye into 
the VP, a region of moderate mGluR5 expression, reveals that approximately 82% 
of mGluR5 mRNA containing neurons in the NAc project to this region (Lu et al. 
1999).  The mGlu5 receptor is located primarily post-synaptically.  Indeed, 
electron microscopy reveals the predominant expression of mGluR5 protein in 
the cortex, hippocampus and NAc is on dendritic spines, though slight expression 
of mGluR5 on pre-synaptic axon terminals occurs in these brain regions (Mitrano 
and Smith 2007;Romano et al. 1995).  The localization of mGluR5 on post-
synaptic neurons within the limbic brain regions makes them a suitable target for 
study on stimulant-induced reward. 
Subtype-selective mGluR5 allosteric modulator ligands have unique 
characteristics that gives them potential for novel substance use disorder 
pharmacotherapy.   These ligands do not bind to the orthosteric 
agonist/antagonist binding site but instead bind non-competitively to a specific 
site located within the seven transmembrane-domain region of the receptor.  
Most allosteric modulators are active only when endogenous agonist is bound to 
the receptor in order to physiologically potentiate or decrease effects of the 
agonist itself.   Through this mechanism of action, the use of allosteric 
modulators decreases the likelihood of unwanted side effects that occur with 
traditional agonist/antagonist therapies that are often plagued with 
compensatory effects subsequent to receptor over/under-activation (see for 
review (Wang et al. 2009)).  The ligand 2-methyl-6-(phenylethynyl)-pyridine 
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(MPEP) binds to specific residues within the seven-transmembrane spanning 
region in order to negatively modulate mGluR5 (Malherbe et al. 2003).  MPEP is 
found to specifically decrease agonist-induced activity of mGluR5 and is 
systemically active (Gasparini et al. 1999).  However, MPEP is also shown to have 
inverse agonist activities in reducing the constitutive activity of mGluR5 (Goudet 
et al. 2004;Muhlemann et al. 2005;Pagano et al. 2000).  The ligand 3-[(2-
methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) acts at the same allosteric site 
as MPEP but has greater potency and selectivity for the mGluR5 (Cosford et al. 
2003).  Both MPEP and MTEP are useful, systemically active, pharmacological 
tools for determining the functional role of mGluR5 in vivo. 
The use of allosteric modulators demonstrates the functional importance 
of mGluR5 in stimulant-mediated behaviors.  When MPEP (50mg/kg, i.p.) is 
given after the acquisition of amphetamine-induced associative learning on the 
test day, it blunts the expression of Meth-induced CPP in rats (Herzig et al. 
2005).  Additionally, MPEP (100nmol, intracerebroventricular) given prior to 
Meth pairing in a specific context hinders the development of the Meth-induced 
place conditioning in mice (Miyatake et al. 2005).  Therefore, the use of MPEP 
demonstrates the importance of mGluR5 activation during both the development 
and expression phases of stimulant-induced associative learning processes.  
Another mGluR5 NAM, MTEP, has been used in operant tasks to demonstrate 
the reinforcing properties of stimulants.  Administration of MTEP dose-
dependently (at 1 and 3mg/kg) reduces the self-administration of Meth without 
altering operant responding for a natural food reinforcer (Osborne and Olive 
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2008).  Furthermore, MTEP (3mg/kg, i.p.) reduces the total number of lever 
responses in a progressive ratio paradigm of Meth self-administrations, as well as 
the total number of Meth infusion reinforcers earned (Gass et al. 2009).  
Moreover, after stable self-administration is acquired and the association 
between the lever and Meth infusion is extinguished, a pre-treatment of MTEP (1 
and 3mg/kg, i.p.) reduces cue and Meth-primed reinstatement of drug-seeking 
behavior.  Throughout these studies, responding for food remains unaltered by 
MTEP treatments up to the highest dose tested, 3mg/kg (Gass et al. 2009).   This 
collective evidence suggests that mGluR5 activation is needed for the acquisition 
and retrieval of cue- and Meth-primed drug-seeking behaviors.  An area that 
remains to be explored, however, is the role of mGluR5 in the maintenance of 
stimulant-associated memories.  This is a critical gap for the treatment of 
substance use disorders and therapeutic intervention at this time period would 
aid relapse prevention in the drug-withdrawn substance abuser. 
The expression and cellular localization of glutamate receptor proteins, 
including mGluR5, can be altered by stimulant administration.  Much of the 
literature to date reports the consequences of cocaine administration on 
glutamate receptor protein levels; less is known about the effects of Meth or 
Amph.  Studies utilizing synaptosomal fractionation procedures determined that 
21 days after a sensitizing course of cocaine administration there are enhanced 
expression levels of mGluR5 as well as AMPA and NMDA receptor subunits in 
the membrane fraction of mPFC (Ghasemzadeh et al. 2009b) and NAc tissue 
(Ghasemzadeh et al. 2009a).  These effects are not observed one day after the end 
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of cocaine treatment (Ghasemzadeh et al. 2009a;Ghasemzadeh et al. 2009b).  
The Wolf laboratory also demonstrated an increase the surface expression of 
AMPA receptor subunits, GluR1 and GluR2/3 at 21 days, and GluR1 and GluR2 in 
the NAc at 14 days, but not one day, following cocaine-induced sensitization 
(Boudreau et al. 2007;Boudreau and Wolf 2005).  Furthermore, one day after an 
acute challenge administration of cocaine eliciting expression of motor 
sensitization, surface expression levels of GluR1 and GluR2 AMPA receptor 
subunits decreased in the NAc (Boudreau et al. 2007).  However, 21 days 
following a repeated Amph treatment course that induced motor sensitization, 
GluR1 and GluR2 membrane surface expression levels remain unchanged in the 
NAc (Nelson et al. 2009).  Metabotropic glutamate receptor mRNA levels are 
altered following Amph-induced sensitization in the NAc.  Three hours after 
repeated Amph, mGluR1 levels are increased and mGluR5 levels are decreased in 
this brain region.  While the alterations in mGluR1 are transient, mGluR5 levels 
remain decreased up to at least 28 days after the last Amph treatment (Mao and 
Wang 2001).  Similar results are reported using synaptosomal fragmentation 
subsequent to a single, acute injection of Amph in the striatum (Shaffer et al. 
2010).  That is, one hr after Amph administration, mGluR5 membrane fraction 
levels are decreased, but the decreases are transient since they normalize by five 
hrs post-Amph (Shaffer et al. 2010).  Shaffer and colleagues also observe a 
transient increase in mGluR5 levels in the mPFC one hr after Amph that is also 
normalized by five hr, while no alterations in mGluR1 expression were found in 
the striatum or mPFC subsequent to Amph treatment (Shaffer et al. 2010).  These 
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collective results demonstrate that glutamate receptor redistribution following 
cocaine sensitization enhances over the course of time.  However, glutamate 
receptor trafficking is differentially regulated by stimulants cocaine and Amph.  
Therefore, investigation into the effects of the stimulant Meth on changes in 
glutamate receptor profiles in reward-related brain regions will fill a gap in our 
understanding of the literature.  
The mGlu5 receptors influence neuronal plasticity through the modulation 
of ionotoropic glutamate receptors.  The activation of group I mGluRs (mGluR1 
and mGluR5) in hippocampal neurons gives rise to NMDA and AMPA receptor 
internalization, which results in a loss of electrophysiological function 
determined by a decrease in excitatory post synaptic potentials (Snyder et al. 
2001).  Zhang and colleagues show a mechanism by which mGluR1/5-induced 
internalization of AMPA receptor subunits occurs.  Internalization and de-
phosphorylation of GluR1 and GluR2 subunits induced by mGluR1/5 activation 
was reversed by inhibition of the striatal enriched protein tyrosine phosphatase  
(STEP) and this effect is specific to mGluR5.  Furthermore, activation of 
mGluR1/5 results in an increase in synaptic fragments of STEP61 isoform in 
hippocampal tissue (Zhang et al. 2008).  The STEP61 isoform occurs as a result of 
alternative splicing and is named for its molecular weight of 61kDa (Sharma et al. 
1995).  This specific STEP isoform is associated with membranes and localized to 
the endoplasmic reticulum of neurons (Bult et al. 1996).  The inhibition of STEP 
activity in the striatum results in blockade of Amph-induced motor sensitization, 
which illustrates that the function of STEP is behaviorally relevant to stimulant-
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mediated behaviors (Tashev et al. 2009).  Specific activation of mGluR5 results in 
dephosphorylation and subsequent internalization of AMPA receptor subunits 
via STEP61 activity which may be a necessary component of Amph-induced motor 
sensitization.  
 
Significance 
 
The goal of the current dissertation was to expand our knowledge of the 
role of the mGluR5 system in Meth addiction and in the co-morbidity of 
schizophrenia and Meth use disorders.  First, we sought to determine the role of 
mGluR5 in the maintenance of Meth-induced associative learning and we further 
characterized cellular adaptations of mGluR5 in reward-related brain regions at 
two behaviorally relevant time points.  From the literature review, it can be seen 
that advanced biochemical assays are being utilized to determine the cellular 
adaptations of the glutamate system including mGluR5 subsequent to cocaine 
administration.  However, the dynamics of mGluR5 following Meth-induced 
motor sensitization and associative learning remain unknown.  Our findings will 
help guide the field of psychostimulant addiction and determine if mGluR5 could 
be considered as a potential target for future pharmacotherapies. Our second 
focus was the effects of Meth exposure in pharmacological and developmental 
rodent models of schizophrenia.  Since the neurocircuitry of stimulant addiction 
and schizophrenia show clear overlap, we sought to determine how behavioral 
outcomes of each might be correlated in individual rodents.  Rodent models of 
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schizophrenia demonstrate sensitivity to the effects of stimulant.  We reveal here 
a direct correlation between sensorimotor gating deficits associated with 
schizophrenia and Meth-induced sensitization and associative learning.  We 
determined that augmenting mGluR5 signaling also increase Meth-induced 
associative learning in a developmental rodent model of schizophrenia.   These 
novel findings will add to the knowledge of behavioral dysfunction associated 
with the co-occurrence of Meth abuse and schizophrenia.  
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Figure 1.  Schematic of the prepulse inhibition (PPI) of the acoustic 
startle response in rodents.  When a strong acoustic stimulus (PULSE) of 
120dB(A) is presented alone a large startle response subsequently occurs.    When 
a weaker acoustic stimulus (PRE PULSE) between 68-77dB(A), for example, is 
presented before the strong, startling PULSE stimulus, the startle response is 
diminished.  The average startle magnitude that is measured is a result of the 
force the rat exerts on the enclosure in the PPI apparatus that is coupled to a 
sensor that transmits the information to the PC computer. Figure is modified 
from Swerdlow & Geyer 1998 Schizophrenia Bulletin 24(2):285-301 and includes 
original data traces of average startle magnitude obtained by A. Herrold in saline 
treated male Sprague-Dawley rats. 
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Figure 2.  Neurocircuitry of reward and sensorimotor gating.  Pictured 
here are the brain structures which are involved in stimulant-induced behaviors 
which also modulate the primary circuitry responsible for mediating the acoustic 
startle response.  Glutamate (Glu) projections are depicted in green, 
dopaminergic (DA) in blue and GABAergic (GABA) in red.  mPFC, medial 
prefrontal cortex; NAc, nucleus accumbens; VP, ventral pallidum; Hipp, 
hippocampus; MDT, medial dorsal thalamus; Amg, amygdala; VTA, ventral 
tegmental area; PPTg, pedunculopontine nucleus; PnC, nucleus reticularis pontis 
caudalis; SC, superior colliculus, IC, inferior colliculus; Coch, cochlear nucleus. 
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CHAPTER III 
RATIONALE FOR METHODOLOGY AND PRELIMINARY STUDIES 
 
Methamphetamine conditioned place preference dose determination 
To determine the dose of Meth to be used with repeated conditioning 
sessions in the CPP task to induce a reliable and persistent preference of the 
Meth-paired context, a Meth dose-response study (0.1, 0.3, and 1.0mg/kg, in the 
volume of 1ml/kg (i.p.)) was conducted using 36 male Sprague-Dawley rats.  The 
CPP experiment consisted of three phases during which activity and time spent in 
each compartment was monitored: pre-test, conditioning, and CPP tests.  For the 
pre-test, rats were given access to the entire CPP box (see Fig. 3B) in a drug-free 
state for 30min.  The CPP box consists of two large chambers with distinct yet 
neutral cues separated by sliding Plexiglas doors from a smaller center chamber 
with a smooth white floor and white sides (Fig.3C&D).  Rats were then assigned 
to Meth and saline paired chambers in a counter-balanced manner.  That is, half 
of the rats were paired with Meth in the chamber of the CPP box where they 
spent the least amount of time on the pre-test and the other half were paired with 
saline in the chamber where they spent the greatest amount of time on the pre-
test.  Also, the time spent in each of the large chambers during the pre-test was 
balanced so that there was no statistical difference between the sides for which 
they were paired for each group.   
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Rats were then administered Meth at a dose of 0.1, 0.3, or 1.0mg/kg, i.p. on days 
1, 3, and 5 and then immediately placed in the assigned, Meth-paired chamber for 
45min.  On days 2, 4, and 6, rats were administered saline (1ml/kg, i.p.) and then 
immediately placed in the opposite compartment for 45min.  Three days later, 
rats were tested for conditioned preference (CPP Test 1) in a drug-free state.  
Then rats were repeatedly tested for persistence of preference weekly up to CPP 
Test 3 (see Fig. 4A for experimental timeline).  A two-way repeated measures 
ANOVA statistical analysis with a post hoc Newman Keuls test for multiple 
comparisons was conducted to determine preference; preference was defined as a 
significantly greater amount of time being spent in the Meth-paired compared to 
the saline-paired chamber.  Rats that spent greater than two standard deviations 
above or below the mean in any chamber on any test day were removed from 
statistical analysis. Rats conditioned with Meth at a dose of 0.1mg/kg (n=10) 
demonstrated a significant preference for the Meth-paired chamber on CPP Tests 
1 and 2 (post hoc Newman Keuls, p<0.01; effect of Chamber F(1,18)=27.917, 
p<0.0001; effect of CPP Test Day F(2,36)=0.008, p=0.992; Interaction 
F(2,36)=3.670, p=0.0035, Fig.4B).  Rats conditioned with Meth at a dose of 
0.3mg/kg (n=10) significantly preferred the Meth-paired chamber over the 
saline-paired chamber on CPP Tests 1 and 2 (post hoc Newman Keuls, p<0.01; 
effect of Chamber F(1,18)=10.542, p=0.004; effect of CPP Test Day F(2,36)=0.034, 
p=0.967; Interaction F(2,36)=10.998, p=0.002, Fig. 4C).    Rats conditioned with 
Meth at a dose of 1.0mg/kg (n=10) demonstrated a significant preference for the 
Meth- compared to the saline-paired chamber on CPP Tests 1, 2, and 3 (post hoc 
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Newman Keuls, p<0.01; effect of Chamber F(1,18)=31.451, p<0.0001; effect of CPP 
Test Day F(2,36)=0.023, p=0.977; Interaction F(2,36)=2.271, p=0.118, Fig. 4D).    
Therefore, the 1.0mg/kg Meth dose appeared to provide the most consistent and 
enduring preference in this conditioning paradigm, thus it was chosen for the 
completion of the current dissertation work.  For future studies that will 
determine antagonism (Chapter IV) and correlation of CPP with other behavioral 
outcomes (Chapter VII), a different experimental design was used in which the 
rats are paired with Meth on the side where they spent the least amount of time 
on the pre-test.  Pairing rats with a drug on the side in which they spent the least 
amount of time on the pre-test raises some concern as to whether reward or 
anxiolytic properties of the drug are being assessed.  However, studies in our lab 
were conducted in order to determine the anxiolytic properties of the Meth 
dosing regimen chosen using an elevated plus maze.  Work completed by Robin 
Voigt in the Napier lab has determined that neither acute nor repeated treatment 
of Meth (1mg/kg, i.p.) produced anxiolytic or anxiogenic properties compared to 
saline (1ml/kg, i.p.) treatment.  Studies in the published literature have employed 
the method of pairing rodents with a rewarding stimulant on the side in which 
the least amount of time was spent in the pre-test during conditioning (Li et al. 
2001;Nomikos and Spyraki 1988).  Thus, we felt comfortable moving forward 
with this behavioral treatment paradigm with Meth CPP. 
Motor activity was also assessed at each conditioning session (after the 
initial 10min where animals are settling down from initial injection).  Rats were 
removed from motor assessments for an individual activity parameter if activity 
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counts for Day 1 or Day 5 were greater than two standard deviations above or 
below the mean.  A two-way repeated measures ANOVA with post hoc Newman 
Keuls test for multiple comparisons was utilized to determine the effects of each 
dose of Meth on motor activity on the first (Day 1) and last (Day 5) day of 
administration and to compare acute effects of each dose.  Rats administered 
Meth at a dose of 1.0mg/kg demonstrated increased horizontal activity (Fig. 5A) 
and time spent in stereotypy (i.e., repetitive movements; Fig. 5C) on conditioning 
Day 1 compared to rats administered 0.3 or 0.1mg/kg Meth (two-way repeated 
measures ANOVA with post hoc Newman Keuls test, p<0.01).  However, Meth 
administration in this paradigm at any dose tested failed to develop motor 
sensitization (i.e., there was not an increase in motor activity on Day 1 compared 
to Day 5 for any motor parameter at any Meth dose tested).    Statistical results 
for each motor parameter:  Horizontal activity; Dose F(2,31)=27.134, p<0.0001, 
Test Day F(1,31)=1.846, p=0.184, Interaction F(2,31)=4.144, p=0.025.  Vertical 
activity; Dose F(2,30)=14.278, p<0.0001, Test Day F(1,30)=0.0005, p=0.983, 
Interaction F(2,30)=3.793, p=0.034.  Stereotypy time; Dose F(2,31)=21.424, 
p<0.0001, Test Day F(1,31)=2.480, p=0.125, Interaction F(2,31)=2.874, p=0.072. We 
have found in the Napier laboratory that while this treatment course of Meth 
reliably induces CPP, motor sensitization does not always occur.  This could be 
due to the Meth dose or treatment interval, since Meth administered daily for five 
days at a dose of 2.5mg/kg (s.c.) has induced motor sensitization in the Napier 
laboratory.  These data also demonstrate that CPP and motor sensitization can be 
dissociated and likely model different aspects of the addiction phenomenon.
40 
 
 
 
Figure 3.  Behavioral testing apparatus.  A total of 16 test boxes were used 
for the completion of the current dissertation acquired from Accuscan 
Instruments, Inc., Columbus, OH.  A) The CPP box consists of two larger 
chambers (25cm x 30cm x 30cm) separated with sliding Plexiglas doors by a 
smaller center chamber (13cm x 30cm x 30cm) equipped with two banks of 
photobeams attached to the metal frame (24 horizontal and 12 vertical 
photobeams).  At the start of the pre-test or CPP test, the doors placed inside the 
box.  The rat is then placed in the small center chamber enclosed by the sliding 
doors.  B)  Immediately after the rat is placed in the center chamber, the sliding 
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doors are removed to allow the rat free access to the entire CPP box during the 
pre-test or CPP test for 30min.  C)  During conditioning sessions, rats are placed 
in an assigned chamber separated by one sliding door for 45min.  Each larger 
chamber has distinct, yet neutral visual and tactile cues.  Pictured here is the 
white, opaque patterned floor with an over-turned paint dish glued to the center 
with epoxy.  The visual cues are the vertical stripes on the surrounding walls of 
the chamber.    D)    Pictured here is an alternative chamber configuration with 
the grid floor and Plexiglas rectangular insert glued with epoxy to the center of 
the floor.  The visual cues are horizontal stripes on the surrounding walls of the 
chamber.  The floors are removable and floor type is randomized with visual cues 
in the CPP box during the assignment of chamber for conditioning. 
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Figure 4.  Methamphetamine dose response CPP study.  A) Timeline for 
behavioral experimentation.  Rats were pre-tested in a drug free state on day -2.  
Three days later, rats were given Meth at a dose of 0.1mg/kg (N=10),  0.3mg/kg 
(N=10), or 1.0mg/kg (N=10) on days 1, 3, and 5 and placed in their assigned 
chamber.  All rats were administered saline (1ml/kg, i.p.) and placed in the 
opposite chamber on days 2, 4, and 6.  Rats were then tested for initial preference 
on day 9 (CPP Test 1) in a drug-free state.  Rats were then repeatedly tested for 
persistence of preference in a drug-free state on day 12 (CPP Test 2) and day 23 
(CPP Test 3).  Solid lines with filled squares represent time spent on the Meth-
paired chamber.  Dotted lines with empty squares represent time spent on the 
saline-paired chamber.  Solid lines with filled triangles represent time spent in 
the center chamber (center chamber not included in statistical measures, only 
used for visual comparison).  B)  Rats conditioned with Meth at a dose of 
0.1mg/kg (i.p.) only expressed a significant preference for the Meth-paired 
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chamber on CPP Tests 1 and 2.  C)  Rats conditioned with Meth at a dose of 
0.3m/kg (i.p.) spent significantly more time in the Meth-paired chamber on CPP 
Tests 1 and 2.  D) Rats conditioned with Meth at a dose of 1.0mg/kg (i.p.) 
expressed a significant preference for the Meth-paired chamber on CPP Tests 1 to 
3.  Two-way repeated measures ANOVA with post-hoc Newman Keuls, **p<0.01. 
44 
 
 
Meth 0.1mg/kg
Meth 0.3mg/kg
Meth 1.0mg/kg
0
1000
2000
3000
4000
5000
Day 1 Day 5
**
**
**
**
H
o
ri
z
o
n
ta
l 
 A
c
ti
v
it
y
 /
 3
5
m
in
0
500
1000
1500
**
**
V
e
rt
ic
a
l 
 A
c
ti
v
it
y
 /
 3
5
m
in
Day 1 Day 5
0
200
400
600 **
**
**
**
S
te
re
o
ty
p
y
 T
im
e
 (
s
e
c
) 
/ 
3
5
m
in
Day 1 Day 5
(12)(12)(11) (11)(11)(11)
(11)(11)(11) (11)(10)(10) (12)(12)(11) (11)(11)(11)
A) B) C)
 
Figure 5.  Motor activity induced by Meth during conditioning.  Motor 
activity was assessed on conditioning Day 1 and Day 5 (Fig. 4A) for all doses of 
Meth (0.1, 0.3, and 1.0mg/kg, see key) for the last 35min of the conditioning 
session.  Sample size is represented within bars (n).  A)  Rats treated with 
1.0mg/kg Meth demonstrated increased horizontal activity on Day 1 and Day 5 
compared to rats treated with 0.3 or 0.1mg/kg Meth during conditioning.  
However, rats treated with 0.1, 0.3 or 1.0mg/kg Meth did not demonstrate an 
increase in horizontal activity on Day 5 compared to Day 1.  B)  There was an 
increase in vertical activity in rats treated with 1mg/kg Meth compared to rats 
treated with 0.1 or 0.3mg/kg on Day 5.  C)  Rats treated with 1.0mg/kg Meth 
demonstrated increased stereotypy time on Day 1 and Day 5 compared to rats 
treated with 0.3 or 0.1mg/kg Meth during conditioning.  However, there was no 
difference in stereotypy time between Days 1 and 5 for any Meth dose tested.  
Two-way repeated measures ANOVA with post hoc Newman Keuls test for 
multiple comparisons, **p<0.01.
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mGluR 1/5 allosteric modulator selection 
 
MPEP, 2-methyl-6-(phenyl-ethynyl)-pyridine, mGluR5 NAM 
 The mGluR5 NAM, MPEP, is systemically active and is mGluR subtype 
selective (Gasparini et al. 1999).  However, this ligand does display some off-
target activity at the ionotropic NMDA receptor at high concentrations (NMDAR 
IC50=18µM; Table 1) (Cosford et al. 2003).  The use of MPEP at a dose of 
30mg/kg, i.p. has been shown to blunt the development and expression of 
morphine-induced CPP (Herzig and Schmidt 2004), which has been validated in 
our lab (Herrold et al. 2005).  This dose of MPEP does not produce rewarding 
effects on its own as assessed in a CPP paradigm (McGeehan and Olive 2003).  
However, preliminary data from our lab suggests that it blunts motor activity.  
Because administration of MPEP at a dose of 30mg/kg, i.p. did not blunt the 
preference for cocaine, and a dose of 50mg/kg, i.p. did not affect preference for 
ecstasy using CPP, we felt that 30mg/kg, i.p. of MPEP should not disrupt the 
ability of rats to perform the CPP task.  We also determined in preliminary 
studies that MPEP (30mg/kg, i.p.) given after Meth conditioning but prior to the 
CPP test (Fig. 6A) failed to disrupt the expression of Meth-induced CPP.  These 
results demonstrated that MPEP at 30mg/kg, i.p. failed to disrupt the 
maintenance of the Meth-associated context (Fig. 6B&C).  These results could be 
due to the time period at which the mGluR5 NAM was administered, the number 
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of administrations, or the dose given.  In Chapter IV the variable of time period at 
which mGluR5 is critical for the maintenance of CPP is further addressed.     
 
MTEP, 3-[(2-methyl-1,3-thiazol-4-ul)ethynyl]pyridine, mGluR5 NAM 
The novel mGluR5 NAM, MTEP, demonstrates increased selectivity and 
potency over MPEP (Cosford et al. 2003) (Table 1.); thus, studies included in 
Chapter IV and VI of the current dissertation project were carried out with this 
ligand.  In vitro selectivity data for MTEP demonstrate IC50 (half maximal 
inhibitory concentration) greater than 100µM for the group I subtype 1 
metabotropic glutamate receptor (mGluR1) and greater than 300µM over the 
ionotropic NMDA receptor subunit NR2B (Cosford et al. 2003).  Furthermore, 
full receptor occupancy occurs after a 10mg/kg, i.p., dose of MTEP in rat 
hippocampal brain tissue (Busse et al. 2004).    
The dose of MTEP selected to test the effects of mGluR5 blockade on the 
maintenance of Meth-induced CPP (Chapter IV) was 3mg/kg, i.p.  This dose is 
the maximal effective dose shown to reduce self-administration of Meth without 
affecting self administration of food reward (Gass et al. 2009;Osborne and Olive 
2008).  Furthermore, MTEP at 3mg/kg, i.p. reduced cue- and Meth-induced 
reinstatement of Meth self administration behavior (Gass et al. 2009).  In order 
to determine if blockade of mGluR5 could block the development of Meth-
induced motor sensitization (Chapter VI), a 5mg/kg, i.p., dose of MTEP was used.  
This dose of MTEP (5mg/kg, i.p.) was chosen since it reduces the expression of 
cocaine-induced rearing activity, a motor parameter more frequently seen to be 
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augmented by repeated Meth treatment in our laboratory, without affecting 
vertical activity in saline pre-treated rats (Dravolina et al. 2006). 
 
JNJ16259685, (3,4-dihydro-2H-pyranol[2,3]b quinolin-7-yl)(cis-4-
methoxycylohexyl)methanone, mGluR1 NAM 
 The mGluR1 NAM, JNJ16259685, is selective, systemically active, and 
highly potent drug (Table 1).  In vivo potency data reveal an ED50 (half maximal 
effective dose) equal to 0.04mg/kg, s.c. in the rat cerebellum and 0.014mg/kg, s.c 
(Lavreysen et al. 2004).  Furthermore, in vitro data demonstrate JNJ16259685 
to be a selective ligand without non-specific effects on other mGluRs up to 
concentrations of 10µM (Lavreysen et al. 2004).  A dose of 0.3mg/kg 
JNJ16259685 was used for the current dissertation project (Chapter IV) since it 
reduces self-administration of ethanol in alcohol preferring rats without effecting 
responding for sucrose reward (Besheer et al. 2008).   
 
CDPPB, 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide, mGluR5 PAM 
 The mGluR5 positive allosteric modulator, PAM, CDPPB, is shown to be 
systemically active and selective.  In vitro selectivity data for CDPPB demonstrate 
an IC50 greater than 9.7µM for other metabotropic glutamate receptors 
(mGluR17-4,8).  In vivo potency data demonstrate an EC50 (half maximal 
effective concentration) of 20nM (Lindsley et al. 2004) (Table 1). 
In order to determine if augmenting mGluR5 could enhance Meth-induced 
place preference in isolation-reared rats (Chapter VII), a 3mg/kg, s.c., dose of 
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CDPPB was used.  This dose of CDPBB (3mg/kg, s.c.) was chosen since it was 
most effective in facilitating the extinction of cocaine-induced CPP (Gass and 
Olive 2009).  Doses of CDPPB that could be rewarding on their own were also 
avoided, since this mGluR5 PAM was to be given prior to Meth conditioning in 
the CPP paradigm.  The 3mg/kg CDPPB dose had no effect on Amph-induced 
motor activity (Kinney et al. 2005).  Furthermore, a higher dose of CDPPB 
(10mg/kg, s.c.) had no effect on extracellular dopamine concentrations in the 
NAc or mPFC (Lecourtier et al. 2007).  Therefore, we felt that a dose of 3mg/kg, 
s.c. of CDPPB would selectively enhance signaling through mGluR5. 
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Table 1. mGluR ligands used for the current dissertation project.  All mGluR ligands 
used are group and sub-type selective.  Please refer to text for citations. 
 
mGluR1-4, 8 
IC50=9.7µM
mGluR5 
IC50=1.31±0.39µM, 
no activity on 
mGluR3-4,6 up to 
10µM
mGluR1 IC50>100µM
NR2B IC50>300µM
mGluR1 IC50>100µM
NR2B IC50=18µM
Selectivity
EC50=20nM
ED50=0.014mg/kg, 
s.c. (thalamus)
ED50=0.040mg/kg, 
s.c. (cerebellum)
ED50=1mg/kg, i.p.
Hippocampal brain 
concentration after 
3mg/kg = 1.4±0.2µM
ED50=2.1mg/kg, i.p.
Hippocampal brain 
concentration after 
3mg/kg = 
0.83±0.05µM
Potency
(rat receptor)
(3,4-dihydro-2H-
pyrano[2,3]b 
quinolin-7-yl)(cis-4-
methoxycylohexyl) 
methanone
JNJ16259685: mGluR1 NAM
Chemical
Name
mGluR Compound
2-methyl-6-
(pheylethynyl) 
pyridine
3-cyano-N-(1,3-
diphenyl-1H-
pyrazol-5-
yl)benzamide
CDPPB: mGluR5 PAM
3-([2-methyl-1,3-
thiazol-4-
ul)ethynyl]pyridine
MTEP: mGluR5 NAM
MPEP: mGluR5 NAM
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Figure 6.  Effects of MPEP (30mg/kg) on maintenance of Meth-
induced CPP. A)  Timeline of behavioral experiment.  Rats were given access to 
the entire test box on the pre-test (protocol day -2).  All rats were then 
administered Meth (1mg/kg, i.p.) and then placed in the chamber where they 
spent the least amount of time on the pre-test on days 1, 3, and 5.  On days 2, 4, 
and 6 rats were injected with saline (sal, 1ml/kg, i.p.) and placed in the opposite 
chamber.  Rats were given injections of saline vehicle (3ml/kg, i.p.) or MPEP 
(30mg/kg, i.p.) in their home cage on days 7 and 8.  Conditioning sessions lasted 
for 45min.  Twenty-four hours later, rats were given access to the entire CPP box 
in a drug-free state on day 9 for 30min.  A total of 24 rats were used for the 
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following comparisons.  Eight rats from the Meth/Sal group (conditioned with 
Meth and given saline on days 7 and 8) were rats used in the Meth dose response 
study that were paired on the side in which they spent the least amount of time 
on the pre-test.  The remaining 16 rats were tested in a separate behavioral run 
where 4 were added to the Meth/Sal group, and 12 were administered Meth 
during conditioning and MPEP on days 7 and 8 (Meth/MPEP group).  Rats were 
removed as outliers if time spent in any chamber on the pre-test or CPP test was 
greater than two standard deviations above or below the mean.  Both the B) 
Meth/Sal group (t(10)=5.237, p=0.0004) and the C) Meth/MPEP group 
(t(9)=3.846, p=0.004) expressed a significant preference for the Meth-paired 
chamber after conditioning (CPP Test) compared to the initial preference (Pre 
Test).  Paired t-test, **p<0.01, ***p<0.001.   
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Selection of Rodent Schizophrenia Models 
In order to investigate the converging neuropathologies of schizophrenia 
and stimulant use disorders, we chose to use pharmacological and developmental 
models of schizophrenia that both exhibit deficits in sensorimotor gating of the 
acoustic startle response measured by PPI.  Deficits in PPI are a well-established 
behavioral outcome that occurs in schizophrenia patients (Braff et al. 2001) and 
are easily assessed with high construct validity.   Deficits in PPI are induced by 
Amph administration in both humans and rodents (Swerdlow et al. 2003).   
Recently, two separate laboratories have published repeated, escalating 
treatment courses of Amph administration that produce robust deficits in PPI 
that chronically persist (Peleg-Raibstein et al. 2008;Tenn et al. 2005).  This was 
an important outcome measure, as behavioral assessments of reward were 
designed to follow and emulate a co-morbid schizophrenia and stimulant 
addiction brain state.  The study conducted by Tenn and colleagues demonstrates 
that PCP does not produce persistent PPI deficits, which ruled out its use in our 
behavioral paradigm (Tenn et al. 2005).  The Amph treatment course employed 
by Peleg-Raibstein was utilized in Chapter VII since it allowed for rapid induction 
(six days as opposed to three weeks as in the Tenn et al. 2005 study) of an 
enduring brain state that is biochemically similar to that of the schizophrenia 
neuropathology as described in the Literature Review (Chapter II)(Peleg-
Raibstein et al. 2008).   However, because the use of two such similar stimulants 
to model separate behavioral outcomes presents itself as a potential confound, we 
chose to validate our results obtained from the repeated Amph treatment 
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paradigm with the use of a developmental rodent model of schizophrenia.  The 
early stressor of maternal separation and isolation rearing following weaning is 
another means of inducing PPI deficits in rodents (Geyer et al. 1993).  Unlike the 
neonatal ventral hippocampal lesion model, isolation rearing is easily executed 
and does not employ additional surgical techniques.  In summary, repeated 
escalating Amph and isolation rearing are two behavioral models of 
schizophrenia with high construct validity that allow for sensorimotor gating 
assessments in a chronic treatment paradigm. 
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CHAPTER  IV 
mGluR5 BUT NOT mGluR1 IS NECESSARY FOR MAINTENANCE OF 
METHAMPHETAMINE-INDUCED ASSOCIATIVE LEARNING 
 
Abstract 
Conditioned place preference (CPP) reflects the significance of contextual 
cues that are repeatedly associated with rewarding effects of abused drugs like 
methamphetamine (Meth).  Glutamate neurotransmission is augmented in 
response to exposure to stimulants and cues associated with their use.  Activation 
of group I metabotropic glutamate receptors (mGluR) is critical for the 
acquisition and expression of behavioral tasks mediated by stimulants.  We 
hypothesized that the maintenance of Meth-induced behaviors would also 
require activated mGluR, and that the role of mGluR1 versus mGluR5 may differ.  
Negative allosteric modulators (NAMs) of these receptors were evaluated, since 
this class of drugs have the advantage of acting only on agonist- (i.e., glutamate) 
occupied receptors and thus provide a more targeted action.  Conditioning with 
Meth every other day for six days resulted in significant preference for the Meth-
paired compartment.   
 
55 
 
Two daily injections of the mGluR1 NAM, JNJ16259685 (0.3mg/kg, i.p.) or its 
vehicle on days 13 and 14 after Meth-conditioning did not influence the 
maintenance of Meth-induced CPP; however, administration of the mGluR5 
NAMs MTEP (3mg/kg, i.p.) and MPEP (30mg/kg, i.p.) inhibited maintenance 
processes necessary for CPP to be expressed.  These findings demonstrate a 
subtype-specific role of mGluR5 receptors in the maintenance of place preference 
memory and potential of mGluR5 NAMs as a useful target for addiction therapy. 
 
Introduction 
Methamphetamine (Meth) addiction is a problem of global health concern 
for which there is no FDA-approved pharmacotherapy (Elkashef et al. 2008).  
Even after protracted abstinence, Meth-addicted individuals are prone to cue-
elicited relapse (Hartz et al. 2001).  One aspect of addiction that makes it such a 
persistent phenomenon is the strength of learned associations between the 
rewarding effects of drugs and the context in which drugs are administered 
(O'Brien et al. 1992).  Drug-induced associative learning can be studied in 
rodents and humans using conditioned place preference (CPP) (Childs and deWit 
H. 2009;Tzschentke 2007).   
Withdrawal from stimulant treatment results in dynamic changes within 
the cortico-striatal glutamate transmitter system.  At early time points after 
stimulant administration, small transient changes in glutamate receptor proteins 
occur, perhaps as a compensatory response to drug-induced glutamate 
transmitter levels in brain regions such as the nucleus accumbens (NAc) and 
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medial prefrontal cortex (mPFC) (Ghasemzadeh et al. 2009a;Ghasemzadeh et al. 
2009b;Shaffer et al. 2010;Shoblock et al. 2003).  During extended withdrawal 
from long-term cocaine abuse, the frontal cortex of humans is hypoactive (Bolla 
et al. 2004;Goldstein and Volkow 2002).  In rats withdrawal from repeated 
stimulant exposure reduces glutamate levels in NAc and mPFC (Baker et al. 
2003;Lominac and Szumlinski 2008), and ionotropic and metabotropic 
glutamate receptors are increased in these brain regions (Ary and Szumlinski 
2007;Boudreau and Wolf 2005;Ghasemzadeh et al. 2009a;Ghasemzadeh et al. 
2009b).  After an extended withdrawal in human stimulant abusers, the FC 
becomes hyper-responsive to drug-associated cues (Childress et al. 1999;Grant et 
al. 1996).  In stimulant-withdrawn rodents, re-exposure to drug or drug-
associated cues increases limbic glutamate levels beyond that seen in rats without 
a stimulant treatment history (Chen et al. 2001;Pierce et al. 1996;Qi et al. 2009).  
Drug cues hinder abstinence in addiction; therefore, there should be great 
therapeutic value in normalizing the glutamatergic responses to drug-associated 
cues.  
Glutamate acts on both ionotropic and metabotropic receptors.  Group I 
mGluRs include both metabotropic glutamate receptor subtype 1 (mGluR1) and 5 
(mGluR5), which are located primarily post-synaptically (Conn and Pin 1997).  
Because of the localization of group I mGluRs within the brain systems important 
for stimulant-mediated behavior, negative allosteric modulators (NAMs) of 
mGluR1 and 5 may provide an important avenue to normalize the hyper-
responsive glutamate system after repeated stimulant administration (Lu et al. 
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1999;Romano et al. 1995;Testa et al. 1994a).  Binding to sites that are remote 
from the orthostatic position, allosteric modulators alter the efficacy of 
endogenous agonists (Pin et al. 2003;Wang et al. 2009).  Allosteric modulators 
also avoid many of the unwanted side effects that can occur with direct acting 
agonists/antagonists, where compensatory effects and widespread action are 
prevalent (Wang et al. 2009).  Group I mGluR NAMs have recently been used in 
rodent models of addiction (Carroll 2008;Olive 2009).   The mGluR5 NAM 3-[(2-
methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) decreases self-administration 
of Meth, as well as cue- and Meth-primed reinstatement of Meth self-
administration (Gass et al. 2009;Osborne and Olive 2008).  Likewise, the related 
NAM, 2-methyl-6-(phenylethynyl)-pyridine (MPEP), reduces the development 
and expression of Meth- and amphetamine-induced associative learning, 
respectively (Herzig et al. 2005;Miyatake et al. 2005).  The mGluR1 NAM, 
JNJ16259685, decreases ethanol self-administration (Besheer et al. 2008), and 
another mGluR1 NAM, EMQMCM, reduces cocaine-induced motor activity 
(Dravolina et al. 2006) as well as cue- and drug-induced reinstatement of 
nicotine self administration in rodents (Dravolina et al. 2007).  While negative 
modulation of mGluR1 and mGluR5 decreases reward-mediated behaviors, 
evidence suggests that these receptor subtypes may play different roles in 
acquisition, consolidation and retention of memory (Salinska 2006;Simonyi et al. 
2007;Steckler et al. 2005).  For example, the mGluR1 receptor is important for 
the acquisition, while the mGluR5 receptor may be more critical for the retention, 
of spatial memories (Steckler et al. 2005).  What remains unknown is the role of 
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these receptors, and potential subtype-specific effects, in the maintenance of 
stimulant-associated memories. 
The maintenance of drug memories underlies relapse; therefore, a better 
understanding of the role of group I mGluRs in this relationship may aid relapse 
reduction.  We hypothesize that post-conditioning administration of mGluR5 
NAMs will disrupt the Meth – context memory association and thus decrease the 
subsequent expression of Meth-induced CPP.  We chose to administer 
therapeutic interventions at 13 and 14 days post-conditioning, a time frame when 
extracellular limbic glutamate is increased (Chen et al. 2001), and our lab has 
shown neuronal changes subsequent to repeated Meth administration (McDaid 
et al. 2006b), and when there is evidence of persistent up-regulation in glutamate 
receptors (Ghasemzadeh et al. 2009a;Ghasemzadeh et al. 2009b).  Comparison 
of the mGluR1 and mGluR5 NAMs will allow us to differentiate between the 
involvements of the mGluR subtypes in this Meth-mediated behavior.   
 
Materials and Methods 
Animals 
  Eighty male, 225-250g, Sprague-Dawley rats were used.  Rats were treated 
in accordance with NIH Guide for the care and use of laboratory animals and the 
Rush University Institutional Animal Care and Use Committee.  Rats were 
allowed to habituate to the environmentally controlled vivarium (23-25ºC; 
7:00AM/7:00PM light dark cycle) at least one week prior to the start of 
59 
 
behavioral testing and given food and water ad libitum.  All studies were 
conducted during the light phase. 
Drugs 
(+)Methamphetamine hydrochloride (Meth, Sigma-Aldrich, St. Louis, 
MO) in 0.9% NaCl sterile saline was given at a dose of 1mg/kg as the base.  Our 
lab and others have used this dose to successfully induce Meth CPP in rats 
(Herrold et al. 2009;Kitanaka et al. 2010;Li et al. 2002;Schindler et al. 2002).  
The mGluR1 NAM, JNJ16259685 (Tocris Bioscience, Ellisville, MO) was 
administered at a dose of 0.3mg/kg, which reduces ethanol self-administration 
without reducing natural rewards (Besheer et al. 2008).  The mGluR5 NAM, 3-
[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP, Tocris Bioscience) was 
administered at a dose of 3mg/kg, which reduces Meth self-administration 
(Osborne and Olive 2008) as well as cue- and drug-induced reinstatement of 
Meth self-administration (Gass et al. 2009).  The mGluR5 NAM 2-methyl-6-
(phenyl-ethynyl)-pyridine (MPEP; a gift from Novartis Institutes for BioMedical 
Research; Basel, Switzerland) was administered at a dose of 30mg/kg, which 
reduces the development and expression of morphine-induced CPP (Herzig and 
Schmidt 2004).  All NAMs were dissolved in 10% w/v (2-hydroxypropyl)-γ-
cyclodextrin in sterile water solution (termed vehicle, Sigma-Aldrich).  All drugs 
and their vehicles were given via intraperitoneal (i.p.) injection in a volume of 
1ml/kg. 
 Conditioned Place Preference (CPP) 
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CPP boxes (Accuscan Instruments, Inc., Columbus, OH) used for the study 
are described in a previous publication from our laboratory (Shen et al. 2006).  
Rats were transported to the behavioral testing room at least 30min prior to 
experimentation.  Timeline of the behavioral paradigm is illustrated in Fig. 7A.  
All rats were given a pretest that demonstrated no significant group preferences 
for either chamber.  Some individual rats tended to prefer one chamber over the 
other; thus, rats were paired with Meth in the chamber in which they spent the 
least amount of time during the pretest.  Rats were treated with Meth on days 1, 3 
and 5, and saline on days 2, 4 and 6 and then immediately placed in the 
appropriate chamber for 45min.  On day 9, untreated rats were tested for 
chamber preference (CPP Test 1) by giving them free access to the entire box for 
30min.  Following the procedures employed by Paolone and colleagues (Paolone 
et al. 2009), if the difference between pretest and CPP Test 1 was at least a 10% 
(>180s), the rats were used for assessing the effects NAMs.  This helped assure a 
sufficient ‘signal’ was used to ascertain the antagonism capacity of mGluR1/5 
NAMs (54 out of 80 rats met this criterion).  On days 10-17, all rats were given 
once daily vehicle (1ml/kg) injections in their home cage.  On days 18 and 19, rats 
were given in their home cage a once-daily injection of either vehicle (1ml/kg), 
JNJ16259685 (0.3mg/kg), MTEP (3mg/kg), or MPEP (30mg/kg).  On day 22, 
rats were tested for preference and motor activity was assessed (CPP Test 2) as 
described previously for CPP Test 1 in a drug-free state.   
Statistics 
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Differences in time spent per chamber between pretest and CPP Test 1 was 
determined via a paired t-test.  Preference was determined based on a significant 
increase in amount of time spent on the Meth- vs. saline-paired chamber on CPP 
Test 1 and 2 via a two- way repeated measure (rm) ANOVA with post hoc 
Newman Keuls test with  α=0.05 for all tests.  Statistical outliers for a given 
measure were removed if data fell outside 2 standard deviations from the mean.  
Data are represented as the mean + standard error of the mean (SEM). 
 
Results 
The time spent in the two large chambers was not different during the 
pretest for all rats tested (846.3±42.9sec vs. 813.1±42.6sec; t(79)=0.391, p=0.697, 
N=80).  Three days after conditioning, rats demonstrated a robust preference for 
the Meth- (930.3±32.0sec) vs. the saline-paired chamber (694.1±31.6sec, 
t(79)=3.732, p<0.001, n=80) as a whole.  Rats that showed more than a 10% 
change in preference on the pretest vs. CPP Test 1 (n=47), spent 1097.7±28.4sec 
in the Meth-paired chamber and 539.7±28.2sec in the saline-paired chamber 
during CPP Test 1 (t(46)=9.913, p<0.001).  Thus, the culling procedure does not 
drastically alter behavioral outcomes. 
Rats given post-conditioning vehicle (Fig. 7B, n=11) or JNJ16259685 (Fig. 
7C, n=12) spent significantly more time in the Meth- vs. saline-paired chamber 
on both CPP Test 1 and 2 (two-way rmANOVA with post hoc Newman Keuls, 
p<0.01).  Thus, the conditioning protocol induced place preference that persisted 
for at least 16 days and was not diminished by repeated testing or post-
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conditioning injections of vehicle or the mGluR1 NAM.  However, rats treated on 
days 18 and 19 with the mGluR5 NAMs, MTEP (Fig. 7D, n=15) or MPEP (Fig. 7E, 
n=9), failed to maintain a preference for the Meth-paired chamber on CPP Test 2 
(two-way rmANOVA with post hoc Newman Keuls, p>0.05).  There were no 
between group differences on CPP Test 2 in horizontal beam breaks (vehicle 
3814±27, JNJ16259685 3250±22, MTEP 3640±24, and MPEP 3086±29; 
F(3)=1.601, p=0.203) or vertical beam breaks (vehicle 693±82, JNJ16259685 
607±61, MTEP 547+38, MPEP 523+74; F(3)=1.394, p=0.257).  These data 
indicate that mGluR1/5 NAM treatment history did not affect spontaneous motor 
activity on the subsequent CPP test day. 
 
Discussion  
Previous studies have implicated the mGluR1 and 5 in drug-mediated 
behaviors, but none to-date have determined the role of these receptors in the 
maintenance of stimulant-associated contextual memories.  Acquisition of spatial 
learning is impaired by administration of JNJ16259685 prior to training on the 
Morris water maze (Steckler et al. 2005).  Yet, mGluR1 NAM treatment after 
training on the Morris water maze only partially impairs performance on a 
subsequent test of spatial memory retention (Steckler et al. 2005).  Retention of 
passive avoidance learning is also spared following mGluR1 NAM treatment 
(Gravius et al. 2005).  Though mGluR1 is important for drug reinforcement 
behaviors, it may not be as critical for the maintenance of spatial memories which 
play a role in CPP behavior.  The current study provided the first evaluation of 
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mGluR1 NAMs on previously acquired drug-context associations induced by 
repeated Meth administration.  In this paradigm, the mGluR1 NAM 
JNJ16259685 did not alter subsequent expression of place preference.  This 
outcome may reflect the delayed post-conditioning time of the NAM 
administration, and it is possible that its administration sooner after place 
conditioning might result in a disruption of the drug-context association.  
Supporting this possibility, mGluR1 NAM administration 3 days after repeated 
cocaine blunted the expression of cocaine-induced motor sensitization (Dravolina 
et al. 2006).  Future studies with chronic or early post-conditioning treatment of 
JNJ16259685 would further elucidate the involvement of mGluR1 system in 
maintenance of Meth-associated memories.  
Our results suggest that activation of mGluR5 at 13-14 days post-
conditioning is necessary for the maintenance of Meth-induced CPP, since rats 
that were treated with the mGluR5 NAMs MTEP or MPEP failed to demonstrate 
preference for the Meth-paired context.  The use of two mGluR5 NAMs, MTEP 
and MPEP, (as well as the comparison to the mGluR1 NAM, JNJ16259685) 
strongly imply that this is an mGluR5-specific phenomenon.  The post-
conditioning time of mGluR5 modulation may also be important, since pilot data 
from our lab suggest that an early post-conditioning administration (2 and 3 days 
after Meth injection) of MPEP does not alter subsequent expression of Meth-
induced CPP (i.e., CPP remained statistically significant (t(11)=3.292, p=0.007) 
when tested one day after two daily home cage injections of MPEP (30mg/kg, 
i.p.)).  In Meth self-administering rats that have undergone extinction training, 
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MTEP pre-treatment reduces cue-induced reinstatement (Gass et al. 2009).  
Thus, mGluR5 appear to be important for several aspects of Meth reward-
mediated behaviors (CPP and self administration) as well as multiple phases of 
Meth-induced associative learning (expression and maintenance).    
Since NAMs act on agonist-bound receptors, results from the current 
study indicate the importance of glutamate acting on mGluR5 receptors two 
weeks after acquisition of CPP to sustain the conditioned Meth memory.  
Therefore, brain regions that highly express mGluR5, such as the NAc, may be 
key mediators in this behavioral phenomenon (Testa et al. 1994a).  Though the 
literature on glutamate transmitter effects subsequent to Meth administration is 
limited, increases in NAc glutamate have been shown to occur 3 weeks after 
repeated Meth (Lominac and Szumlinski 2008).  Another possibility is that areas 
of modest mGluR5 expression, such as the VP, may be characterized by excessive 
glutamate release following Meth conditioning, resulting in a proportionally large 
number of agonist-occupied mGluR5.  For example, following 14 days after 
repeated amphetamine, increases in glutamate occur to an acute challenge of the 
drug in the VP (Chen et al. 2001).  Our laboratory has shown that withdrawal 
from repeated treatment of cocaine results in enhanced response of VP neurons 
to glutamate (McDaid et al. 2005) and an up-regulation of mGluR5 in the VP 
following 14 days of withdrawal from Meth (unpublished results).  The current 
study suggests that adaptations in the mGluR5 system occurred approximately 
two weeks after the acquisition of Meth-induced associative learning. 
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Cue-elicited relapse is a significant obstacle to abstinence for Meth addicts 
(Hartz et al. 2001); thus, a pharmacotherapy that can inhibit the maintenance of 
associative processes should aide in reducing cue evoked drug-seeking.  This 
study has identified a critical time-frame at which negative modulation of 
mGluR5 receptors is sufficient to disrupt the maintenance of Meth-induced 
context associations.  These novel findings add to current understanding of the 
neurobiological underpinnings of Meth associated memories and indicate that 
mGluR5 NAMs deserve further exploration as potential pharmacotherapy for the 
Meth-withdrawn human addict. 
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Figure 7.  The mGluR5 NAMs MTEP and MPEP, but not the mGluR1 
NAM JNJ1625985, inhibit the expression of Meth-CPP.  A)  Timeline 
of treatment and testing.  Rats were pre-tested for initial bias on day -2 and 
subsequently paired with Meth (1mg/kg, i.p.) on days 1, 3, and 5 and saline 
(1ml/kg, i.p.) on days 2, 4, and 6 for 45min.  Chamber preference was assessed on 
day 9, (CPP Test 1), in a drug-free state in order to verify that the preference 
developed.  On days 18 and 19, rats were given either vehicle (1ml/kg), 
JNJ1625985 (0.3mg/kg), MTEP (3mg/kg), or MPEP (30mg/kg).  Rats were 
tested for preference three days later (protocol day 22, CPP Test 2) in a drug-free 
state.  B) Rats treated with vehicle (n=11) demonstrated a significant difference 
in amount of time spent in the Meth- vs. saline-paired chamber during CPP Test 
1 and 2 (significant main effect of chamber F(1,20)=23.075, p=0.0001, a non-
significant main effect of test F(1,20)=0.054, p=0.818, and a significant chamber-
test interaction F(1,20)=9.099, p=0.007). C) Likewise, rats treated with the 
mGluR1 NAM JNJ1625985 (n=12) spent more time in the Meth- compared to the 
saline-paired chamber on CPP Tests 1 and 2 (a significant main effect of chamber 
F(1,22)=95.531, p<0.0001, a non-significant main effect of test F(1,22)=0.0002, 
p=0.987, and a non-significant chamber-test interaction F(1,22)=0.911, p=0.350).  
In contrast to these effects, administration of mGluR5 NAMs disrupted the 
maintenance of Meth-induced CPP.  D) Rats treated with the mGluR5 NAM 
MTEP (n=15) demonstrated a significant preference for the Meth-paired 
chamber during CPP Test 1 but the preference was not observed during CPP Test 
2 (a significant main effect of chamber F(1,28)=14.686, p=0.001, a non-significant 
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main effect of test F(1,28)=0.088, p=0.769, and a significant chamber-test 
interaction F(1,28)=7.048, p=0.013).  E) Likewise, rats treated with MPEP (n=9) 
did not maintain the significant preference for the Meth-paired chamber 
observed during CPP Test 1 after the day 17 & 18 intervening NAM treatments (a 
significant main effect of chamber F(1,16)=22.785, p=0.0002, a non-significant 
main effect of test F(1,16)=0.024, p=0.879, and a significant chamber-test 
interaction F(1,16)=14.930, p=0.001).  CPP data are represented as time spent in 
the Meth-paired chamber (black solid square with solid black line), saline-paired 
chamber (white square with dotted black line), or center chamber (black solid 
triangle with solid black line, not included in statistics but illustrated for 
qualitative purposes) on CPP Test 1 (left set of data points / column labeled under 
graph) and CPP Test 2 (right set of data points / column labeled under graph).  
Data points represent the mean + SEM.  Repeated measure ANOVA with post-
hoc Newman Keuls test for multiple comparisons, **p<0.01 
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CHAPTER V 
NOVEL SURFACE EXPRESSION TECHNIQUES FOR ex vivo 
ASSESSMENT OF METABOTROPIC RECEPTORS IN THE 
MAMMALIAN BRAIN: UTILITY IN MEASURING mGlu5 
RECEPTORS AFTER METHAMPHETAMINE- 
INDUCED ASSOCIATIVE LEARNING 
 
Abstract 
 
Altered expression of receptors and their distribution between the cell 
membrane surface and the cytoplasm is a means by which psychomotor 
stimulants alter neuronal transmission.  Indeed, ionotropic glutamate receptor 
distribution is altered in cocaine-sensitized rats, and such changes may 
contribute to the neuropathology of addictive behaviors.  However, stimulant-
induced effects on intracellular distribution of metabotropic receptors are not 
well known.  The current study fills this gap by adapting the 
bis(sulfosuccinimidyl)suberate (BS3) cross-linking technique, which has been 
successfully employed to measure changes in ionotropic receptor distribution, to 
assess surface and intracellular components of metabotropic glutamate for the 
first time.  Metabotropic glutamate receptor subtype 5 (mGluR5) is involved in 
the behavioral effects of stimulants; including conditioned place preference and 
motor sensitization.   
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The current report evaluated if mGluR5 sub-cellular distribution is regulated in 
the limbic brain regions of rats conditioned with methamphetamine (Meth).  
Repeated Meth conditioning (1mg/kg) resulted in a significant preference for the 
Meth-paired context as well as a sensitized motor response.  The medial 
prefrontal cortex (mPFC), nucleus accumbens (NAc) and ventral pallidum (VP) 
were subsequently assayed for changes in receptor distribution.  Meth-
conditioned rats demonstrated a significant decrease in the surface to 
intracellular ratio of mGluR5 in the mPFC, but not the NAc or the VP.  This study 
demonstrates the utility of the BS3 cross-linking technique to generate an ex vivo 
snapshot of metabotropic glutamate receptor systems after repeated stimulant 
administration. 
 
Introduction 
 
Receptors located at the neuronal surface serve as targets for 
extracellularly released neurotransmitters.  Internalization renders the receptors 
unavailable to these transmitters, and this is an important means to regulate 
neurotransmission.  Understanding stimulant-induced changes in receptor 
distribution may provide insight into neuropathology of stimulant abuse.  
Ionotropic glutamate receptor subunit surface and intracellular expression can be 
detected ex vivo using the membrane impermeable cross-linking reagent 
bis(sulfosuccinimidyl)suberate (BS3).  This technique, pioneered by Boudreau 
and Wolf (Boudreau and Wolf 2005), was utilized to define the role of AMPA 
receptor subunit surface expression in the synaptic plasticity that occurs 
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subsequent to repeated cocaine (Boudreau et al. 2007;Boudreau et al. 
2009;Ferrario et al. 2010) or amphetamine (Nelson et al, 2009) administration.  
Metabotropic receptors provide an important means to fine tune excitatory 
ionotropic transmission and thus likely regulate the maladaptations that occur 
after repeated stimulant administration.  
The behavioral role of these metabotropic receptors has been a topic of 
great interest, and selective ligands have been used in various rodent models, 
including conditioned place preference (CPP) and motor sensitization.  CPP is a 
well-established method of measuring the rewarding attributes of abused drugs 
by assessing the preference for environmental contextual cues previously 
associated with drug administration (Childs and deWit H. 2009;Tzschentke 
1998;Tzschentke 2007).  Motor sensitization is the augmentation in motor 
activity that occurs with repeated administration of a drug, and the brain 
adaptations associated with this simple behavioral readout may model some of 
the brain adaptations that occur in the human stimulant abuser (Robinson and 
Berridge 1993;Stewart and Badiani 1993).  Metabotropic glutamate receptors are 
critical for stimulant-mediated reward (Carroll 2008;Kenny and Markou 
2004;Olive 2009;Xi and Gardner 2008) as well as learning and memory 
processes (Anwyl 1999;Conn and Pin 1997).  Specifically, group I subtype 5 
metabotropic glutamate receptors (mGluR5), are necessary for the development 
of Meth- (Miyatake et al. 2005) and expression of amphetamine-induced 
associative learning (Herzig et al. 2005).  These findings underscore that mGluR5 
represent a receptor system engaged during stimulant-induced behaviors, and 
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thus it was selected for our assessments of surface expression following Meth-
induced CPP and/or motor sensitization. 
Trafficking of mGlu5 receptors is a dynamic process, and a variety of in 
vitro methods have been used to detect surface expression of mGluR5 (Ango et 
al. 2002;Kumpost et al. 2008;Lee et al. 2008).  However, none of these methods 
allow for the resolution of both surface and intracellular components of 
metabotropic receptors within the same sample nor had the methods been 
adapted for ex vivo tissue samples.  These are important assay attributes for 
understanding changes imposed by behaviorally relevant treatments of Meth, as 
well as for future evaluations of the potential of these receptor systems as targets 
for anti-addiction pharmacotherapies.  To fill this gap, we modified the Boudreau 
and Wolf assay developed for AMPA receptors (Boudreau and Wolf 2005) to 
provide assessments of metabotropic glutamate receptors.  With this assay, the 
membrane impermeable cross-linking agent, BS3, binds to extracellular basic 
residues (via an amide bond) of proteins inserted into the membrane, resulting 
in a high molecular weight aggregate that is easily differentiated from the 
intracellular protein by using an antibody for protein detection targeted to the 
carboxy-terminal region of the receptor (Mattson et al. 1993).  This high 
molecular weight aggregate makes up the surface component, and the 
intracellular component is resolved at the normal molecular weight for the 
protein of interest within the same lane of the SDS-PAGE gel.  The mGluR5 are 
well suited for this assay since they are part of the group C G-protein coupled 
receptor family characterized by a large extracellular, amino-terminal domain 
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where there are many basic amino acids to which the BS3 agent can bind 
(Hermans and Challiss 2001;Pin et al. 2003).  This assay is also efficient, since 
ample signal detection is attained without pooling brain tissue samples from 
multiple animals.  These features make this assay ideal for a high through-put, 
rapid determination of metabotropic receptor distribution that may occur with 
stimulant reward-mediated behaviors.   
The goals of this study were two fold:  First, was to adapt the BS3 cross-
linking technique to resolve surface versus intracellular pools of mGluR5 within 
the same ex vivo tissue sample.  Second, was to apply this assay to test the 
hypothesis that changes in these receptors would occur in brain regions 
important for reward and memory taken from rats that exhibit Meth-induced 
CPP and/or motor sensitization.   
 
Materials and Methods 
Animals 
A total of 32 male Sprague-Dawley rats weighing between 250-275g at the 
start of experimentation were used.  Rats were acclimated to handling procedures 
and to the housing vivarium (Rush University Medical Center, accredited 
through the Association for Assessment and Accreditation of Laboratory Animal 
Care) for at least one week prior to the start of behavioral testing.  The vivarium 
was maintained at 23-25°C temperature on a 12hour light cycle (7AM lights on: 
7PM lights off) and rats had ad libitum access to food and water.  
Experimentation took place during the light cycle of the rats.  During this time, 
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rats have been shown to produce the most robust CPP performance to 
amphetamine (Webb et al. 2009).  All procedures were approved by the Rush 
University Institutional Animal Care and Use Committee and were carried out in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals (National Research Council, 1996).   
Drugs 
 (+)Methamphetamine hydrochloride (Meth; Sigma-Aldrich, St. Louis, 
MO) was administered at a dose of 1mg/kg as the base in a 0.9% sterile saline 
solution.  Meth or its vehicle was administered intraperitoneally (i.p.) in a volume 
of 1ml/kg. 
Test Apparatus 
Conditioned place preference (CPP) and motor behaviors were quantified in 
activity boxes that consisted of two large conditioning chambers (25cm x 30cm x 
30cm) and a small center chamber (13cm x 30cm x 30cm) (Accuscan 
Instruments, Inc., Columbus, OH).  Behavior in each chamber was measured via 
two banks of photo-beams (24 horizontal and 12 vertical) so as to measure the rats’ 
motor movements in three dimensional space.   Beam counts were analyzed with 
Versamax analyzer and software (Accuscan Instruments, Inc., Columbus, OH).  
The two large conditioning chambers each had distinct visual (horizontal vs. 
vertical stripes) and tactile (textured floor) cues.  One chamber had vertical 
stripes on the walls and a randomly patterned floor with an overturned paint dish 
glued in the center (termed Chamber A); the other chamber (i.e., Chamber B) had 
horizontal stripes on the walls with a square patterned floor and a flat, 
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rectangular piece of Plexiglas glued in the center; center chamber had solid color 
walls with a flat, smooth floor. The chambers were separated from each other by 
removable Plexiglas doors.   
 
Conditioned Place Preference Procedure 
Rats were transported from the vivarium to the behavioral testing room for 
habituation at least 30min prior to experimentation.  The testing room was dimly 
lit with white noise continuously present (White noise generator, San Diego 
Instruments, San Diego, CA).  The behavioral paradigm consisted of three 
phases: pre-test, conditioning, and CPP test (Fig. 8A).  For the pre-test, rats were 
placed in the center chamber; and doors were immediately removed to allow 
access to the entire CPP box for 15min (900s).  Time spent in Chamber A was 
348±26s and time spent in Chamber B equaled 459±24s.  As time spent in the 
two conditioning chambers differed (t(31)=2.215, p=0.0343), treatment 
assignments were counterbalanced as follows: half the rats were assigned to 
receive Meth or saline (day 1) in the chamber in which they spent the greatest 
amount of time during the pre-test and the other half were assigned to received 
Meth or saline (day 1) in the chamber in which they spent the least amount of 
time during the pre-test.  Rats were assigned to one of two treatment groups: 
Meth-conditioned (n=16; Meth administered on days 1, 3, & 5 and saline 
administered on days 2, 4, & 6) or saline-conditioned (n=16; saline administered 
on days 1-6).  During conditioning (protocol days 1-5, Fig. 8A), rats received the 
appropriate injection (Meth 1mg/kg or saline 1ml/kg) and were immediately 
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placed into the appropriate chamber of the CPP box for 45min.  Motor activity 
was assessed throughout the session.  To test for the expression of the preference 
(i.e., CPP test on day 9), drug-free rats were placed in the center chamber; and 
doors were immediately removed to allow access to the entire CPP box for 15min.  
Time spent as well as motor activity in each chamber was determined.  
Tissue Preparation and Immunoblotting 
Rats were decapitated without anesthesia, and mPFC, VP, and NAc tissues 
(Fig. 10) were harvested within approximately 4min of decapitation one day after 
the CPP test.  The tissue preparation and surface receptor cross-linking 
methodology was adapted from that of Boudreau and Wolf (Boudreau and Wolf 
2005).  After being dissected, each brain region was chopped into 400µm slices 
with a McIlwain tissue chopper (Mickle Laboratory Engineering Co. LTD, Goose 
Green, UK) and immediately placed into artificial cerebrospinal fluid (aCSF) with 
2mM Bis(sulfosuccinimidyl)suberate (BS3; Thermo Scientific, Rockford, IL).  The 
cross-linking reaction took place for 30min with gentle agitation at 4°C; 
administration of 100mM glycine terminated the cross-linking reaction (10min at 
4°C).  The supernatant was separated from the tissue pellet by centrifugation at 
14000rpm for 2min (4oC), and the supernatant was removed and the tissue pellet 
was re-suspended in lysis buffer (25mM HEPES, 500mM NaCl, 2mM EDTA, 
20mM NaF, 0.1% Nonidet P-40 (v/v), 1mM DTT, 1mM PMSF, 1 x protease 
inhibitor cocktail (Calbiochem, La Jolla, CA), phosphatase inhibitor cocktail I 
(Sigma-Aldrich) and phosphatase inhibitor cocktail II (Sigma-Aldrich).  To 
disrupt the cellular membrane, tissues were sonicated and subsequently 
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aliquoted and frozen at -80°C for future use.  Tissue homogenate samples were 
prepared with in 1:1 dilution of Laemmli sample buffer (Bio-Rad, Hercules, CA) 
with β-mercaptoethanol.   
For control experiments (Fig. 11), two separate saline treated rats of the same 
weight from a separate pilot study were prepared without cross-linking (Non-
Xlink).  Brain regions (Fig. 10) were hand dissected and immediately fast-frozen 
on dry ice then kept at -80°C until tissue preparation.  For tissue preparation, 
brain regions were Dounce homogenized and sonicated in lysis buffer (25mM 
HEPES, 1mM EGTA, 1mM EDTA, 100nM okadaic acid, 1mM sodium 
orthovanadate, 100uM PMSF, 10µg/ml of pepstatin, leupeptin & aprotinin in 
cocktail form).  Protein concentrations were determined via the Bradford method 
(Bradford 1976) and samples were prepared with sample buffer (NuPAGE LDS 
Sample Buffer, Invitrogen, Carlsbad, CA) and reducing agent (NuPAGE Sample 
Reducing Agent, Invitrogen), aliquoted and frozen until use at -80°C.    
To allow for immunoblotting, protein samples (20µg) were loaded into 4-
15% Tris-HCl gradient gels (Bio-Rad) and electrophoresed at 200V for 45min.  
The gels were then transferred to a Hy-Bond PVDF membrane (GE Healthcare 
Limited, Buckinghamshire, UK) for 1.5hr at a current of 1.25A.  Nonspecific 
binding was blocked by incubation of the membrane with TBST (0.05% Tween 
20, Sigma-Aldrich), 1% normal goat serum, and 5% non-fat dry milk for at least 
1hr.  Membranes were then incubated with mGluR5 (1:15,000 in TBS; Upstate, 
Temecula, CA), or actin (1:20,000 in TBST and 5% non-fat dry milk, Santa Cruz 
Biotechnology, Inc.) overnight at 4°C.  Membranes were washed repeatedly with 
78 
 
78 
 
TBST and then incubated with the appropriate HRP-conjugated secondary 
antibody for mGluR5 (goat anti-rabbit 1:15,000 in TBST; Jackson 
ImmunoResearch, West Grove, PA) and actin (goat anti-rabbit 1:20,000 in TBST 
and 5% non-fat dry milk; Santa Cruz Biotechnology, Inc.).  Membranes were 
subsequently washed with TBST, TBS, and distilled water.   
Chemiluminescent substrate (SuperSignal West Pico, Thermo Scientific, 
Rockford, IL) was applied to the membrane to visualize the protein of interest on 
autoradiography film (HyBlot CL, Denville Scientific, Inc., Metuchen, JN).  
Optical density was determined via densitometric analysis with Un-Scan-It 
Software (Silk Software,Inc., Orem, Utah).   
To detect protein levels of Homer1b/c and actin (loading control), the Snap 
I.D. system (Millipore, Billerica, MA) was used for antibody incubation and 
washing.  After samples were electrophoresed on 10% acrylamide Tris gels and 
transferred onto PVDF membranes as stated above, membranes were blocked for 
nonspecific binding with filtered 0.5% non-fat dry milk in TBS-T (0.1% Tween-
20) then vacuumed through the Snap I.D.  Primary antibody for mGluR5 
(0.5µl/ml; Upstate), Homer 1b/c (2.67µl/ml; Millipore) or actin (0.33 µl/ml, 
Santa Cruz Biotechnology) was then applied and incubated on the membranes for 
10min and subsequently vacuumed through the Snap I.D. system.  Membranes 
were incubated with the appropriate HRP-conjugated IgG secondary antibody: 
goat anti-rabbit (actin 0.33µl/ml; Jackson) and rabbit anti-rat (Homer1b/c 
1.33µl/ml, Millipore).  After vacuuming through the secondary antibody, 
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membranes were washed and exposed to chemilumenescent substrate as 
described above.    
For pre-absorption assays, immunoblotting was conducted as stated above.  
The PVDF membrane was cut in half and antibody plus the blocking peptide 
(pre-incubated for 1hr at room temperature) was applied to half the other half 
was processed as described previously; membranes were incubated overnight at 
4°C.  The mGluR5 synthetic blocking peptide (1:500 in 1xTBS; Neuromics 
Antibodies, Edina, MN) used was specific to the epitope of the anti-mGluR5 
rabbit immunoaffinity purified IgG primary antibody (1:15,000 in 1xTBS; 
Upstate).  Immunoblots were subsequently washed, incubated with the 
appropriate secondary antibody, and developed as described previously. 
Statistics 
CPP:  Preference was considered to have been achieved when a significantly 
greater amount of time was spent in the Meth-paired compared to the saline-
paired chamber during the CPP test; paired t-test, (α=0.025).  Development of 
motor sensitization was determined by a significant increase in activity between 
the first (conditioning day 1) and last (conditioning day 5) injection of drug; 
paired t-test (α=0.05).  Immunoblotting: Optical density of the entire smear of 
surface signal component (as pictured in Fig. 12, denoted S) and intracellular 
component (I) were determined and a ratio was calculated (S/I ratio) by dividing 
the S by I.  Total protein was calculated by adding the S and I components and 
dividing this value by the actin loading control.  The individual S and I 
components were calculated by dividing the optical density of S and I by the 
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loading control, actin.  The S/I ratio, total protein, S and I values were 
normalized to the average saline treatment groups within each gel and multiplied 
by 100 to determine Optical Density (% Average Saline) as shown in Fig. 11.  
Student’s t-tests (α=0.05) were used to determine differences between Meth and 
saline treatment groups in surface/intracellular (S/I) ratio, total protein, surface 
(S) component and intracellular (I) component for mGluR5.  All data are 
represented as mean ± standard error of the mean (SEM).  Statistical outliers 
were determined as more than two standard deviations above or below the mean 
for any data set.  For the immunoblotting data, 95 out of 720 data points were 
removed.  Four out of 128 data points were removed in the motor sensitization 
data, and no outliers were removed from the CPP data. 
 
Results 
The conditioning protocol (Fig. 8A) successfully induced a preference for 
the Meth-paired chamber in rats that were Meth-conditioned (t(15)=4.489, 
p=0.0004; Fig. 8C) that was not evident in rats that were treated with saline 
(t(15)=1.063, p=0.3044, Fig. 8B).  The repeated administration of Meth (1mg/kg) 
lead to a significant increase in horizontal activity (t(15)=2.611, p=0.0197), and 
vertical time (t(15)=2.250, p=0.0399) between the first (conditioning day 1) and 
last (conditioning day 5) administration (Fig. 9A,B).  Rats treated repeatedly with 
saline (1ml/kg), however, demonstrated a significant decrease in horizontal 
activity (t(13)=3.027, p=0.0097) and vertical time (t(13)=5.160, p=0.0002) to the 
fifth compared to the first injection (Fig. 9C,D).  These data indicate that rats 
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given repeated, intermittent Meth developed motor sensitization, while rats given 
saline habituated to the environment in which it was administered. 
A pre-absorption assay validated antibody specificity for the mGluR5 
primary antibody used for the immunoblotting experiments (Fig. 11A-C).  In this 
experiment, pre-absorption with the respective blocking peptide completely 
inhibited binding of the antibody in tissue with (Xlink) and without (Non-Xlink) 
the BS3 cross-linking reagent (Fig. 11B).   Shown in Fig. 11 is NAc for mGluR5.  
Comparison of Xlink and Non-Xlink tissue  demonstrated that the high molecular 
weight aggregate (which corresponds to the BS3 bound receptor inserted into the 
surface of the membrane) was not present in the Non-Xlink tissue and that the 
molecular weights of the intracellular components for the mGluR5 (Fig. 11A) 
were found at the expected molecular weight in both Xlink and Non-Xlink tissue 
(mGluR5 molecular weight approximately 130kD).  Thus, the cross-linking 
procedure allows for the simultaneous detection of the high molecular weight 
aggregate inserted into the membrane surface versus receptors that are located in 
the intracellular compartment of the cell.  To validate that BS3 did not permeate 
the cell membrane, we used cross-linked tissue to evaluate Homer 1b/c, a protein 
that is located exclusively in the intracellular compartment.   Immunoblots of 
Homer 1b/c resulted in a discrete band at approximately 47kD which correctly 
corresponds with the molecular weight of Homer 1b/c and no high molecular 
weight aggregate was detected (Fig. 11C).   
Evaluation of distribution of mGlu5 receptors revealed excellent detection 
levels in all brain regions tested (i.e., mPFC, NAc and VP).  While no changes 
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were observed for the mGluR5 receptor in the NAc (S/I ratio, t(28)=0.346, p= 
0.731; total protein, t(29)=1.96, p=0.059; surface, t(29)=1.342, p=0.190; 
intracellular, t(29)=0.2235, p=0.8247, Fig. 12B) or the VP (S/I ratio, t(29)=1.33, 
p=0.195; total protein, t(29)=0.265, p=0.793; surface, t(29)=0.7878, p=0.4372, 
intracellular, t(28)=1.635, p=0.1133, Fig. 12C), Meth-conditioning significantly 
reduced the mPFC mGluR5 S/I ratio (t(28)=3.14, p= 0.004) and increased the 
intracellular component (t(30)=2.98, p=0.005) without altering total protein 
(t(29)=0.11, p= 0.909) or the surface component (t(29)=0.3836, p=0.7041; Fig. 
12A).    Thus, brain and receptor specific changes were observed in the S/I ratio of 
the mGluR5 in the mPFC of Meth-conditioned rats.  
 
4.  Discussion 
 We demonstrated for the first time that ex vivo BS3 cross-linking 
methodology can be applied to metabotropic glutamate receptors.  We also 
revealed that this methodology can detect brain region-selective differences in 
responding to Meth in behaviorally relevant doses.  That is, in the mPFC, the S/I 
ratio and intracellular levels of mGluR5 was significantly reduced after repeated 
Meth administration that induced CPP and motor sensitization.   
Distribution of mGluR5 can be determined using a variety of techniques.  
Biotinylation has been successfully employed in vitro (Lee et al. 2008); however, 
this technique may produce highly variable results because intracellular and 
surface components are quantified in separate gels.  Synaptosomal fractionation 
has also been used to determine the distribution of mGluR5 receptors ex vivo 
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(Ghasemzadeh et al. 2009a;Ghasemzadeh et al. 2009b;Shaffer et al. 2010); 
however, this technique does not specifically determine levels of receptor protein 
inserted into the surface of the cellular membrane.  The technique used in the 
current study, pioneered by Boudreau and Wolf (Boudreau and Wolf 2005) to 
evaluate the surface expression of AMPA receptor subunits, provides several 
advantages.  The membrane impermeable cross-linking agent BS3 binds to 
extracellular basic residues of proteins inserted into the membrane resulting in a 
high molecular weight aggregate that is easily differentiated from the 
intracellular protein by using an antibody for protein detection targeted to the 
carboxy-terminal region of the receptor.  We validated the lack of intracellular 
BS3 binding using Homer 1b/c as an intracellular control since this is a 
scaffolding protein is important for trafficking of the mGluR5 receptor (Ango et 
al. 2002;Roche et al. 1999).  This finding is in keeping with the work of Boudreau 
and Wolf who demonstrated discrete, monomeric banding of tyrosine 
hydroxylase in BS3 cross-linked tissue (Boudreau and Wolf 2005).  It is 
important to note that although this assay has been used to monitor changes in 
the expression and distribution of mGluR5, AMPA receptors (Boudreau et al. 
2007;Boudreau and Wolf 2005;Conrad et al. 2008;Mickiewicz et al. 2006;Nelson 
et al. 2009), and now dopamine receptors (Conrad et al. 2010), it does not work 
for all proteins inserted into the surface of the membrane.  BS3 binds to basic 
amino acid residues in the N-terminal region, and there must be an adequate 
amount of these residues to allow for differentiation of the surface and 
intracellular components.  The mGluR5 are part of the class C family of 
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metabotropic receptors that have very large extracellular domains, which each 
contain many basic amino acid residues (Hermans and Challiss 2001;Pin et al. 
2003).  Another critical technical consideration relates to the fact that BS3 binds 
to the amino (N)-terminal of the receptor.   Consequently, it can mask antibody 
binding sites located in the N-terminus; and so an antibody that binds to the 
intracellular carboxy-terminal region of the receptor must be used.   
In the current study, we observed that in the mPFC of rats showing Meth-
induced CPP, the mGluR5 S/I ratio was decreased compared to saline control 
tissue, but the total mGluR5 protein between Meth and saline groups was not 
different.  This outcome indicated a redistribution of mGluR5 to the intracellular 
pool of the cell, which is in accord with the significant increase in the intracellular 
pool of mGluR5 receptors that we observed for the mPFC.  Thus, it appears that 
cells within the mPFC have adapted to the Meth conditioning treatment such that 
there are fewer mGluR5 on the surface and more in the intracellular pool.   
The decreased S/I ratio and increase in intracellular levels of the mGluR5 
receptor in the mPFC may be a compensatory mechanism to counteract the 
hyperexcitable state after repeated Meth administration.  Meth administration 
increases extracellular glutamate levels in the mPFC (Shoblock et al. 2003) and 
this effect is enhanced by repeated pairing of Meth with environmental cues (Qi 
et al. 2009).  Also, mGluR5 receptors are desensitized with prolonged agonist 
exposure (Catania et al. 1991).  Shaffer and colleagues found that an acute 
treatment of amphetamine increases synaptosomal mGluR5 in the mPFC 
(Shaffer et al. 2010) whereas glutamate levels are unchanged in this region 
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following amphetamine treatment (Shoblock et al. 2003).  One day after repeated 
cocaine, a time frame at which glutamate levels are increased in response to an 
additional cocaine injection (Williams and Steketee 2004), an increase in 
mGluR5 in the mPFC is observed in the synaptosomal fraction (Ghasemzadeh et 
al. 2009b).  The divergent outcomes found in the current study may reflect drug-
specific effects (Meth vs. cocaine), withdrawal time specific effects (four days vs. 
one day) or dissection-dependent effects (ventral vs. dorsal mPFC).  This change 
may also reflect the response to re-exposure to conditioning cues 24hr before the 
tissue was collected.  The current study adds to the literature to demonstrate that 
repeated Meth administration, which was sufficient to induce CPP and MSn, may 
be important for some of the adaptations that contribute to the addiction 
phenomenon. 
No other significant changes in the expression or distribution of the 
mGluR5 receptor were identified in the NAc or VP.  This was an unexpected 
result, as there are a few examples of dynamic effects of mGluR5 expression in 
the NAc in response to other stimulants, cocaine and amphetamine (the VP had 
not been previously studied).  For example, a repeated, sensitizing amphetamine 
administration results in a decrease in mGluR5 mRNA in the NAc that occurs 3hr 
after drug administration and persists up to 28 days (Mao and Wang 2001).  A 
potential explanation for this disparate finding from our study is that there is an 
increase in extracellular glutamate levels in the NAc following amphetamine but 
not Meth administration (Shoblock et al. 2003).  Therefore, mGluR5 receptors 
may have internalized in response to repeated glutamate exposure after repeated 
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amphetamine which would not occur with Meth administration.  In response to 
repeated cocaine administration, on the other hand, synaptosomal protein levels 
of mGluR5 are unchanged at early, and increased following extended (3 week) 
withdrawal (Ghasemzadeh et al. 2009a). Yet, Swanson and colleagues 
demonstrate a decrease in total mGluR5 protein and its associated scaffolding 
protein Homer 1b/c at the same withdrawal time from repeated cocaine 
(Swanson et al. 2001).  Thus, it appears that glutamate receptor adaptations are 
differentially altered by the various stimulant drugs.  There is precedence for this 
conclusion as Wolf and colleagues found differential adaptations in the surface 
expression of AMPA receptor subunits to repeated cocaine (increase in 
GluR1surface expression) and amphetamine (no change in GluR1 levels) 
administration in the NAc using the BS3 cross-linking assay (Boudreau et al. 
2007;Nelson et al. 2009).  As little is known about sub-cellular dynamics of 
mGluR5, following behaviorally relevant Meth administration, our results will aid 
in a more thorough characterization of mGluR5 expression in the NAc in 
response to stimulants.  We have also extended the literature by including the VP 
in our assessments.  Though mGluR5 levels in the VP were unaltered in the 
current study, these findings are an important step in the characterization of a 
brain region known to be involved in motivation to action and incentive salience.    
The current study has demonstrated the application of the BS3 cross-
linking technique to assess surface expression of mGluR5 which provides an ex 
vivo snapshot of the brain of in vivo Meth-induced processes.  We have identified 
brain region specific alterations in surface expression of mGlu5 receptor and 
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exciting potential of this work would be to determine if this receptor 
redistribution is functionally relevant in electrophysiological assays.     
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Figure 8. Meth-induced CPP.  A) Time-line of behavioral protocol.  For the 
pre-test (day -2), drug-free rats were allowed to explore the entire box for 15min.  
Conditioning occurred for six days; for Meth conditioned rats, Meth (1mg/ml/kg, 
i.p.) was paired with one chamber of the box on days 1, 3, & 5, and the saline 
(1ml/kg, i.p.) was paired with the opposite chamber on days 2, 4, & 6).  Saline 
conditioned rats were treated in the same manner but saline was administered on 
all days (days 1-6).  Conditioning sessions were 45min in duration.  Three days 
later (day 9), rats were tested for the expression of Meth-induced CPP in a drug-
free state (15min).  Meth, methamphetamine, Sal, saline, Ø, no drug.  B) Rats 
conditioned with saline (n=16) did not demonstrate a preference for either 
chamber on the CPP Test day (Paired t-test, p>0.025).  C) Rats conditioned with 
Meth (n=16) spent significantly more time in the Meth-paired (dark bar) vs. the 
saline-paired (white bar) chamber during the CPP Test (Paired t-test, 
***p<0.001).   
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Figure 9. Repeated administration of methamphetamine was 
sufficient to induce the development of motor sensitization.  Horizontal 
Activity (number of horizontal beam breaks) in A) Saline (n=14)- and B) Meth 
(n=16)-conditioned rats.  Vertical Time (sec spent breaking beams in the vertical 
plane) in C) Saline-conditioned (n=14) and D) Meth-conditioned (n=16) rats.  
Shown here are mean ± SEM for data obtained on conditioning day 1 and 
conditioning day 5 of the behavioral paradigm (treatment protocol illustrated in 
Fig. 1A).  Paired t-test, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 10. Stereotaxic brain maps indicating regions dissected. This 
figure is modified from Paxinos and Watson (1998) with numbers indicating the 
distance in millimeters from Bregma.  The boxes indicate dissections from the 
mPFC, medial prefrontal cortex, NAc, nucleus accumbens, and VP, ventral 
pallidum. 
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Figure 11. Validation of BS3 cross-linking technique applied to 
mGluR5.  A) Cross-linked (Xlink) and non-cross-linked (Non-Xlink) NAc 
tissues probed for mGluR5 demonstrated mGluR5 receptor protein at ~130kD, 
corresponding to intracellular protein, and a high molecular weight aggregate at 
>400kD, corresponding to surface receptor bound to BS3 which was present in 
Xlink tissue only.  An overexposed blot is pictured here as to demonstrate both 
intracellular and surface proteins on the same exposure.  Also, the same exposure 
was demonstrated in B) for pre-incubation of the antibody with the blocking 
peptide that inhibited all antibody binding, indicating antibody specificity 
demonstrating no signal at longer exposures.  C) A protein that is exclusively 
located in the intracellular cell compartment, Homer1b/c (an intracellular 
scaffolding protein) was detected at 47kD without any high molecular weight 
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aggregate signal indicating that that BS3 cross-linker is not penetrating cellular 
membranes. 
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Figure 12.  mGluR5 S/I ratio was decreased in the mPFC of Meth-
conditioned rats. Treatment group is indicated by key: Sal=saline conditioned 
(open bar), Meth=methamphetamine conditioned (filled bar).  Representative 
immunoblots are illustrated above each set of bar graphs. Data are shown for 
surface to intracellular ratio (S/I Ratio), total protein (Total), surface and 
intracellular receptor components.  A) There was a significant reduction in the 
S/I ratio of Meth-treated rats that expressed CPP in the mPFC.  There was no 
change in total mGluR5 or surface protein in the mPFC.  There was also a 
significant increase in the intracellular component of mGluR5 in the mPFC.  
There were no changes in mGluR5 S/I ratio, total protein, surface or intracellular 
protein components in the B) NAc or C) the VP.  Student’s t-test, **p<0.01. 
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CHAPTER VI 
DIFFERENTIAL DISTRIBUTION OF IONOTROPIC AND 
METABOTROPIC GLUTAMATE RECEPTORS FOLLOWING 
ACUTE AND REPEATED ADMINISTRATION OF 
MORPHINE OR METHAMPHETAMINE: ROLE 
OF mGluR5 IN EXPRESSION OF GluR2 AND 
STEP61 PROTEINS 
 
The current chapter is the result of collaboration with Dr. Amanda 
Mickiewicz, a former student in the Napier laboratory.  Dr. Mickiewicz, as a part 
of her dissertation project, completed the work involving opiates.  In alignment 
with the body of this dissertation work, only results of this chapter dealing with 
methamphetamine will be addressed in the General Discussion. 
 
Abstract 
 
The metabotropic glutamate group I subtype 5 receptor (mGluR5) is 
critical for neuronal and behavioral effects of opiates and stimulants including 
the progressive enhancement (sensitization) of motor activity in laboratory rats.  
The mGluR5 also regulates surface expression of ionotropic AMPA receptor 
subunits through the activation of striatal enriched tyrosine phosphatase isoform 
61 (STEP61).   
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To best study this phenomenon, we measured AMPA subunit and mGluR5 
distribution levels in the same tissue samples harvested from rats after induction 
of motor effects or after sensitized responding to the opiate morphine and the 
stimulant methamphetamine (Meth).  Application of the 
bis(sulfosuccinimidyl)suberate (BS3) cross-linker to medial prefrontal cortex 
(mPFC), nucleus accumbens (NAc) and ventral pallidum (VP) tissue collected 
from rats one day after acute, or fourteen days after repeated morphine or Meth, 
allowed for detection of AMPA receptor subunits (GluR1 and GluR2) and 
mGluR5 surface expression as well as intracellular STEP61 protein via Western 
blot analysis.  Surface expression of GluR1 and GluR2 were decreased in the 
mPFC following acute morphine.  Fourteen days after a sensitizing regimen of 
repeated morphine or Meth, the surface expression to intracellular protein ratio 
of GluR2 in the mPFC and mGluR5 in the VP was increased.    In repeated, 
morphine-treated rats, mGluR5 surface expression decreased without a change in 
STEP61 in the mPFC.  In Meth treated rats, mGluR5 levels were not altered; 
however, STEP61 was decreased.  We hypothesized that function of mGluR5 was 
responsible for the alterations that occurred in GluR2 and STEP61.  After 
administering an mGluR5-selective negative allosteric modulator, MTEP, prior to 
Meth in a separate group of animals, levels of GluR2 and STEP61 were not altered 
in the mPFC after fourteen days of withdrawal.  These data give an excellent 
comparison of glutamate receptor adaptations that occur subsequent to opiate 
and stimulant sensitization.  Furthermore we provide evidence that mGluR5 is 
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functionally responsible for GluR2 and STEP61 alterations induced by 
methamphetamine sensitization. 
 
Introduction 
Repeated administration of opiates and stimulants enhances motor 
activity beyond that obtained with a single injection, a phenomenon often 
referred to as sensitization.  Drug-induced behavioral and neuronal sensitization 
can persist long after the cessation of drug administration.  The neuronal changes 
associated with sensitized behaviors in rats may model some of the persistent 
brain adaptations that occur in the abstinent, but drug-addicted human (Paulson 
et al. 1991;Robinson and Berridge 1993;Sax and Strakowski 2001;Stewart and 
Badiani 1993).   The neuronal circuitry that undergoes sensitization to both 
opiates and stimulants involves the limbic system, including glutamatergic 
projections from the medial prefrontal cortex (mPFC), to the nucleus accumbens 
(NAc) (Christie et al. 1985) and the ventral pallidum (VP) (Carnes et al. 
1990;Fuller et al. 1987;Sesack et al. 1989).  However, these brain structures are 
involved in different phases of the sensitization processes.  The mPFC is 
implicated in the development of behavioral sensitization (Bjijou et al. 
2002;Cador et al. 1999;Pierce et al. 1998;Wolf et al. 1995;Wolf and Xue 1999), 
while the NAc mediates the maintenance and expression of the behavior (Pierce 
and Kalivas 1997;Vanderschuren and Kalivas 2000).  Studies from our laboratory 
demonstrate that the VP is critical for the development, maintenance and 
expression of sensitization (Dallimore et al. 2006;Johnson and Napier 
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2000;McDaid et al. 2005;McDaid et al. 2006a;Mickiewicz et al. 2009).  
Glutamatergic transmission in each of these brain regions is altered following 
repeated treatment of opiates and stimulants, and most of the evaluations of 
neuronal sensitization show that alterations in the mPFC occur during 
development; the NAc is altered during maintenance and expression, whereas 
glutamatergic enhancement occurs in the VP during all three phases of 
sensitization (Chen et al. 2001;Hao et al. 2007b;Johnson and Napier 
1997;LaLumiere and Kalivas 2008;McDaid et al. 2005;McDaid et al. 
2006a;Pierce et al. 1996;Qi et al. 2009).  Thus, to best understand the 
complexities of drug-induced sensitization, an appreciation of the temporal (i.e., 
sensitization phase) and spatial (i.e., brain region) effects of the glutamatergic 
processes need to be considered.   
Group I subtype 5 metabotropic glutamateric receptors (mGluR5) are 
located throughout the limbic circuitry (Lu et al. 1999;Romano et al. 1995;Testa 
et al. 1994b), and these receptors are critical for both opiate- and stimulant-
mediated behaviors, including sensitization (Gass et al. 2009;Herzig et al. 
2005;Herzig and Schmidt 2004;Kotlinska and Bochenski 2007;Miyatake et al. 
2005).  mGluR5 regulates release of glutamate and the functional state of the 
ionotropic receptors.  For example, activated mGluR5 induces internalization of 
AMPA receptors containing the GluR1 and GluR2 subunits (Snyder et al. 2001) 
via de-phosphorylation of AMPA receptor subunits by the striatal-enriched 
protein tyrosine phosphatase, isoform 61 (STEP61) (Zhang et al. 2008).  STEP61 is 
expressed in CNS neurons, including those in striatal and cortical regions 
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(Boulanger et al. 1995;Bult et al. 1996).  Blockade of STEP was recently shown to 
reduce the development of amphetamine-induced behavioral sensitization 
(Tashev et al. 2009).  Therefore, we considered that mGluR5 would be involved 
in the regulation of AMPA receptor surface expression and STEP61 expression in 
brain regions where these proteins were altered by opiates and/or stimulants. 
Regulating the number of receptors available for transmitter activation is 
an important means for regulating function, and processes involved in this 
regulation are important underpinnings of drug-induced neuroplastictiy.  
Increases in AMPA receptor surface expression enhance synaptic strength, which 
promotes both the development and the maintenance of drug-induced 
sensitization (Kauer and Malenka 2007;Wolf et al. 2004).  Little is known about 
these processes during opiate-induced sensitization, and the psychostimulant 
most studied is cocaine.  With repeated, once daily treatments of cocaine, one day 
after the last injection (a time when the animal would be „expecting‟ a subsequent 
cocaine treatment) there is little change in GluR1, GluR2 and mGluR5 levels in 
the mPFC and NAc(Ghasemzadeh et al. 2009a;Ghasemzadeh et al. 2009b); the 
VP was not assessed in these studies.  Following extended (21 days) withdrawal 
from repeated once-daily cocaine administration, there is an overall up-
regulation of these receptor proteins in synaptosomal membrane fractions in the 
NAc and mPFC, as well as enhanced surface expression of GluR1 and GluR2/3 
subunits (Boudreau and Wolf 2005;Ghasemzadeh et al. 2009a;Ghasemzadeh et 
al. 2009b).  Extended withdrawal from repeated amphetamine, on the other 
hand, does not result in altered surface expression of GluR1 or GluR2 in the NAc 
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(Nelson et al. 2009).  These results indicate that the effects of one stimulant on 
glutamate receptor trafficking cannot be generalized to all stimulants.   
The current study was designed to determine if AMPA receptor surface 
expression in limbic brain regions was commonly regulated by the opiates and 
stimulants, if this co-varied with mGluR5 surface expression and STEP levels, 
and if the apparent trafficking processes involved in induction of behavioral 
sensitization were common to those involved in the maintenance.  Furthermore, 
we were able to determine if the mGluR5 receptor mediated these drug-induced 
receptor adaptations via administration of an mGluR5 negative allosteric 
modulator (NAM).  Toward those objectives, we used a new methodology that 
allows for ex vivo assessments of surface expression of receptor proteins in brain 
samples taken from rats subjected to once-daily treatments of the opiate, 
morphine and the stimulant, methamphetamine (Meth) (Mickiewicz & Napier, 
under review; Herrold et al., under review).  To provide a temporal and spatial 
snapshot of maintenance, we harvested the mPFC, NAc and VP following 14 days 
of withdrawal, a time frame that we have observed maintenance-related effects in 
these brain regions in both morphine- and Meth-treated rats (McDaid et al. 
2005;McDaid et al. 2006a;McDaid et al. 2006b;Mickiewicz et al. 2009). To 
ascertain if similar changes in surface expression may be part of the induction 
process, we also assayed ex vivo brain samples taken one day after a single drug 
treatment (i.e., at a time when rats in the repeated treatment protocol received a 
second drug treatment).  
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The experimental outcomes significantly moved the field forward by filling 
several gaps in the literature, include the following “firsts”:  i) Characterization 
of surface expression of both AMPA receptor subunits, as well as mGluR5, 
following a sensitizing regimen of both an opiate and a stimulant. ii) Inclusion 
of the VP in each of these assessments.  iii) Determination of a mechanism for 
mGluR5 regulation of AMPA receptor subunit surface expression subsequent to 
drug-induced sensitization. iv) The ability of the negative allosteric modulator 
MTEP to block both the behavioral and neuronal sensitization induced by Meth.  
These data are particularly informative since surface expression of mGluR5 has 
not been assessed following morphine administration, and the effects of Meth 
administration on AMPA receptor proteins or surface expression of mGluR5 have 
not been studied in ex vivo brain tissue samples.   
 
Materials and Methods 
 
Animals 
Male Sprague-Dawley rats weighing 200-225g upon arrival (Harlan, 
Indianapolis, IN) were housed in pairs under environmentally controlled 
conditions (7:00AM/7:00PM light/dark cycle, temperature maintained at 23-
25oC) with ad libitum access to rat chow and water.  The rats were habituated to 
vivarium conditions for at least one week prior to experimentation.  All 
procedures were conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals (National Research Council, Washington DC) and were 
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approved by the Institutional Animal Care and Use Committees at Loyola and 
Rush University Medical Centers. 
 
Drugs  
Morphine sulfate, obtained from the National Institute on Drug Abuse 
(Bethesda, MD), was dissolved in 0.9% saline to yield a dose of 8mg/ml/kg as the 
salt.   Meth hydrochloride (Sigma, St. Louis, MO) was dissolved in saline to yield 
a dose of 1mg/ml/kg as the salt.  Control rats received the saline vehicle (1ml/kg).  
Injections were given subcutaneously (sc).  3-((2-Methyl-1,3-thiazol-4-
yl)ethynyl)pyridine hydrochloride (MTEP, Tocris Bioscience, Ellisville, MO) was 
dissolved in sterile water containing 20% w/v 2-hydroxypropyl-β-cyclodextrin 
(Sigma) to yield a dose of 5mg/ml/kg as the salt.  MTEP and its vehicle were 
injected intraperitoneally (ip). 
 
Behavioral Assessments and Treatment Protocols 
Rats were transported across the hall from the housing room to the test 
room at least 30min prior to the start of the experiment.  The test room was 
dimly lit (5 -10 foot candles) with white noise continuously present.  Two days 
prior to behavioral assessment, the rats were habituated to the activity boxes for 
1hr, given sc saline injections, and motor activity was monitored for 2hr post-
injection.  The motor score obtained on the second day was used as baseline 
activity.  Drug treatments began one day after baseline collection; rats were 
randomly assigned to receive saline, morphine or Meth.  Motor activity was 
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collected using Plexiglas activity chambers (25cm x 30cm x 30cm) equipped with 
two sets of photobeams (AccuScan Instruments, Inc., Columbus, OH) that 
allowed behavioral quantification in three dimensional space.  Rats were allowed 
to habituate to the motor boxes for 1hr, given a sc injection of the drug (saline, 
morphine, Meth) and then immediately placed back into the motor box for 3hr of 
behavioral monitoring.  For the acute treatment protocol, On Day 1, 32 rats were 
administered the drugs (morphine, Meth or the saline vehicle) and motor activity 
was quantified.   Rats were sacrificed the following day (Day 2) via rapid 
decapitation to collect tissue for biochemical analysis (see below).  For the 
repeated treatment protocol, 64 rats were administered saline, morphine or Meth 
once-daily for three days (Days 1-3), and motor activity was quantified.  
Following a 14 day withdrawal (W/D) period, a subset of rats (n=32) was tested 
for expression of sensitization after administration of morphine or Meth.  Other 
rats (n=32) were not given a drug challenge and were sacrificed via rapid 
decapitation on W/D 14 to collect tissue for biochemical analysis.   
To assess the effects of the mGluR5 NAM, MTEP on repeated Meth 
treatments, rats were given vehicle (20% w/v 2-hydroxypropyl-β-cyclodextrin) or 
the mGluR5 NAM, MTEP 10min before saline (n=12) or Meth (n=10), 
respectively, once-daily for three days (Days 1-3) and motor activity was 
quantified.  On W/D day 14, rats were sacrificed via rapid decapitation to collect 
tissue for biochemical analysis. 
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Protein Cross-Linking with BS3   
The brains were removed within 45-60sec after decapitation and 
immediately chilled in ice-cold artificial cerebrospinal fluid.  The mPFC, NAc, 
and VP were dissected (see Fig. 13) and chopped into 400µm slices using a 
McIlwain tissue chopper (The Vibratome Company, O‟Fallon, MO).  Methods for 
receptor cross-linking were based on Boudreau & Wolf (2005).  Briefly, the slices 
were quickly transferred to centrifuge tubes containing artificial CSF and 2mM 
BS3 (Pierce, Rockford, IL) and incubated for 30min on a rocker at 4°C.  The 
cross-linking reaction was terminated by the addition of 100mM glycine for 
10min at 4°C.  The slices were pelleted by 2min of centrifugation and the 
supernatant discarded.  The pellets were re-suspended in ice-cold lysis buffer 
[25mM HEPES, pH 7.4, 500mM NaCl, 2mM EDTA, 1mM DTT, 1mM  PMSF, 
20mM NaF, 1x phosphatase inhibitor cocktail (Sigma-Aldrich, St. Louis, MO), 1x 
protease inhibitor cocktail (Calbiochem, La Jolla, CA), and 0.1% Nonidet P-40].  
The samples were sonicated for 5sec, centrifuged for 2min, aliquotted, and stored 
at -80°C until analysis.  Total protein concentration of lysates was determined 
according to the Bradford method (Bradford 1976). 
 
Immunoblotting GluR1, GluR2, mGluR5 and STEP 
Samples (20µg) were loaded and electrophoresed on 4-15% gradient Tris-
HCl gels (Bio-Rad, Hercules, CA) and transferred to PVDF membranes for 
immunoblotting.  Non-specific binding sites were blocked using 1% normal goat 
serum and 5% nonfat dry milk in TBS-Tween 20 (TBS-T, Sigma), pH 7.4 for 1hr 
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at room temperature.  Membranes were incubated in primary antibody (GluR1, 
1:1000, Millipore, Billerica, MA; mGluR5, 1:15,000, Millipore; GluR2, 1:4000, 
Millipore; STEP, 1:4000, Millipore; actin, 1:20,000, Santa Cruz Biotechnology, 
Santa Cruz, CA) overnight at 4oC with gentle shaking.  Following six washes for 
5min each in TBS-T, membranes were incubated in HRP-conjugated secondary 
antibody (goat anti-rabbit; either 1:10,000 (Millipore, GluR1 and GluR2), 
1:15,000 (Jackson ImmunoResearch, West Grove, PA, mGluR5), or 1:20,000 
(Jackson, actin); rabbit anti-mouse, 1:4000 (Jackson, STEP)) for 1hr at room 
temperature.  Membranes were again washed in TBS-T (six x 5min), immersed in 
enhanced chemiluminescent substrate (Pico, Pierce, Rockford, IL) for 5min, and 
exposed to HyBlot CL film (Denville Scientific, Metuchen, NJ).  Two bands were 
visualized on film; a dense, high molecular weight band of ~400-600 kDa (cross-
linked GluR1 or mGluR5 corresponding to the surface pool (S)) and a band at 
~106 kDa (GluR1 and GluR2), ~135kDa (mGluR5), (i.e., unmodified GluR1, 
GluR2 or mGluR5 corresponding to the intracellular pool (I)) or ~61kDa (STEP61 
isoform).  Densities of the immunoreactive bands were analyzed using Lab Works 
(UVP, Upland, CA) or Un-Scan It (Silk Scientific, Orem, UT) software.  Images 
were captured using a BioChemi Imaging System (UVP) coupled to a CCD camera 
or a scanner (Epson Electronics America, Inc., San Jose, CA) coupled to a PC 
computer.  All samples were run at least twice and averaged across runs.  
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Data Summaries and Analyses 
Behavior:  For the acute treatment study, a Student‟s t-test was used to 
compare total session counts on Day 1 between saline and drug treatment.  For 
the repeated treatment study, development of sensitization was determined using 
a one-way repeated measures analysis of variance (rmANOVA) comparing motor 
activity on Day1 and Day 3 between treatment groups with a post hoc Newman 
Keuls test for multiple comparisons.  To determine expression of sensitization, a 
Student‟s t-test was used to compare motor responses between treatment groups.  
All data are presented as mean ± SEM. Significance was a priori set at α=0.05 
Immunoblots: The surface/intracellular ratio (S/I) of GluR1, GluR2, and 
mGluR5 was calculated by dividing the optical densities of the surface band by 
the intracellular band.  Total GluR1, GluR2, and mGluR5 were determined by 
adding the optical densities of the surface and intracellular bands and dividing by 
the loading control actin.  The portion of GluR1, GluR2, or mGluR5 on the 
surface was calculated by dividing the optical density of the surface band by actin; 
intracellular GluR1 or mGluR5 was similarly determined by dividing the optical 
density of the intracellular band by actin.  Results from morphine-and Meth-
treated rats were normalized to saline-treated (control) values for each brain 
region.   All data are presented as mean + SEM.  A Student‟s t-test was used to 
compare between saline control and drug treatment groups, with a Bonferroni 
correction for comparing the same control group to each of the two treatment 
groups, setting α=0.025 for accepting significance.   
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Results 
 
Behavioral Response to Acute Drug Administration 
Rats treated with a single morphine injection (8mg/kg sc) demonstrated a 
significant decrease in horizontal activity (t(14)=4.438, p<0.001) and repetitive 
beam breaks (t(14)=4.682, p<0.001) compared to rats given saline (Table 2A).  In 
contrast, a single injection of Meth (1mg/kg sc) resulted in a significant increase 
in horizontal activity (t14=5.700, p<0.001) and vertical time (t(14)=3.099, p<0.01) 
compared to saline treated rats (Table 2B).   
 
Behavioral Response to Repeated Drug Administration  
 The behavioral responses to repeated drug administration are illustrated 
in Fig. 14 and 15.  The development of morphine-induced sensitization was 
demonstrated by comparing motor activity on Days 1, 2 and 3.  Horizontal beam 
breaks (Fig. 14A; F(2,14)=7.94, p=0.005) and repetitive beam breaks (Figure 14B; 
F(2,14)=6.49, p=0.009) were significantly increased with repeated morphine 
treatments.  Similarly, motor sensitization developed following three injections of 
Meth.  When motor activity was compared on Days 1, 2, and 3, vertical beam 
breaks (Fig. 15A; F(2,14)=5.49, p=0.02) and vertical time (Figure 15B; F(2,14)=4.67, 
p=0.03) were significantly increased.  The sensitization was maintained for at 
least 14 days, for a between treatment group analysis showed that responding to 
an acute morphine challenge (8mg/kg sc; given on protocol Day 17) was greater 
in rats with a morphine history compared to those that received morphine for the 
first time (horizontal beam breaks: t(13)=2.77, p=0.02; repetitive beam breaks: 
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t(14)=2.76, p=0.02).  When challenged with Meth 14 days later (Day 17), rats with 
a treatment history of Meth also had higher counts of activity compared to those 
with a saline treatment history (vertical beam breaks: t(14)=2.45, p=0.03; vertical 
time: t(14)=2.68, p=0.02), indicating that sensitization was maintained in the 
Meth-treated animals.   
 A separate group of animals was subjected to the same treatment protocols 
for Days 1-3, but on Day 17, brain tissue was harvested for biochemical analyses.  
As in the previous experiments, drug-treated rats demonstrated increased motor 
activity on Day 3 compared to Day 1.  For morphine, horizontal beam breaks, 
F(2,16)=13.68; repetitive beam breaks, F(2,18)=11.35 (p<0.001).   
  For Meth, vertical beam breaks F(2,18)=6.68, p=0.007; and vertical time, 
F(2,16)=7.27, p=0.006.  Thus, the biochemical results obtained on Day 17 for both 
morphine and Meth-treated rats represent neuronal adaptations that occur in the 
sensitized brain. 
 
Effects of mGluR5 Negative Allosteric Modulator on development of motor 
sensitization 
Miyatake has demonstrated that mGluR5 are involved in the development 
of Meth-induced CPP(Miyatake et al. 2005).  We extended this literature by 
testing if these receptors were critical for the development of Meth-induced 
motor sensitization.  As shown in Fig. 15, there was no effect of repeated vehicle 
and saline treatment (open triangles) or MTEP and Meth treatment (filled 
triangles) on vertical beam breaks (F(1,17)=0.718, p=0.409) or vertical time 
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(F(1,16)=0.002, p=0.964).  Vertical beam breaks did not show an effect of repeated 
treatment day (F(1,34)=1.849, p=0.173) or an interaction between treatment and 
day of testing (F(2,34)=2.042, p=0.145, Fig. 15C).  Vertical time also did not shown 
an effect of repeated treatment day (F(2,32)=1.33, p=0.278) nor was there a 
significant interaction between treatment and day of motor testing (F(2,32)=1.01, 
p=0.376; Fig. 15D).  These data indicate that development of motor sensitization 
did not occur after repeated treatment with Meth in rats pre-treated with the 
mGluR5 NAM, MTEP (5mg/kg, ip). 
 
 
Effect of a single administration of morphine or Meth on the distribution of 
glutamate receptors. 
 
 There were minimal changes observed in the NAc (Table 3A&B) and VP 
(Table 3 A&B) one day after an acute morphine and Meth.  Only the GluR1 S/I 
ratio was significantly decreased in the NAc of morphine compared to saline 
treated rats (Table 3A); yet, total, surface and intracellular GluR1 protein levels 
remained unchanged between treatment groups.  There were no changes in S/I 
Ratio or total GluR2 or mGluR5 proteins in the NAc between saline and 
morphine treated rats (Table 3A).  Furthermore, there were no changes in the S/I 
ratio or total GluR1, GluR2 or mGluR5 protein in the NAc between saline and 
Meth treated rats (Table 3B) or in the VP between saline and morphine (Table 
4A) or saline and Meth treated rats (Table 4B). 
 Evaluations of immunoblots from tissue harvested on one day after 
morphine administration showed that the GluR1 S/I ratio was decreased in the 
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mPFC (t(19)=2.853, p=0.0102).  The decrease in the S/I ratio reflects the slight 
(but not significant) increase in the amount of intracellular GluR1 (t(20)=1.996, 
p=0.0597), decrease in surface GluR1(t(20)=2.182, p=0.0412), and decrease in 
total GluR1 (t(20)=2.187, p=0.0408) in morphine treated rats (Fig. 16B) (Note a 
Bonferroni correction was implemented for comparing the same control group to 
each of the two treatment groups, setting α=0.025 for accepting significance).  
 In the mPFC from morphine-treated rats, the amount of surface GluR2 
was decreased (t(18)=2.523, p=0.0213, Fig. 16D).  However, there was not a 
significant change between saline and morphine treatment groups in total GluR2 
(S+I, t(18)=1.839, p=0.0825), S/I ratio (t(18)=0.8660, p=0.3979) or intracellular 
protein (t(18)=0.2862, p=0.7780). There was no change in the mPFC between 
saline and morphine treated rats in mGluR5 S/I ratio (t(17)=1.476, p=0.1582), 
total protein (S+I, t(17)=1.315, p=0.2059), surface protein (t(17)=1.294, p=0.2130), 
or intracellular protein (t(16)=1.423, p=0.1739, Fig. 16F).  There also was no 
difference between saline and Meth treated rats in mPFC tissues with any 
glutamate receptor protein assayed (Table 5). 
 
Effect of 14day withdrawal from repeated morphine or Meth administration on 
distribution of glutamate receptors. 
No changes resulted in the NAc for GluR1, GluR2, or mGluR5 proteins 
following 14 days of withdrawal from repeated morphine (Table 6A) or Meth 
(Table 6B) treated rats (Student‟s t-test, p>0.025).  Therefore, no STEP61 protein 
levels were assessed in the NAc. 
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In VP tissue collected from rats treated with either morphine (t(18)=2.653, 
p=0.016, Fig. 17B) or Meth (t(19)=3.040, p=0.007, Fig. 17D), there was an 
increase in mGluR5 S/I ratio compared to the saline treatment group.  This 
statistically significant increase in the mGluR5 S/I ratio reflected the non-
significant trends in individual components: a slight increase in the surface 
component and a modest decrease in the intracellular mGluR5 pool.  However, 
there was no change in any other mGluR5 protein component measured 
(Student‟s t-test, p>0.025, Fig. 17B and D).  Moreover, no changes were detected 
in GluR1, GluR2 or STEP61 proteins in the VP between saline and morphine 
(Table 7A) or Meth (Table 7B) (Student‟s t-test, p>0.025). 
mPFC tissue collected 14 days after repeated morphine (8mg/kg), showed 
a significant increase in GluR2 S/I ratio of (t(18)=2.997, p=0.008) compared to 
saline treated rats (Fig. 18C).  Of note, is that the GluR2 I component 
demonstrated a non-significant trend towards a decrease (t(19)=2.146, p=0.045) 
(Fig. 18C).  There was no difference between treatment groups in the amount of 
GluR2 total protein (t(19)=0.476, p=0.640) or S component (t(19)=0.752, p=0.462) 
in mPFC tissues (Fig. 18C).  Decreased in the amount of total mGluR5 
(t(19)=3.062, p=0.006) and S protein (t(19)=2.691, p=0.014) were obtained in the 
mPFC of morphine-treated rats compared to saline controls (Fig. 18F).  However, 
there was no change in the mGluR5 S/I ratio (t(19)=2.057, p=0.054) or I protein 
(t(19)=0.476, p=0.640) in this brain region (Fig. 18F).  There was no change in any 
component of the GluR1 subunit of the AMPA receptor in the mPFC (Student‟s t-
test, p>0.025, Fig. 18B) nor the STEP61 protein (Fig. 18H). 
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Similar to what was observed subsequent to morphine treatment, after 14 
days withdrawal from repeated Meth (1mg/kg), GluR2 S/I ratio was increased in 
the mPFC (t(19)=3.475, p=0.002) (Fig. 19D).  There was also a non-significant 
trend towards a decrease in the GluR2 I component of Meth-treated rats 
(t(20)=2.385, p=0.027, Fig. 19D).  However, there was no difference between 
treatment groups in total (t(20)=0.086, p=0.932) or the S component (t(20)=0.534, 
p=0.599) of GluR2 in the mPFC.  Unlike what was detected after morphine 
treatment, there was a decrease in the level of STEP61 protein in the mPFC of 
Meth- treated rats (t(19)=2.504, p=0.022, Fig. 19H), but no change, in the protein 
components of mGluR5 (Fig. 19F) or GluR1 (Fig. 19B) (Student‟s t-test, p>0.025). 
 
Effects of mGluR5 blockade on distribution of GluR2 and STEP61 subsequent to 
Meth withdrawal. 
To determine if mGluR5 signaling was responsible for the changes in 
GluR2 surface expression and STEP61 seen in the mPFC following repeated Meth, 
the mPFC was harvested after 14 days withdrawal from rats where the mGluR5 
NAM, MTEP was shown to block the development of Meth-induced motor 
sensitization (motor data shown in Figure 15C and D).  The changes that occurred 
subsequent to 14 days withdrawal from Meth in the mPFC were no longer present 
in GluR2 (Fig. 20B) and STEP61 (Fig. 20D) of MTEP and Meth treated rats 
compared to vehicle and saline treated controls (Student‟s t-test, p>0.025). 
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Discussion 
 These studies demonstrate that administration of morphine (8mg/kg, sc) 
or Meth (1mg/kg, sc) produced an increased motor responding to a single 
injection.  A progressive enhancement in motor behavior between the first and 
last of three, daily morphine or Meth administrations of morphine or Meth also 
occurred.  Thus, harvesting tissue one day after the first injection, i.e., a time that 
equaled the inter-dosing interval used for the repeated injection, provided a 
temporal snapshot of the processes that occur during development of 
sensitization.  The expression of motor sensitization was validated in a subset of 
rats behaviorally tested at fourteen days of withdrawal, suggesting that the brain 
was in a sensitized state at the time when tissue was harvested for biochemical 
analysis.  We also determined that the mGluR5 NAM, MTEP (5mg/kg, ip), 
administered prior to Meth during development, precluded sensitization.  This 
finding concurs with prior demonstration that mGluR5 is necessary for the 
development of Meth-induced conditioned place preference (Miyatake et al. 
2005).   
 Several studies have reported changes in AMPA receptor and mGluR5 
distribution in the NAc associated with cocaine treatment, a region important for 
the expression of sensitization.  Cell surface and synaptic AMPA receptor levels 
are increased in the NAc after 2-3 weeks, but not one day of withdrawal from a 
sensitizing regimen of cocaine (Boudreau et al. 2007;Boudreau and Wolf 
2005;Ghasemzadeh et al. 2009a).  A single administration of amphetamine 
transiently decreases synaptosomal mGluR5 levels in the NAc one hour after 
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administration, an effect that is normalized five hours later (Shaffer et al. 2010).  
As with the AMPA receptors, synaptosomal mGluR5 levels remain unchanged 
one day after repeated cocaine administration; yet, these levels are also up-
regulated following long-term (3 weeks) withdrawal in the NAc (Ghasemzadeh et 
al. 2009a).  Supporting our negative findings in the NAc following repeated Meth 
treatment, Nelson and colleagues report that AMPA receptor S/I ratio is 
unchanged in the NAc of rats that are sensitized to amphetamine; however, acute 
amphetamine treatment slightly decreased surface levels of GluR1 after 24hr 
(Nelson et al. 2009).  Therefore alterations in AMPA receptor subunits GluR1 and 
GluR2 appear to be unchanged following repeated Meth or amphetamine 
treatment in the NAc.  Here we show that acute morphine treatment did not alter 
surface levels of GluR1; changes in the ratio were due to a non-significant 
increase in the intracellular levels of GluR1.  Interpreted in the sense that surface 
AMPA receptors are the functional receptors, we would predict that AMPA 
receptor function in the NAc would not be affected by acute morphine treatment.  
This does not conflict with the role of NAc in the long-term effects of repeated 
drug exposure.  AMPA receptors are clearly important for cue and drug-induced 
heroin seeking behavior at the withdrawal time examined in the current study 
(LaLumiere and Kalivas 2008); however, these receptors do not have to be up-
regulated on the cell surface to produce these effects.   
 Our results indicate that specific up-regulation of mGluR5 S/I ratio is a 
common feature of withdrawal from a sensitizing regimen of both the opiate 
morphine and the stimulant Meth in the VP.  Here we demonstrated that 14 days 
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after repeated morphine treatment, there was an increase in the mGluR5 S/I 
ratio due to a slight increase in the surface component of this receptor.  Our lab 
has demonstrated that the VP is a critical mediator in the development (Johnson 
and Napier 2000;Mickiewicz et al. 2009), and maintenance (Dallimore et al. 
2006;McDaid et al. 2006a) of opioid-induced motor sensitization.  We have also 
shown that in VP neurons of morphine sensitized rats there is a significantly 
increased ability to enter depolarization block subsequent to local glutamate 
application (McDaid et al. 2006a).  The activation of mGluR5 influences 
excitability in many ways, including the augmentation of ionotropic glutamate N-
methyl-D-aspartic acid receptor (NMDAR) currents as well as suppression of 
after-hyperpolarization potassium currents (Ireland and Abraham 
2002;Mannaioni et al. 2001).  Therefore, it is possible that augmented mGluR5 
S/I ratio could reduce recovery of VP neurons leading to increased excitability 
and depolarization inactivation in the presence of glutamate agonist.  At this time 
point, however, we saw no alterations in the surface expression of GluR1 or 
GluR2 subsequent to morphine treatment in the VP.  Alternative explanations for 
the observed increase in VP neuronal functionality include posttranslational 
modifications of AMPA receptors to alter the conductance of these channels 
(Derkach et al. 1999), changes in the cellular distribution of other AMPA receptor 
subunits (e.g. GluR3) or NMDA receptors.  Electrophysiological studies with local 
application of selective agonists and antagonists for AMPA and NMDA receptors 
are needed to verify which receptor is functionally up-regulated.  In the present 
study, we also observed an increase in the mGluR5 S/I ratio in the VP of rats 14 
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days after repeated Meth administration due to a decreased shift in the mGluR5 
intracellular component.  Therefore, mGluR5 levels are likely maintained on the 
cell surface while intracellular receptors are degraded, perhaps due to the lack of 
agonist-induced desensitization of mGluR5.  VP neurons are also important for 
coding incentive motivational properties of drug cues following amphetamine 
sensitization (Tindell et al. 2005) and neuronal markers for activity as well as 
synaptogenesis in VP neurons are up-regulated following the expression of 
amphetamine-induced associative learning (Rademacher et al. 2006).  Future 
electrophysiological assessments would help determine the role of mGluR5 on 
the excitability of VP neurons following withdrawal from repeated morphine and 
Meth.   
 We demonstrated here that acute morphine treatment significantly 
reduced the GluR1 S/I in the mPFC, and we propose this is a result of decreases 
in surface expression and increases in intracellular levels of GluR1, suggesting 
that GluR1 was redistributed from the surface to the intracellular compartment.  
These results are consistent with role of the mPFC in the development, but not 
expression, of morphine sensitization (Hao et al. 2007a;Tzschentke and Schmidt 
1999).  Long-term withdrawal from morphine treatment returned GluR1 levels to 
baseline.   These results suggest that a decrease in responsiveness to excitatory 
inputs occurs within the inter-dosing interval timeframe of the treatments (24hr 
after acute or repeated treatment, Mickiewicz & Napier, under review) and prior 
to a long-term withdrawal period (14 days).  In contrast to the observed effects 
following a single morphine treatment, there was no change in AMPA receptor 
117 
 
subunits in the mPFC after a single Meth injection.  A recent study by Simoes and 
colleagues (Simoes et al. 2008) showed an increase in GluR2 in the frontal cortex 
24hr after a single administration of meth.  One possible explanation for the 
contrasting results was the dose of Meth, 30 mg/kg in the Simoes study 
compared to 1mg/kg used here. 
 At the long-term withdrawal period, both surface and total mGluR5 
protein levels are decreased.  Therefore, less mGluR5 was available to be 
activated in the mPFC of morphine-treated rats.  Since mGluR5 activation results 
in internalization of AMPA receptor subunits (Snyder et al. 2001), it follows that 
the GluR2 S/I ratio was significantly increased after 14 days of withdrawal from 
repeated morphine.  Though STEP61 is a key mediator in mGluR5-dependent 
internalization of GluR2 (Zhang et al. 2008), this protein remained unchanged 
fourteen days after repeated morphine.  However, the brain state of the mPFC 
following withdrawal from repeated morphine is adapting in such a way as to 
reduce neuronal calcium levels by favoring AMPA receptor subunit composition 
for the calcium-impermeable GluR2 (Liu and Zukin 2007) as well as decreasing 
mGluR5 surface and total protein which would reduce calcium release from 
intracellular stores (Sladeczek et al. 1985).  Similarly, the GluR2 S/I ratio is 
increased following 14 days of withdrawal from repeated Meth due to a decreased 
shift in the intracellular GluR2 pool.  No alterations occurred in mGluR5 levels in 
the mPFC.   Since STEP61 protein levels were significantly decreased, it appears 
that less phosphatase is available to internalize GluR2 receptors and levels 
increase on the membrane surface.  We determined that this effect was mediated 
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through activation of mGluR5 receptors, as a pre-treatment of MTEP prior to 
Meth administration precluded any changes in mPFC GluR2 or STEP61 levels at 
14 days of withdrawal.  Therefore, the up-regulation of GluR2 S/I ratio and the 
decrease in STEP61 protein likely reflected activation of mGluR5 through Meth-
induced increases in glutamate transmitter in the mPFC (Qi et al. 2009;Shoblock 
et al. 2003). 
 The current study characterized glutamate receptor adaptations induced 
by two drugs of separate classes: the opiate morphine and the stimulant Meth.  
Overlaps for the two drugs included the up-regulation of mGluR5 S/I ratio in the 
VP and GluR2 surface expression in the mPFC after long-term withdrawal.  This 
suggests that there are common glutamatergic mechanisms between the 
adaptations that underlie sensitization.     
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Tables 
Table 2A. Motor Activity evoked by a single injection of morphine.  
 Saline Morphine 
Horizontal Activity 1306±50 555±126*** 
Repetitive Beam Breaks 822±46 339±74*** 
 
 
 
Table 1B. Motor activity evoked by a single injection of 
Methamphetamine. 
 Saline Methamphetamine 
Vertical Activity 113±32 1924±385** 
Vertical Time 70±20 651±143*** 
 
 
(A) Rats given a single administration of morphine (8mg/kg, sc, n=6) 
demonstrated a significant decrease in both horizontal activity and repetitive 
beam breaks compared to rats treated with saline (1ml/kg, sc, n=10).  Behavioral 
assessments occurred over 90min post-injection.  Student‟s t-test, ***p<0.001 
(B) Rats given a single administration of Meth (1mg/kg sc; n=10) demonstrated 
a significant increase in both vertical activity and vertical time compared to rats 
treated with saline (1ml/kg sc; n=6).  Behavioral assessments occurred over 
60min post-injection.  Student‟s t-test, **p<0.01,***p<0.001 
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Table 3A. NAc: 1 Day After Morphine. 
Protein: Component Saline Morphine Statistics 
GluR1 S/I 
Total 
103.1±10.6 
100.3±6.9 
68.3±7.3 
102.2±4.0 
t(18)=2.581, p=0.019* 
t(19)=0.238, p=0.814 
GluR2 S/I 
Total 
97.6±5.2 
115.9±7.6 
113.7±10.7 
112.5±6.6 
t(17)=1.394, p=0.181 
t(18)=0.335, p=0.741 
mGluR5 S/I 
Total 
100.0±7.8 
98.7±10.2 
101.7±16.0 
114.8±11.3 
t(18)=0.103, p=0.919 
t(19)=1.061, p=0.302 
 
 
Table 3B. NAc: 1 Day After Methamphetamine. 
Protein: Component Saline Meth-
amphetamine 
Statistics 
GluR1 S/I 
Total 
103.1±10.6 
100.3±6.9 
142.4±28.3 
112.1±6.4 
t(18)=1.405, p=0.177 
t(19)=1.251, p=0.226 
GluR2 S/I 
Total 
97.6±5.2 
115.9±7.6 
97.3±4.5 
108.1±12.7 
t(18)=0.047, p=0.963 
t(18)=0.550, p=0.589 
mGluR5 S/I 
Total 
100.0±7.8 
98.7±10.2 
103.5±12.1 
106.5±8.8 
t(20)=0.246, p=0.808 
t(20)=0.577, p=0.570 
 
Shown are the mean ± SEM optical density values as percent average saline 
control for each treatment group and corresponding Student‟s t-test statistics.  
S/I ratio and Total (S+I) protein were assessed for GluR1, GluR2, and mGluR5 in 
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VP tissues after one day of a single injection of Saline (1ml/kg, sc), (A) morphine 
(8mg/kg, sc) or (B) Meth(1mg/kg, sc).  There was a significant decrease in the 
GluR1 S/I ratio in the NAc of morphine-treated rats *p<0.025.  However, there 
were no other differences between saline and Meth treatment groups for any 
glutamate receptor protein component assayed.  Shown are mean ± SEM optical 
density values as percent average saline control for each treatment group and 
corresponding Student‟s t-test statistics, with Bonferroni correction as saline 
groups were used for morphine and Meth comparisons, α=0.025.  
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Table 4A. VP: 1 Day After Morphine. 
Protein: Component Saline Morphine Statistics 
GluR1 S/I 
Total 
100.9±12.2 
99.6±5.7 
133.6±21.8 
111.5±7.0 
t(20)=1.370, p=0.186 
t(20)=1.328, p=0.199 
GluR2 S/I 
Total 
100.0±7.1 
100.0±4.5 
115.0±8.8 
96.0±3.9 
t(18)=1.340, p=0.197 
t(18)=0.649, p=0.525 
mGluR5 S/I 
Total 
100.0±9.7 
95.6±5.14 
131.4±22.1 
118.2±12.5 
t(20)=1.381, p=0.182 
t(19)=1.729, p=0.100 
 
Table 4B. VP: 1 Day After Methamphetamine.  
Protein: Component Saline Meth- 
amphetamine 
Statistics 
GluR1 S/I 
Total 
100.9±12.2 
99.6±5.7 
108.7±16.0 
101.9±6.3 
t(20)=0.397, p=0.696 
t(20)=0.279, p=0.783 
GluR2 S/I 
Total 
100.0±7.1 
100.0±4.5 
105.3±11.4 
98.3±6.2 
t(18)=0.412, p=0.685 
t(18)=0.222, p=0.827 
mGluR5 S/I 
Total 
100.0±9.7 
95.6±5.1 
97.8±14.6 
135.1±18.3 
t(19)=0.129, p=0.898 
t(19)=2.164, p=0.043 
S/I ratio and Total (S+I) protein were assessed for GluR1, GluR2, and mGluR5 in 
the VP tissues after one day of acute Saline (1ml/kg, sc), (A) morphine (8mg/kg, 
sc) or (B) Meth (1mg/kg, sc) treatment.  There were no differences between 
saline and morphine treatment groups for any glutamate receptor protein 
component assayed.  Shown are mean ± SEM optical density values as percent 
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average saline control for each treatment group and corresponding Student‟s t-
test statistics, α=0.025.
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Table 5. mPFC: 1 Day After Methamphetamine. 
Protein: Component Saline Meth-
amphetamine 
Statistics 
GluR1 S/I 
Total 
100.9±17.2 
100.7±3.7 
81.5±19.6 
92.4±4.9 
t(18)=0.733, p=0.473 
t(19)=1.376, p=0.185 
GluR2 S/I 
Total 
100.4±9.7 
101.5±6.7 
95.4±14.3 
88.6±5.8 
t(17)=0.296, p=0.770 
t(17)=1.285, p=0.216 
mGluR5 S/I 
Total 
101.5±10.3 
100.1±6.7 
136.2±27.6 
100.2±8.4 
t(16)=1.281, p=0.218 
t(16)=0.008, p=0.994 
 
S/I ratio and Total (S+I) protein were assessed for GluR1, GluR2, and mGluR5 in 
the mPFC tissues after one day of acute Saline (1ml/kg, sc) or Meth (1mg/kg, sc) 
treatment.  There was no difference between treatment groups for any glutamate 
receptor protein assayed.  Shown are mean ± SEM optical density values as 
percent average saline control for each treatment group and corresponding 
Student‟s t-test statistics, α=0.025 (Bonferroni correction). 
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Table 6A. NAc: 14 Days After Morphine.  
Protein: Component Saline Morphine Statistics 
GluR1 S/I 
Total 
99.9±7.5 
106.4±7.2 
154.2±32.9 
111.1±7.3 
t(19)=1.844, p=0.081 
t(20)=0.447, p=0.659 
GluR2 S/I 
Total 
99.6±9.0 
99.5±4.5 
113.6±16.6 
91.2±8.8 
t(19)=0.762, p=0.455 
t(19)=0.855, p=0.403 
mGluR5 S/I 
Total 
101.3±11.7 
100.9±3.6 
129.2±10.8 
101.5±6.3 
t(20)=1.726, p=0.099 
t(20)=0.079, p=0.938 
 
 
Table 6B. NAc: 14 Days After Methamphetamine. 
Protein: Component Saline Meth- 
amphetamine 
Statistics 
GluR1 S/I 
Total 
99.9±7.5 
106.4±7.2 
84.1±10.2 
113.7±7.1 
t(19)=1.278, p=0.217 
t(20)=0.716, p=0.482 
GluR2 S/I 
Total 
99.6±9.0 
99.5±4.5 
101.2±13.5 
84.9±9.4 
t(18)=0.102, p=0.920 
t(17)=1.524, p=0.146 
mGluR5 S/I 
Total 
101.3±11.7 
100.9±3.6 
118.5±23.7 
94.0±5.1 
t(19)=0.706, p=0.489 
t(20)=1.141, p=0.267 
 
There were no differences between (A) saline and morphine (8mg/kg sc, once 
daily for 3 days) or (B) saline (1ml/kg sc, once daily for 3 days) and Meth 
treatment (1mg/kg sc for 3 days) groups for any glutamate receptor protein 
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component assayed.  Shown are the mean ± SEM optical density values as 
percent average saline control for each treatment group and corresponding 
Student‟s t-test statistics, α=0.025 (Bonferroni correction). 
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Table 7A. VP: 14 Days After Morphine. 
Protein: Component Saline Morphine Statistics 
GluR1 S/I 
Total 
99.1±9.0 
99.7±5.6 
123.1±23.4 
99.4±8.6 
t(19)=1.057, p=0.304 
t(20)=0.037, p=0.970 
GluR2 S/I 
Total 
98.9±6.3 
101.1±5.7 
99.6±11.0 
102.0±10.3 
t(20)=0.058, p=0.954 
t(20)=0.075, p=0.941 
STEP61  100.0±8.3 
 
94.1±8.2 
 
t(20)=0.503, p=0.621 
 
 
Table 7B. VP: 14 Days After Methamphetamine. 
Protein: Component Saline Meth- 
amphetamine 
Statistics 
GluR1 S/I 
Total 
99.1±9.0 
100.6±5.8 
114.5±15.2 
109.6±3.6 
t(20)=0.906, p=0.376 
t(20)=1.258, p=0.223 
GluR2 S/I 
Total 
98.9±6.3 
101.1±5.7 
88.8±13.4 
130.0±12.6 
t(19)=0.735, p=0.471 
t(20)=2.262, p=0.035 
STEP61   100.0±8.3 
 
107.3±9.6 
 
t(19)=0.573, p=0.574 
 
There were no differences between (A) saline and morphine (8mg/kg sc, once 
daily for 3 days) or (B) saline (1ml/kg sc, once daily for 3 days) and Meth 
treatment (1mg/kg sc for 3 days) groups for any glutamate receptor protein 
component assayed.  Shown are the mean ± SEM optical density values as 
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percent average saline control for each treatment group and corresponding 
Student‟s t-test statistics, α=0.025 (Bonferroni correction). 
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Figure 13.  Stereotaxic maps of brain regions assayed.  Illustrations of 
stereotaxic maps of rodent brain were modified from Paxinos and Watson (1998).  
The bold outlines correspond to dissections of the medial prefrontal cortex 
(mPFC), nucleus accumbens (NAc) and ventral pallidum (VP) brain tissues 
assayed in the current study.  Numbers indicate distance in millimeters of the 
respective brain section from bregma. 
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Figure 14. Development and expression of morphine sensitization. 
Data were collapsed for 90min after administration of morphine.  A) Horizontal 
Beam Breaks, B) Repetitive beam breaks.  There was no statistical difference 
between days 1, 2 or 3 of the saline treatment (open symbols, n=6-8). In the 
morphine-treated groups, there were significant differences between treatment 
days (filled circles=animals used for biochemistry; filled squares=animals used 
for behavioral verification).  A challenge injection of morphine was administered 
on day 17 (14 days withdrawal) to rats with a saline (open square, n=7-8) or 
morphine (filled square, n=8) treatment history; rats with a morphine treatment 
history expressed sensitization.  One-way rmANOVA with post hoc Newman-
Keuls, ## p<0.01 (biochemistry group), †† p<0.01 (behavior group); Student‟s t-
test, * p<0.05. 
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Figure 15.  Development and expression of Meth sensitization.  Data 
were collapsed for 60min after administration of Meth.  A) Vertical Beam Breaks, 
B) Vertical Time.  There was no statistical difference between days 1, 2 or 3 of the 
saline treatment (open symbols, n=6-8). In the Meth-treated groups, there were 
significant differences between treatment days (filled diamonds = animals used 
for biochemistry; filled triangles = animals used for behavioral verification).  A 
challenge injection of Meth was administered on day 17 (14 days withdrawal) to 
rats with a saline (open triangle, n=8) or Meth (filled triangle, n=8) treatment 
history; rats with a Meth treatment history expressed sensitization.  There was no 
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development of motor sensitization from Day 1 to Day 3 assessed by Vertical 
Beam Breaks C), or Vertical Time D), in rats treated with MTEP and Meth (solid 
triangles) or Vehicle and saline (open triangles).  There was also no difference 
between treatment groups in either motor activity parameter on Day 1 of drug 
administration.  One-way rmANOVA with post hoc Newman-Keuls, ## p<0.01 
(biochemistry group), † p<0.05 (behavior group); Student‟s t-test, * p<0.05. 
133 
 
 
Figure 16.  Decreased surface expression of GluR1 and GluR2 
occurred in the mPFC of rats treated acutely with morphine.  
Representative immunoblots for A. GluR1, C. GluR2, and E. mGluR5 in mPFC 
tissues harvested one day after a single injection of saline (SAL, 1ml/kg, sc) or 
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morphine (MOR, 8mg/kg, sc) treatment.  Distinct surface and intracellular 
components are labeled for each protein on each representative immunoblot with 
corresponding molecular weight of the intracellular component quantified.  B. 
GluR1 S/I ratio was decreased in MOR treated rats, but Total, S and I 
components remain unchanged.  D.  GluR2 S component was decreased in MOR 
treated rats but S/I ratio, Total and I GluR2 protein did not change.  F.  mGluR5 
S/I ratio, Total, S and I protein did not change between SAL and MOR treated 
rats in the mPFC.  White bars represent saline (SAL) and white bars with 
horizontal lines represent morphine (MOR) treated rats.  Numbers within bars 
represent sample number (N). Unpaired t-test, *p<0.025. 
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Figure 17. Increased mGluR5 surface expression occurred in the VP 14 
days after morphine or Meth treatment.  Representative immunoblots 
probed for mGluR5 in the VP 14 days after morphine (MOR, 8mg/kg, sc) A. or 
Meth (METH, 1mg/kg, sc) C. treatment. Distinct surface and intracellular 
components are labeled for each protein on each representative immunoblot with 
corresponding molecular weight of the intracellular component quantified.  B.  
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The mGluR5 S/I ratio was increased in MOR treated rats but Total, S and I 
components remained unchanged.  D.  The mGluR5 S/I ratio was also increased 
in the VP of METH compared to saline treated rats.  However, mGluR5 Total, S 
and I protein components were not altered by treatment history.  White bars 
represent saline (SAL), white bars with horizontal lines represent morphine 
(MOR), and filled black bars represent Meth (METH) treated rats.  Numbers 
within bars represent sample number (N). Student‟s t-test, *p<0.025. 
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Figure 18.  Surface expression of GluR2 is increased in the mPFC 14 
days after morphine administration.  Representative immunoblots for A. 
GluR1, C. GluR2, E. mGluR5, and G. STEP61 in mPFC tissues harvested 14 days 
after repeated injections of saline (SAL, 1ml/kg, sc) or morphine (MOR, 8mg/kg, 
sc) treatment.  B.  The GluR1 S/I ratio, Total, S and I protein components 
remained unchanged between saline and morphine treatment groups in the 
mPFC 14 days after morphine administration.  C.  There was a significant 
increase in the GluR2 S/I ratio of morphine compared to saline treated rats in the 
mPFC without a change in Total, S or I GluR2 protein components.  F.  There 
was a significant decrease in mGluR5 Total and S components of morphine 
treated rats without a change in the mGluR5 S/I ratio or I component between 
saline and morphine treatment groups.   H.  There was no difference between 
saline and morphine treatment groups in the level of STEP61 after 14 days in the 
mPFC.  White bars represent saline (SAL) and white bars with horizontal lines 
represent morphine (MOR) treated rats.  Numbers within bars represent sample 
number (N). Unpaired t-test, *p<0.025. 
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Figure 19.  GluR2 surface expression is increased and STEP61 levels 
were decreased 14 days after repeated Meth administration in the 
mPFC.  Representative immunoblots for A. GluR1, C. GluR2, E. mGluR5, and 
G. STEP61 in mPFC tissues harvested 14 days after repeated injections of saline 
(SAL, 1ml/kg, sc) or Meth (METH, 1mg/kg, sc) treatment.  B.  There was no 
difference in GluR1 S/I ratio, Total, S or I components in the mPFC between rats 
with a saline or Meth treatment history.  D.  The GluR2 S/I ratio was elevated in 
Meth compared to saline treated rats 14 days after drug administration.  
However, GluR2 Total, S and I components remained unchanged.  E.  mGluR5 
S/I ratio, Total, S and I components remain unchanged 14 days after saline and 
Meth in mPFC tissue.  H.  STEP61 was significantly reduced in the mPFC of rats 
14 days after Meth compared to saline.  White bars represent saline (SAL) and 
filled black bars represent Meth (METH) treated rats.  Numbers within bars 
represent sample number (N). Student‟s t-test, *p<0.025. 
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Figure 20.  Levels of GluR2 and STEP61 remain unaltered 14 days 
following repeated treatment with mGluR5 antagonist, MTEP, and 
Meth in the mPFC. Representative immunoblots for A. GluR2 and C. STEP61 
in mPFC tissues harvested 14 days after a repeated injections of vehicle and saline 
(VEH/SAL; 1ml/kg, ip; 1ml/kg sc) or MTEP and Meth (MTEP/METH; 5mg/kg, 
ip; 1mg/kg, sc) treatment.  B.  There are no GluR2 S/I ratio, Total protein, S or I 
protein component differences between VEH/SAL and MTEP/METH treated rats 
in mPFC.  D.  There are no differences in STEP61 levels between VEH/SAL and 
MTEP/METH treated rats in the mPFC.  White bars with slanted black lines 
represent vehicle and saline treated rats (VEH/SAL) and filled black bars with 
slanted white lines represent MTEP and Meth (MTEP/METH) treated rats.  
Numbers within bars represent sample number (N). Student‟s t-test, p>0.025. 
 
 
142 
 
CHAPTER VII 
PHARMACOLOGICAL AND DEVELOPMENTAL MODELS OF 
SCHIZOPHRENIA: DIFFERENCES IN SENSORIMOTOR 
GATING, AND RESPONDING TO METHAMPHETAMINE 
AND AN mGluR5 POSITIVE ALLOSTERIC 
 MODULATOR 
Abstract 
Schizophrenia patients have a higher incidence of substance use disorders than 
the general population.  Amphetamines including methamphetamine (Meth) 
exacerbate symptoms of psychosis in schizophrenia patients.  Our objective was 
to study the detrimental effects of stimulants on deficits associated with 
schizophrenia and the underlying sensitivity of this population to stimulant 
addiction.  We chose to induce a schizophrenia-like brain state via 
pharmacological and developmental means with two well-established models of 
this neuropathology: repeated, escalating amphetamine (Amph) (Peleg-Raibstein 
et al. 2008) and isolation rearing (Geyer et al. 1993).  Both of these models are 
known to produce deficits in sensorimotor gating assessed by prepulse inhibition 
(PPI) of the acoustic startle response.  Therefore, we measured PPI deficits in 
both models and compared these assessments with the rewarding and motor 
responses to Meth via conditioned place preference (CPP) and motor 
sensitization, respectively. 
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CPP implements reward and associative learning, both of which are associated 
with negative symptoms of schizophrenia; thus, we hypothesized that 
sensorimotor gating deficits would be inversely correlated with Meth-induced 
CPP.  Because motor sensitization in rodents is hypothesized to parallel the 
course of psychosis in humans and positive symptoms of schizophrenia, we 
hypothesized that PPI deficits would be positively correlated with Meth-induced 
activity and motor sensitization.  We found that PPI deficits in both 
pharmacological and developmental schizophrenia models negatively correlated 
with Meth-induced CPP.  Both schizophrenia-like rodent models also 
demonstrated enhanced sensitivity to the hypermotoric effects of Meth.  By 
strengthening the signal of associative learning with the addition of the Meth cue 
or by enhancing the glutamatergic system, Meth-induced CPP was enhanced.  
These novel findings demonstrate that schizophrenia-like rodents are less 
sensitive to the rewarding and more sensitive to the hypermotoric properties of 
Meth.  Sensorimotor gating deficits can predict both of these Meth-induced 
behaviors.  Therefore, this work provides pre-clinical rationale for the use of PPI 
as a predictor for Meth addiction in schizophrenia patients. 
 
Introduction 
A diagnosis of schizophrenia increases the likelihood of a substance abuse 
disorder by approximately five times over that of the general United States 
population (Regier et al. 1990).    A recent clinical assessment demonstrated that 
25% of schizophrenia patients also meet criteria for psychostimulant dependence 
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(Compton et al. 2005).  This dual diagnosis is particularly problematic for 
stimulants because these abused drugs exacerbate symptoms in schizophrenia 
patients (Angrist et al. 1980;Janowsky and Davis 1976).  Methamphetamine 
(Meth) is a powerful stimulant with high abuse liability and remains the third 
most widely used illicit drug world-wide (United Nations Office on Drugs and 
crime 2009).  It is well documented the Meth abuse can induce a psychotic state 
similar to that of schizophrenia (Harris and Batki 2000;McKetin et al. 2006;Scott 
et al. 2007).  Therefore, elucidating correlations between behaviors associated 
with the schizophrenia brain state and Meth-abuse would provide insight into 
each disorder as well as the dual diagnosis. 
Behavioral overlaps between laboratory animals and humans provide a 
powerful means to model, and thus study, the human condition.  Sensorimotor 
gating deficits measured by prepulse inhibition (PPI) occur in human 
schizophrenia patients and in rodent models of this disorder, illustrating the 
cognitive fragmentation that occurs with this neuropathology (Braff et al. 
2001;Swerdlow and Geyer 1998).  Acoustic startle response PPI refers to a 
normal suppression of the startle reflex that occurs when a strong startling 
stimulus is preceded by a weaker stimulus (i.e., a warning signal, termed the „pre-
pulse‟) (Graham 1975;Hoffman and Searle 1968;Ison et al. 1973;Swerdlow and 
Geyer 1998).  Deficits in this behavior can be induced by pharmacological or non-
pharmacological means.  Acute (Swerdlow et al. 2003) and repeated (Peleg-
Raibstein et al. 2008) amphetamine administration induce PPI deficits in the 
acoustic startle response in rodents and humans.  These deficits are reversed by 
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antipsychotic drugs (Geyer et al. 2001), which supports the value of this measure 
as an indicator of the schizophrenia-like brain.  Early environmental stressors, 
such as rearing young rats in isolation, result in sensorimotor gating deficits that 
are also reversed by antipsychotic medication (Bakshi et al. 1998;Geyer et al. 
1993).  Both Amph treatment and isolation rearing in laboratory rats are widely 
used to model aspect of the human schizophrenia brain.   Since these two models 
are produced by vastly different means, with differential effects on the adult 
brain, we sought to compare them in terms of modeling the co-morbidity of 
schizophrenia and stimulant abuse. 
Human stimulant abuse is modeled in rodents via a wide variety of 
paradigms and outcome measures.  Key to the phenomenon of drug addiction is 
the neuronal adaptations that are imposed by repeated drug exposure.  
Behavioral outcomes of such adaptations that are easily measured in laboratory 
rats include stimulant-induced motor activity and associative learning.  The 
augmentation of motoric responses to stimulants that occurs after repeated 
treatment is termed motor sensitization (Stewart and Badiani 1993). The acute 
effects of Amph (e.g., euphoria, hyper-vigilance) appear to “sensitize” with 
repeated exposure and can result in psychotic state that is akin to the positive 
symptoms of schizophrenia (Angrist et al. 1980;Strakowski et al. 1996).  
Developmental rodent models of schizophrenia, including isolation rearing, 
render rodents more sensitive to the motor stimulating effects of cocaine, 
nicotine, Amph, and Meth (Berg and Chambers 2008;Chambers and Taylor 
2004;Dai et al. 2004;Smith et al. 1997).  Thus, motor sensitization appears to be 
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an excellent outcome measure that mirrors the clinical evidence for an increased 
propensity for substance abuse in schizophrenia.  Self-administration of cocaine 
and Meth are also enhanced in developmental, rodent models of schizophrenia, 
indicating that these drugs are more reinforcing in a schizophrenia brain state 
(Brady et al. 2008;Chambers and Self 2002).  Associative learning underlies the 
well-described phenomenon wherein environmental cues associated with drug 
administration take on the salience of the drug, and exposure to these cues can 
evoke drug craving in drug-withdrawn addicts (Hartz et al. 2001;Hogarth et al. 
2010;Mucha et al. 1998;Panlilio et al. 2005;Tolliver et al. 2010).  Conditioned 
place preference (CPP) is a classical conditioning paradigm that can assess 
salience attributed to drug-associated contextual cues in both rodents and 
humans (Childs and deWit H. 2009;Tzschentke 1998;Tzschentke 2007).  In the 
CPP paradigm, unique contextual cues (the conditioned stimulus) are temporally 
paired with a reward (e.g., a stimulant; the unconditioned stimulus), and once an 
association is formed between the context and the stimulant, the subject tends to 
spend more time in that context (or place) even in a drug-free state.  The CPP 
procedure involves components of reward as well as associative learning, both of 
which are deficits associated with the negative symptoms of schizophrenia (i.e., 
anhedonia and working memory deficits).  Schizophrenia-like rodents fail to 
demonstrate drug-induced CPP subsequent to conditioning with morphine or 
amphetamine (Le et al. 2002;Wongwitdecha and Marsden 1995;Wongwitdecha 
and Marsden 1996).  These studies demonstrate that CPP paradigms serve as a 
useful index of negative symptoms of schizophrenia such as anhedonia and 
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working memory deficits, whereas motor sensitization may be more analogous to 
the positive symptoms.  The objective for the current study was to compare 
behavioral outcomes associated with schizophrenia in both pharmacological and 
developmental models of the disorder and to correlate these outcomes with 
Meth-induced CPP and motor sensitization in the same animal.  We hypothesized 
that sensorimotor gating deficits would be inversely related to Meth-induced CPP 
and positively related with motor sensitization. 
The brain state that is reflected schizophrenia and stimulant addiction 
includes a dysregulation in glutamate transmission (Bardo 1998;Carlsson et al. 
1999;Goff and Coyle 2001;Tzschentke 1998).  One regulator of glutamate 
transmission is the group I subtype 5 metabotropic glutamate receptor 
(mGluR5).  This receptor is highly expressed in brain regions important for 
stimulant reward and associative learning including the nucleus accumbens, 
medial prefrontal cortex and hippocampus (Kerner et al. 1997;Lu et al. 
1999;Testa et al. 1994b).  The mGluR5 is critical for the acquisition of Meth-
induced CPP (Miyatake et al. 2005), expression of Amph-induced CPP (Herzig et 
al. 2005), as well as Meth self-administration (Osborne and Olive 2008) and the 
cue-induced reinstatement of this behavior (Gass et al. 2009).  Alternatively, 
augmenting mGluR5 activity through the use of a selective positive allosteric 
modulator (PAM) facilitates extinction learning of cocaine-induced CPP (Gass 
and Olive 2009).  Schizophrenia-like rats demonstrate that Meth is, in fact, 
reinforcing in self-administration paradigms.  Thus, by enhancing the 
glutamatergic signal during the acquisition or expression process of CPP, 
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schizophrenia-like rodents may be better able to make Meth-induced 
associations.  We therefore hypothesized that administration of an mGluR5 PAM 
during conditioning would enhance Meth-induced associative learning in rodent 
models expressing a deficit in this behavior.   
This novel study demonstrated for the first time a direct correlation 
between sensorimotor gating deficits and drug-induced associative learning in 
the same subject.  Furthermore, we revealed that the two, distinct schizophrenia-
like models demonstrate divergent sensitivities to the rewarding and incentive 
motivational properties of Meth.  Finally, we determined that augmenting the 
mGluR5 system altered Meth-induced associative learning in a rodent model of 
schizophrenia.  
 
Methods 
Animals 
Male Sprague-Dawley rats were used for all experiments.  Rats from the 
acute (Experiment 1) and repeated, escalating amphetamine studies (Experiment 
2) were habituated to the vivarium at Rush University Chicago for one week 
prior to experimentation and were handled at least three times prior to the onset 
of behavioral experimentation.  Rats in the isolation rearing experiment 
(Experiments 3 and 4) arrived at post natal day 21, which was one day after 
weaning.  Isolation-reared rats were housed alone and social-reared rats were 
housed in groups of 4 per cage until rats reached approximately 225g, then social 
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reared rats were housed in groups of 2 per cage prior to behavioral testing.  The 
vivarium was maintained at a constant temperature between 23-25°C.  All rats 
were given access to food and water ad libitum and were tested during the light 
cycle (7:00AM to 7:00PM).  Experimentation took place during the light cycle of 
the rats.  During this time, rats have been shown to produce the most robust CPP 
performance to amphetamine (Webb et al. 2009).  All studies were conducted 
with approval by the Rush University Institutional Animal Care and Use 
Committee in accordance with NIH Guide for the care and use of laboratory 
animals. 
 
Drugs 
(+)Methamphetamine hydrochloride (Meth, NIDA, Bethesda, MD and 
Sigma Aldrich, St. Louis, MO) and amphetamine sulfate (Amph, Sigma Aldrich) 
were dissolved in sterile 0.9% saline.  Meth was given at a dose of 1mg/kg (as the 
base).  Amph dosage varied between 1 to 8mg/kg (as the base), based on 
treatment protocol of Peleg-Raibstein and colleagues described below (Peleg-
Raibstein et al. 2008).  Meth, Amph, and saline vehicle were given at a volume of 
1ml/kg and injected intraperitoneally (i.p.).  The mGluR5 positive allosteric 
modulator, 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB; Tocris 
Bioscience, Ellisville, MO) was given in a suspension of 20% w/v 2-
hydroxypropyl-β-cyclodextrin (Sigma Aldrich) in sterile water at a dose of 
3mg/kg.  The dose of CDPPB used (3mg/kg) most efficiently facilitated extinction 
learning subsequent to cocaine CPP without affecting motor activity (Gass and 
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Olive 2009).  CDPPB and its vehicle (20% 2-hydroxypropyl-β-cyclodextrin) were 
given at a volume of 1ml/kg subcutaneously (s.c.).   
 
Behavioral Equipment 
Conditioned Place Preference 
Small animal activity boxes (Accuscan Instruments, Inc., Columbus, OH) 
were used for the CPP and motor sensitization evaluations.  The boxes (63cm x 
30 cm x 30 cm) consisted of two large chambers (25cm x 30cm x 30cm) and one 
smaller center chamber (13cm x 30cm x 30cm).  The two large chambers had 
unique yet neutral contextual cues of horizontal or vertical white wall stripes 
(visual cue) and patterned floor with overturned paint dish and grid floor with 
flat Plexiglas dish (tactile cues).  The center chamber had a smooth white floor 
and white opaque walls.  Removable sliding doors separated the compartments.  
The CPP boxes were equipped with photosensors (24 which measure horizontal 
movements and 12 which measure vertical movements) and particular patterns in 
the beam breaks were used to assess motor activity and time spent in each 
chamber. 
 
Acoustic Startle 
Acoustic startle boxes (SR-Lab, San Diego Instruments, San Diego, CA) 
were equipped with Plexiglas cylinder animal enclosures attached to piezoelectric 
sensors.  A speaker for delivery of acoustic pulses was located above the 
enclosure.  A digital sound level meter (RadioShack, Fort Worth, TX) was used to 
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assess sound levels using the dB(A) weighted scale and all sound measurements 
for these studies used this scale.  
 
Experimental Procedures 
Thirty min prior to the start of behavioral testing, all rats were habituated 
to testing room, located in the same suite as the animal vivarium.  Background 
white noise of 65dB was present throughout CPP and acoustic startle testing 
(white noise generator, San Diego Instruments). 
 
Experiment 1. 
Timeline for behavioral experiments illustrated in Fig. 21A.  Rats were 
acclimated to startle testing with a baseline startle session.  This session included 
a total of 38 trials presented in a pseudo-random order, including 16 „Pulse 
Alone‟ (120dB), six of each 68, 71, and 77dB „Prepulse + Pulse‟ trials, and four „No 
Stimulus‟ trails.  Four Pulse Alone trials were given at the beginning and end of 
the test session to allow for a comparison of stable responding and eliminate 
initial habituation of startle response in each test session (Geyer et al. 1990).   
These data were not included in the data analysis.  Outcomes from the baseline 
acoustic startle data were used to assign treatment groups.  On protocol day 5, 
half of the rats (n=12) received saline (1ml/kg) and the other half received Amph 
(3mg/kg) (n=12) 30min prior to the first PPI Test.  Each test session consisted of 
88 trials, presented in a pseudo-random order, including 24, 120dB Pulse Alone 
trials, 16 of each 68, 71 and 77dB Prepulse + Pulse trials, and 16 No Stimulus 
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trials.  Again, the four 120dB Pulse Alone trials at the start and end of the test 
session were excluded from data analysis.  A second PPI test was conducted four 
days later (protocol day 9), wherein the pretreatment was reversed, rats that 
previously received saline, received Amph and rats that previously received 
Amph, received saline.  Subsequently, rats were tested for Meth-induced CPP.  To 
do so, drug-free rats were first allowed to explore the entire activity box (pre-
tested) and time spent in each chamber was determined.  As a group, rats had no 
preference for one chamber over the other (t-test, p>0.05).  However, individual 
rats demonstrated preference and thus rats were paired with Meth in the 
chamber in which they spent the least amount of time on the pre-test.  Half of the 
rats were then conditioned with Meth (1mg/kg) on days 14, 16, and 18 by placing 
rats in the chamber where the least amount of time was spent during pre-test 
their initially non-preferred side immediately after the Meth injection.  On days 
15, 17, and 19 rats were placed into the opposite chamber immediately following 
saline (1ml/kg) administration.  The other half of rats were paired with saline on 
days 14, 16, and 18 and Meth on days 15, 17, and 18.  Conditioning lasted for 
45min and motor activity was continuously monitored.  Three days after the last 
conditioning session, rats were tested for context preference.  The CPP test was 
conducted by placing untreated rats into the center chamber with the sliding 
doors shut.  The doors were then immediately removed to allow access to the 
entire CPP box for 30min.  Time spent in each chamber and motor activity was 
monitored.  See Fig. 21A for timeline of behavioral procedures. 
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Experiment 2. 
Timeline for behavioral experiments illustrated in Fig. 22A.  The 16 rats 
used for this experiment went through the same acclimation, baseline, and saline 
pre-treatment startle sessions as in Experiment 1.  Four days later, rats were 
subjected to six days of Amph treatment using the escalating dosing protocol 
described by Peleg–Raibstein and colleagues (Peleg-Raibstein et al. 2008).  On 
day 1, rats were injected with 1mg/kg Amph at 7AM, 2mg/kg at 1PM and 3mg/kg 
at 7PM.  On day 2, rats received 4mg/kg of Amph at 7AM, 5mg/kg at 1PM and 
6mg/kg at 7PM.  On day 3, rats were administered 7mg/kg of Amph at 7AM, 
8mg/kg at 1PM and 8mg/kg at 7PM.  On days 4-6, rats received 8mg/kg of Amph 
at 7AM, 1PM, and 7PM.  PPI test sessions took place 30min after the fifth (second 
to last) Amph injection (8mg/kg) on the sixth day of injections in order to test 
rats during the light cycle and to keep time of day for startle sessions consistent.  
To determine the enduring effects of the escalating Amph treatment on deficits, 
an additional PPI test was conducted six days after the last Amph treatment.  The 
same test session design was used as in the acute study for each PPI test session.  
Following PPI testing, Meth-induced CPP was conducted to determine the effects 
of escalating Amph on reward-mediated learning.  Rats were conditioned with 
Meth and tested for preference (see Fig. 22A, protocol days 25-36) as described 
in the acute study, however all rats were paired with Meth on the first 
conditioning day and saline on the second day of conditioning. 
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Experiment 3. 
The protocol timelines for this study are illustrated in Fig. 23A and 24A.  
After 8 weeks of isolation (n=12) or social (n=12) rearing, rats were subjected to 
an acoustic startle session (as described for Experiments 1 and 2) after a 30min 
pretreatment of saline (1ml/kg).  This determined the sensorimotor gating 
deficits associated with rearing conditions.  The startle session was repeated on 
protocol days 56 and 59.  This retesting for startle responding was based on 
reports that isolation reared rats may need to be tested repeatedly in order for a 
rearing-induced deficit (as indicated by %PPI) to be present (Bakshi et al. 1998).  
Following these initial startle sessions, three startle sessions (protocol days 70, 78 
and 82) were completed after pre-treatment of 0.5, 1.0, or 1.0mg/kg Amph.  The 
conditioned place preference procedure involves components of reward as well as 
associative learning.  Subsequent to Amph startle sessions, rats were subjected to 
Meth-CPP (protocol days 83-98) as described above for Experiments 1 and 2.  
One day after the CPP test (protocol day 99), rats were tested again for acoustic 
startle response after a 30min pretreatment of saline (1ml/kg) to determine the 
effects that Meth-conditioning had on gating deficits.  After 12 days of withdrawal 
from Meth, rats received Meth (1mg/kg) and then placed in their drug-paired 
chamber to test for the expression of Meth-induced motor sensitization (see Fig. 
24A, protocol day 106).  Finally, after 41 days from the original CPP test, rats 
were tested again for preference immediately after administration of Meth 
(1mg/kg) (protocol day 139 in Fig. 24A) to test for state-dependent expression of 
associative learning. 
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Experiment 4. 
Protocol timeline for this study is illustrated in Fig. 25A.  After 8 weeks of 
isolation, 24 rats were tested for sensorimotor gating deficits in two separate 
startle sessions (protocol days 56 and 59) as in the isolation rearing study.  Rats 
were then subjected to Meth-induced CPP protocols on day 60-71, wherein they 
received a pre-treatment of the mGluR5 PAM CDPPB (3mg/kg; n=12) or its 
vehicle (20% 2-hydroxypropyl-β-cyclodextrin, 1ml/kg; n=12) 20min prior to each 
conditioning session (i.e., before both the Meth and saline pairings).  To 
determine the effects of CDPPB treatment on subsequent sensorimotor gating 
and motor activity, 24 hr after the CPP Test, rats were subjected to another 
acoustic startle session (PPI Test 3; protocol day 72).  On day 79, rats were given 
an acute challenge of Meth (1mg/kg) and placed in the chamber where Meth was 
administered during conditioning (Motor Test).  To determine the effects of 
acutely enhancing mGluR5 signaling on expression of Meth context preference, a 
second CPP test was conducted on day 85 wherein 20min prior to testing, rats 
that received CDPPB during conditioning were administered vehicle, and rats 
that received vehicle during conditioning received CDPPB.   
 
Statistics 
%PPI was calculated by the following equation: %PPI = 100 - (Average 
Startle Magnitude on Prepulse + Pulse Trials / Average Startle Magnitude on 
Pulse Alone Trials ) x 100.  Data were analyzed with a two-way repeated 
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measures analysis of variance (rmANOVA) with post hoc Newman Keuls test, 
α=0.05.  An Amph effect score was calculated by averaging the %PPI scores 
across prepulse intensities per rat and the group average with Amph was 
subtracted from that of saline pretreatment.  CPP was evaluated by comparing 
time spent in the Meth-paired chamber compared to time spent in the same 
chamber during the pretest.  Preference was defined as a significant increase in 
time spent in the Meth-paired chamber from during the pre-test to the CPP test 
using a paired t-test, α=0.05.  The development of motor sensitization was 
determined by a paired t-test between motor activity during the first and last 
Meth injection, α=0.05.  Motor parameters of horizontal activity, total distance 
traveled, vertical activity, vertical time, stereotypy count and stereotypy time 
were chosen to analyze as they reliably represent the motor profile induced by 
low doses of Meth.  Pearson correlation was used to compare %PPI Amph effect 
score to time spent on the Meth-paired chamber on the CPP test or motor activity 
ratio (activity on last day of Meth injection / activity on first day of Meth 
injection).  Data are presented as the mean + the standard error of the mean 
(SEM). 
 
Results 
Experiment 1. 
As shown in Fig. 21B, 3mg/kg i.p. Amph produced deficits in PPI.  There 
was no difference in %PPI response based on the order of Amph administration 
at any pre-pulse intensity (69, 71 or 77dB) (unpaired t-test between rats given 
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saline on PPI Test 1 and PPI Test 2, p<0.05; unpaired t-test between rats given 
Amph on PPI Test 1 and PPI Test 2, p<0.05); thus, PPI data under each pre-
treatment condition were pooled.   
Deficits in %PPI were observed at all pre-pulse intensities tested (68, 71 
and 77dB, Fig. 21B) when rats (n=24) were given a 30min pretreatment with 
Amph (3.0mg/kg) compared to saline (1ml/kg).  A two-way rmANOVA resulted 
in a significant Treatment effect F(1, 46)=30.504, p<0.001, Pre-pulse Intensity 
effect F(2, 92)=34.771, p<0.001 and Treatment x Pre-pulse Intensity interaction F(2, 
92)=10.847, p<0.001 (post-hoc Newman Keuls test significance shown in Fig. 
21B).  Thus, as pre-pulse intensity increased, the %PPI deficit decreased. 
Subsequent Meth-conditioning (conducted on protocol days 11-22) 
revealed that rats (n=22) demonstrated a significant preference for the Meth-
paired compartment on the CPP test compared to the pre-test (t(21)=4.481, 
p<0.001, Fig. 21C).  Since Meth pairing on the first or second day of conditioning 
did not influence the magnitude of time spent in the Meth-paired chamber 
during the CPP test (unpaired t-test, t(22)=0.036, p=0.972) Fig. 21C results are the 
pooled data from both pairing paradigms.    To assess whether the magnitude of 
PPI deficits correlated with the magnitude of CPP, the %PPI Amph effect score 
(determined from protocol day 5 and 9 data) and time spent on the Meth paired 
side on the CPP Test (protocol day 22) were compared in the same rat.  There was 
not a correlation between %PPI Amph effect score and CPP Test time spent in the 
Meth-paired chamber (Pearson correlation, r=0.081, p=0.721, Fig. 21D).  These 
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data show that responding to a single dose of Amph did not induce sensorimotor 
gating deficits that predicted responding to Meth-induced CPP.   
The conditioning procedure also resulted in the development of motor 
sensitization to Meth in horizontal activity (t(21)=3.227, p=0.004) and stereotypy 
count (t(22)=2.376, p=0.027) parameters (Table. 8).  To determine the correlation 
between sensorimotor gating deficits and subsequent sensitization to Meth, the 
horizontal motor activity ratio (activity on the last / first Meth injection) was 
compared to the %PPI Amph effect score.  There was a significant, positive 
correlation between horizontal motor activity ratio and %PPI Amph effect score 
(Pearson correlation, r=0.433, p=0.044, Fig.21E) indicating that rats with larger 
deficits in sensorimotor gating exhibited more robust sensitized motor response 
to Meth.  Correlation assessments were also performed on stereotypy count data, 
as this parameter demonstrated sensitization in this cohort of rats.  However, 
there was not a significant correlation for the stereotypy count data set (data not 
shown).   
 
Experiment 2. 
Testing for Amph (8mg/kg i.p.)-induced PPI deficits on the last day of the 
repeated, escalating Amph administration protocol (PPI Test 2 on protocol day 
14; Fig. 22A) revealed deficits in %PPI as compared to saline (PPI Test 1) at 71 
and 77dB pre-pulse intensities.  Two-way rmANOVA revealed a significant 
Treatment effect F(1, 30)=4.396, p=0.045, a significant Pre-pulse Intensity effect 
F(2,60)=60.801, p<0.0001 and no Treatment x Pre-pulse Intensity interaction 
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F(2,60)=2.519, p<0.089 (post hoc Newman Keuls test, p<0.01, Fig. 22B).  
Subsequent Meth conditioning revealed that rats had a significant preference for 
the Meth-paired chamber (paired t-test, t(15)=3.936, p<0.01, Fig. 22C).  Based on 
the PPI results generated on protocol day 5 and 14 and CPP results from protocol 
day 36,  there was a significant correlation between %PPI Amph effect score and 
CPP Test time spent in the Meth-paired chamber (Pearson correlation, r=-0.588, 
p=0.017, Fig. 22D).  That is, the rats that had low sensorimotor gating deficits 
had a greater preference for the context associated with the rewarding effects of 
Meth.  Additionally, these data indicate that repeated administration of Amph 
induces PPI deficits that inversely correlate with the strength of Meth-induced 
CPP.  
 Development of motor sensitization, determined by comparing the first 
and last Meth injection, did not occur during conditioning to any parameter 
measured, due to the repeated Amph treatment history (paired t-test, p>0.05; 
Table 9).  There was also no correlation between the horizontal motor activity 
ratio (activity on day of last / activity on day of first Meth injection) and %PPI 
Amph effect score (Pearson correlation, r=-0.027, p=0.919, Fig. 22E).   
 
Experiment 3. 
After eight weeks of isolation or social rearing, rats were tested for deficits 
in %PPI with saline pretreatment (PPI Tests 1-3, Fig. 23A).  No differences were 
observed between isolation and social reared groups (two-way rmANOVA, 
p>0.05, data not shown).  Amph administered 30min prior to the startle test 
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session did not induce sensorimotor gating deficits that distinguish isolation (PPI 
Tests 3-6, two-way rmANOVA with post-hoc Newman Keuls test, p>0.05, data 
not shown).  Rats were subsequently conditioned with Meth (see Fig. 23A).  
Motor sensitization was assessed during conditioning and place preference was 
subsequently assessed three days later in a drug-free state.  On conditioning day 
1, isolation compared to social reared rats demonstrated an increase in horizontal 
activity (paired t-test, t(20)=2.268, p=0.035) and total distance (unpaired t-test, 
t(20)=3.962, p=0.001) (Table 10).  Therefore, rearing history plays a role in the 
acute motoric response to Meth.  Furthermore, it can be seen that the motor 
responses subsequent to the initial Meth injection in the repeated, escalating 
Amph treated rats (Experiment 2, Table 9) are heightened compared to social 
reared rats (Table 10).  Though different treatment conditions were employed to 
induce a schizophrenia-like brain state, common outcomes, such as enhanced 
response to an acute treatment of Meth, can occur.  Both social and isolation 
reared rats developed motor sensitization to Meth over the course of conditioning 
sessions (Table 10).  There is not a difference between social and isolation reared 
rats in the magnitude of motor sensitization development. 
Social but not isolation-reared rats demonstrated a significant preference 
for the Meth-paired chamber after conditioning compared to the amount of time 
spent in the same chamber during the pre-test (unpaired t-test, t(11)=2.756, 
p<0.05, Fig. 23B&C).   The data were similar to those obtained from the Amph 
models of schizophrenia (compare with Fig. 21C and 22C).    
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To determine if rearing history in conjunction with Meth conditioning 
differentially influenced PPI, rats were tested for acoustic startle response after 
the CPP test (i.e., on day 99; see Fig. 23A).  For this PPI test, all rats were 
subjected to a 30min pretreatment with saline.  Isolation reared rats had a lower 
%PPI score at the 71 and 77dB pre-pulse intensity.  A two-way rmANOVA 
resulted in a Rearing Condition effect that was close to significance F(1,19)=4.313, 
p=0.052, a significant Pre-pulse Intensity effect F(2,38)=51.172, p<0.0001 , and no 
effect of Rearing Conditioning x Pre-pulse Intensity interaction F(2,38)=0.215, 
p=0.807.  Because the Rearing effect demonstrated a trend and there was a 
significant effect of Pre-pulse Intensity, a post hoc test was conducted (post-hoc 
Newman Keuls test, p<0.05, Fig. 23D).   
On day 106 (which was 12 days after the last Meth conditioning session; 
refer to Fig. 24A), all rats were habituated to the Meth-paired chamber, then 
given a Meth injection (1mg/kg), and immediately placed back into the Meth-
paired chamber.  Because of the significant effect of rearing condition to the acute 
response of Meth demonstrated by the total distance parameter (Table 10), a time 
course evaluation of motor expression was conducted.  For total distance, a two-
way rmANOVA resulted in a no Rearing Condition effect F(1,19)=3.547, p=0.075, 
and significant Time effect F(8,152)=7.950, p<0.0001 and Rearing Condition x 
Time interaction F(8,152)=2.345, p=0.021.  A post-hoc Newman Keuls test revealed 
condition differences at 5, 30, and 35min after Meth injection (p<0.05, Fig. 24B).  
As rats are injected (i.p.) and immediately placed in the activity box, the 
hyperactivity that resulted at 5min in the isolation reared rats is likely due to a 
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heightened conditioned motor response and/or rearing condition alone.  Rats 
reared in isolation for at least four weeks demonstrate increased motor activity, 
in general, compared to social reared counterparts (Bakshi and Geyer 1999).  
Also, these data demonstrate that during the time of peak Meth effects (30-
35min), the rearing condition may have also influenced the expression of Meth-
induced motor sensitization. 
In contrast to the rearing condition differences in motor responding to an 
acute challenge of Meth, place preference measure during an acute Meth 
challenge did not distinguish the two groups.  That is, on day 139 (Fig. 24A), 
when rats were tested for preference immediately after an administration of Meth 
(1mg/kg), both the social-reared (unpaired t-test, t(20)=4.72,p<0.001, Fig. 24D) 
and the isolation-reared (unpaired t-test, t(20)=5.01, p<0.001, Fig. 24E) rats 
demonstrated a preference for the Meth paired side.  These data demonstrate 
that isolation reared rats were able to express Meth-induced associative learning 
after they were primed with the drug cue. 
 
Experiment 4. 
Comparing findings from Experiment 3 and 4 (i.e., data from Fig. 23C and 
Fig. 24D) indicated that isolation-reared rats can acquire CPP tasks and this is 
expressed if a drug cue (i.e., the unconditioned stimulus) was present during 
testing for the salience of the paired context (i.e., the conditioned stimulus).  This 
suggested that if the salient signal strength is enhanced during conditioning, 
isolation-reared rats should be able to express preference in a drug-free state.  As 
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augmenting mGluR5 activity with a PAM facilitates extinction learning of 
cocaine-induced CPP (Gass and Olive 2009), we hypothesized that a mGluR5 
PAM should be able to boost association learning during Meth conditioning, and 
in so doing, aid isolation-reared rats to acquire the task.  Therefore, as shown in 
Fig. 25A, isolation reared rats were administered the mGluR5 PAM, CDPPB 
(3mg/kg, n=11) or its vehicle (1ml/kg, n=11) prior to conditioning and then 
subsequently tested for preference (CPP Test 1, Fig. 25A).  Here, as we 
hypothesized, isolation-reared rats demonstrated preference for the Meth-paired 
context when tested in the drug free state (Fig. 25B, gray bars).  To determine if 
acute mGluR5 activation altered the expression of Meth-induced CPP, these rats 
were retested (see Fig. 25A, CPP Test 2; protocol day 85) 20min after CDPPB 
(3mg/kg, n=11) or vehicle (1ml/kg, n=11) administration.  CDPPB enhanced 
preference for the Meth-paired chamber in rats that received vehicle pre-
treatment during conditioning (Fig. 25B, left set of gray and black bars) and this 
enhancement reached the level obtained in rats that received CDPPB during 
conditioning.  
 Rats were tested for sensorimotor gating deficits one day following CPP 
Test 1 in a drug free state (protocol day 72, see Fig. 25A).  It was determined that 
there was no difference in %PPI between isolation reared rats given a treatment 
of CDPPB or its vehicle prior to conditioning sessions (protocol days 63-68) on 
PPI Test 3 in a drug-free state (two-way rmANOVA, non significant effect of 
Treatment: F(1,17)=0.005, p=0.942, a significant effect of Pre-Pulse F(2,34)=45.052, 
p<0.0001, and a non significant Interaction F(2,34)=1.154, p=0.327; Fig. 25C).  
164 
 
Therefore, while CDPPB enhanced development and expression of Meth-induced 
CPP, it had no effect on sensorimotor gating deficits.  It was also determined that 
there was no difference between CDPPB or vehicle treatments during 
conditioning on motor activity to a challenge administration of Meth (1mg/kg, 
i.p.) after extended withdrawal on protocol day 79 (two-way rmANOVA with post 
hoc Newman Keuls, p>0.05, data not shown).  Therefore, while CDPPB enhanced 
development and expression of Meth-induced CPP, it had no effect on 
sensorimotor gating deficits or on motor activity induced by Meth in isolation 
reared rats. 
 
Discussion 
The current study provides several novel findings, including the following: 
1) Both pharmacological and developmental rodent models of schizophrenia 
demonstrated deficits in Meth-induced associative learning.  2) Isolation-reared 
rats were able to express Meth CPP in a state-dependent manner.  3) The 
mGluR5 system was critical for the acquisition and expression of Meth-induced 
associative learning in isolation-reared rats. 
 
Enhanced motor activity occurs in schizophrenia-like rodent models. 
Results from Experiments 1 through 3 demonstrated that schizophrenia-
like rodents were more sensitive to the motoric properties of Meth.  In 
Experiment 1, sensorimotor gating deficits induced by an acute administration of 
Amph correlated positively with Meth-induced motor sensitization.  
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Demonstrated in Experiment 3, isolation reared rats  showed greater motor 
activation to an acute administration of Meth compared to their social reared 
counterparts.  Rats administered with repeated, escalating Amph (Experiment 2) 
were also hyperactive in response to the first Meth injection compared to social 
reared control animals.  Furthermore, the level of sensitized motor responding to 
an acute Meth challenge following withdrawal from repeated exposure to Meth 
was greater in Isolation reared rats compared to social reared rats (Experiment 
2).  Hyperactivity in response to Amph and Meth administration is a well-
documented feature of post-weaning isolation in rodents (Dai et al. 2004;Smith 
et al. 1997).  Because the isolation-reared rats used in the current study did not 
display initial deficits in %PPI, (note: PPI deficits do not occur 100% of the time 
in these animals (Fone and Porkess 2008)) it was important to demonstrate this 
sensitivity to acute administration of Meth,.  These findings are in alignment with 
the neonatal ventral hippocampal lesion (NVHL), schizophrenia model in which 
enhanced cocaine- and nicotine-induced motor sensitization occurs (Berg and 
Chambers 2008;Chambers and Taylor 2004).  An increased sensitivity to the 
motoric properties of Meth also parallels the human condition in which 
amphetamines exacerbate psychosis in schizophrenia patients (Angrist et al. 
1980;Janowsky and Davis 1976).  
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Sensorimotor gating deficits predict magnitude of Meth-induced associative 
learning.  
Results from the repeated, escalating Amph treatment (Experiment 2) and 
isolation rearing experiments (Experiment 3) converge to demonstrate that 
schizophrenia-like rats show deficits in Meth-induced associative learning.  We 
revealed that sensorimotor gating deficits induced pharmacologically (Peleg-
Raibstein et al. 2008) inversely correlated with Meth-conditioned contextual 
preference.  These results suggest that schizophrenia-like rats are less sensitive to 
the rewarding properties of Meth.   
Because of the potential confound of cross-sensitization between Amph 
and Meth (Hall et al. 2008), we chose to validate the repeated, escalating Amph 
findings using the developmental rodent model of schizophrenia, isolation 
rearing.  We determined that isolation-reared rats failed to express Meth-induced 
associative learning (Experiment 3).  This finding is in keeping with our results 
for the repeated, escalating Amph experiment and the literature in which 
isolation reared rats and NVHL rats fail to express Amph-induced CPP (Le et al. 
2002;Wongwitdecha and Marsden 1995).  There are two likely explanations for 
these findings due to the nature of the CPP assessment: 1) schizophrenia-like rats 
are deficient in the ability to perceive reward, or 2) schizophrenia-like rats have 
deficits in mnemonic processes that result in a failure to express learned 
associations between contextual cues conditioned with Meth.   
Another novel finding of the current study is that %PPI was decreased in 
isolation-reared rats compared to social-reared rats after Meth conditioning.  
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Prior work demonstrated that isolation-reared rats have increased sensorimotor 
gating deficits in response to a sensitizing regimen of Meth (Dai et al. 2004).  We 
extended this finding to reveal that these deficits occur in drug-free, Meth-
conditioned rats thus supporting our hypothesis that Meth-induced CPP is 
negatively associated with sensorimotor gating deficits.   
Reward and associative learning are both measured in Meth-induced CPP.  
These properties are also associated with negative symptoms of schizophrenia 
(i.e., anhedonia, cognitive fragmentation, and working memory deficits).   NVHL 
rodents will expend more effort than unlesioned controls in order to receive the 
Meth reinforcer (Brady et al. 2008).  This suggests that schizophrenia-like 
rodents are more motivated by the reinforcing properties of Meth.  Therefore, it 
may be hypothesized that schizophrenia-like rodents are capable of experiencing 
Meth reward but may be less sensitive to these properties.  There are conflicting 
reports on spatial learning and memory abilities in rodent models of 
schizophrenia including isolation rearing.  Isolation-reared rats show an 
enhanced ability to locate a submerged platform in the Morris water maze 
experiment demonstrating superior acquisition of spatial learning over social-
reared counterparts (Wongwitdecha and Marsden 1995).  However, others report 
no differences in acquisition in Morris water maze training (Quan et al. 
2010;Schrijver et al. 2002), or that isolation-reared rats take longer to find the 
platform indicating deficits in multiple phases of the learning process  (Dai et al. 
2004;Hellemans et al. 2004).  Results for spatial memory retention are also 
varied, with reports demonstrating no difference between rearing conditions 
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(Hellemans et al. 2004;Schrijver et al. 2002) or a deficit in isolation reared rats 
(Quan et al. 2010).  There results suggest that isolation rearing rodents may 
exhibit working memory deficits in the acquisition or expression phase of 
mnemonic processes.  Therefore, spatial working memory necessary to associate 
an environmental context with the rewarding properties of a stimulant may be 
compromised in schizophrenia-like rats.  Cognitive assessments in non-human 
primates given repeated, escalating doses of Amph show deficits in some aspects 
of working memory but not in acquisition of visual discrimination tasks that 
assess associative learning between contextual cues and food reward (Castner et 
al. 2005).  Working memory deficits and anhedonia in schizophrenia patients are 
well documented (Driesen et al. 2008;Park and Holzman 1992).  Therefore, these 
negative symptoms may be assessed in the CPP task in schizophrenia-like 
rodents. 
 
Meth and mGluR5 PAM administration enhances associative learning 
performance in isolation- reared rats. 
We observed that when isolation-reared rats were administered Meth 
prior to a CPP test, the animals were capable of expressing a preference for the 
context previously paired with Meth (Experiment 3).  These novel findings 
suggest that isolation-reared rats can demonstrate that associative learning had 
occurred when they were tested in the presence of the unconditioned stimulus.  
The addition of the drug cue during the CPP Test replicates the physiological 
state that occurred during conditioning and increases the ability of the 
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schizophrenia-like rodent to express the previously acquired association.  
Therefore, schizophrenia patients experiencing negative symptoms including 
anhedonia and working memory deficits may be less sensitive to the rewarding 
properties of stimulants, but when conditions are appropriate, they may be able 
to make stimulant-induced associations.     
The mGlu5 receptor is critical for the development of Meth-induced 
associative learning (Miyatake et al. 2005) and for the facilitation cocaine-
induced place preference extinction learning (Gass and Olive 2009).  Our 
findings demonstrate that mGlu5 receptors were also critical for both the 
acquisition and expression of Meth-induced CPP in a rodent model of 
schizophrenia.  Our results also suggest that the magnitude of preference for the 
Meth-paired context was more enhanced by pre-conditioning treatment with the 
mGluR5 positive allosteric modulator, as rats that were administered CDPPB 
prior to conditioning spent more time on the Meth-paired chamber compared to  
rats that were administered CDPPB on the CPP Test day.  One explanation for 
our findings is that CDPPB administration compensated for a deficient mGluR5 
system in isolation-reared rats.  Isolation rearing decreases levels of mGluR5 in 
the prefrontal cortex (Gregory and Szumlinski 2008;Melendez et al. 2004) a 
brain region essential for working memory and executive function.  The mGluR5 
PAM is also known to enhance acquisition of extinction learning of cocaine-
induced place preference (Gass and Olive 2009).  These evidences converge to 
indicate that mGlu5 receptors contributed to the positive results obtained with 
the Meth „state-dependent‟ CPP test in the isolation-reared rats pre-treatment in 
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the current study.  This possibility was corroborated by the ability of isolation-
reared rats to demonstrate Meth-induced CPP following treatment with the 
mGluR5 NAM, CDPBB during conditioning.  Therefore, when associative 
learning signals are strengthened in schizophrenia-like rats via Meth or an 
mGluR5 PAM, a preference for cues previously paired with Meth can be 
subsequently expressed.   
 In summary, the results of the current study converged to demonstrate 
that sensorimotor gating deficits are inversely correlated with Meth-induced 
associative learning, whereas sensitivity to motor activity is enhanced in 
schizophrenia-like rats.  We further demonstrated isolation reared rats could 
express state-dependent CPP and that mGluR5 is a critical mediator for both 
acquisition and expression of Meth-induced associative learning.  Both working 
memory and anhedonia predict substance abuse likelihood in schizophrenia 
patients (Potvin et al. 2008a;Potvin et al. 2008b).  Thus, the results of the 
current study suggest that sensorimotor gating deficits may predict the 
propensity of schizophrenia patients to for Meth-induced associative memories.
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Tables 
Table 8.  Motor responses to Meth after acute Amph treatment. 
 
Motor  
Parameter First 
Injection 
Last 
Injection 
Horizontal 
Activity 
4991±254 6106±285** 
Total Distance 
(cm) 
1095±54 1314±127 
Vertical 
Activity 
1622±178 1468±165 
Vertical Time 
(sec) 
689±86 656±87 
Stereotypy 
Count 
3006±188 3748±254* 
Stereotypy 
Time (sec) 
526±35 631±44 
 
For this study, Amph was given on protocol days 5 or 9; the first and last Meth 
injections were given on protocol days 14 or 15 and 18 or 19, respectively.  Data 
are number of beam breaks, distance (cm) or time (sec) detected by photobeams 
in the small animal activity box used for CPP.  Data represent mean ± SEM.  
n=20-23.  Paired t-test, *p<0.05, **p<0.01. 
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Table 9.  Motor responses to Meth after repeated, escalating Amph 
treatment. 
 
Motor  
Parameter 
Meth Conditioning 
First 
Injection 
Last 
Injection 
Horizontal 
Activity 
7416±416 7981±374 
Total Distance 
(cm) 
1546±121 1678±130 
Vertical 
Activity 
1696±103 1616±156 
Vertical Time 
(sec) 
566±48 735±146 
Stereotypy 
Count 
4981±369 5369±367 
Stereotypy 
Time (sec) 
804±53 846±62 
 
For this experiment, Amph was given in an escalating dosing paradigm (1 to 8 
mg/kg, i.p.) on protocol days 9 to 14.  The first and last Meth injections were 
administered on protocol days 28 and 32, respectively.  Data are number of beam 
breaks, distance (cm) or time (sec) detected by photobeams in CPP box.  Data 
represent mean ± SEM.  n=13-16.  Paired t-test, p>0.05. 
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Table 10.  Motor responses to Meth following social or isolation 
rearing. 
 
Motor  
Parameter 
Social Rearing Isolation Rearing 
First 
Injection 
Last 
Injection 
First 
Injection 
Last 
Injection 
Horizontal 
Activity 
4365±250 5460±339* 5305±308† 6136±411 
Total Distance 
(cm) 
924±53 1223±123* 1416±106†† 1780±162 
Vertical 
Activity 
1459±116 1709±199 1840±262 1363±144* 
Vertical Time 
(sec) 
559±54 670±87* 748±116 574±64 
Stereotypy 
Count 
2487±226 3399±311** 2900±179 3893±279** 
Stereotypy 
Time (sec) 
417±40 567±55** 477±27 701±56** 
 
For this experiment, the first and last Meth injections were administered on 
protocol days 90 and 94, respectively.  Data are number of beam breaks, distance 
(cm) or time (sec) detected by photobeams in CPP box.  Data represent mean ± 
SEM.  Social n=11-12, Isolation n=11.  Paired t-test within Social or Isolation 
Rearing groups, *p<0.05, **p<0.01.  Unpaired t-test between Social and Isolation 
Rearing groups, †p<0.05, ††p<0.01. 
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Table 11.  Motor responses to Meth by rats reared in isolation 
following pre-treatment of CDPPB or its vehicle. 
Motor  
Parameter 
Vehicle CDPPB 
First 
Injection 
Last 
Injection 
First 
Injection 
Last 
Injection 
Horizontal 
Activity 
4282±282 5285±315** 4256±289 5619±293*** 
Total 
Distance (cm) 
1131±105 1401±167* 1097±106 1301±134* 
Vertical 
Activity 
1639±134 1760±197 1528±124 1959±181* 
Vertical Time 
(sec) 
642±76 695±94 642±75 1080±246 
Stereotypy 
Count 
2283±568 2976±249** 2193±174 3145±208*** 
Stereotypy 
Time (sec) 
391±28 492±39** 381±31 513±33** 
 
For this experiment, the first and last Meth injections were administered on 
protocol days 63 (Day 1) and 67 (Day 5), respectively.  Data are number of beam 
breaks, distance (cm) or time (sec) detected by photobeams in CPP box.  Data 
represent mean ± SEM.  Vehicle (1ml/kg, s.c.) n=11-12, CDPPB (mGluR5 PAM, 
3mg/kg, s.c.) n=11-12.  Paired t-test within Social or Isolation Rearing groups, 
*p<0.05, **p<0.01, ***p<0.001.   
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Figure 21.  Deficits in sensorimotor gating induced by acute 
administration of Amph predict motor but not reward responses to 
Meth.   
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A) Timeline of behavior/treatment protocol for Amph-induced deficits in 
prepulse inhibition (PPI) assessments (protocol days 1-11) and Meth-induced 
conditioned place preference (CPP; protocol days 14-22).  On day 1, all rats 
(n=22) were tested with a baseline startle session.  On days 5, half of the rats 
were given a 30min pretreatment with saline (1ml/kg, i.p.) and the other half 
were given Amph (3mg/kg, i.p.) and then subjected to the startle session.  On day 
9 the treatment groups were switched and rats that previously received saline 
received Amph prior to the startle session.  Rats were then pre-tested (protocol 
day 11) and conditioned with Meth every other day for six days (protocol days 14-
19).  Rats were tested for place preference on protocol day 22.  B)  PPI Test 1 and 
2 (protocol days 5 and 9).  Data represented here are pooled based on pre-PPI 
Test treatment history.  Rats demonstrated a significant deficit in %PPI 30min 
after a pre-treatment of Amph compared to saline at 68, 71 and 77dB prepulse 
intensities (two-way rmANOVA with post hoc Newman Keuls test, *p<0.05, 
**p<0.01).  C)  CPP Test (protocol day 22).  Rats showed a significant increase in 
time spent in the Meth-paired chamber after conditioning compared to the pre-
test (unpaired t-test, ##p<0.01).  D)  There was no correlation for CPP 
magnitude (i.e., Time spent in the Meth-paired compartment) vs. the %PPI  
Amph Effect Score.  E)  There was a significant correlation between the 
development of motor sensitization and the %PPI Amph Effect Score (Pearson 
correlation, r=0.433, p=0.044).  Motor sensitization as assessed by a ratio of 
horizontal activity on the first over the last injection of Meth during the 
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conditioning phase.   Sal = saline, 1ml/kg, i.p.; Amph = amphetamine, 3mg/kg, 
i.p.; Meth= methamphetamine, 1mg/kg, i.p. 
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Figure 22.  Deficits in sensorimotor gating induced by a repeated, 
escalating administration of Amph predict reward, but not sensitized 
motor, responses to Meth.   
A) Timeline of behavior/treatment protocol for Amph-induced deficits in 
prepulse inhibition (PPI) assessments (protocol days 1-20) and Meth-induced 
conditioned place preference (CPP; protocol days 25-36).  On day 1, all rats 
(n=16) were tested with a baseline startle session.  On protocol day 5, rats were 
subjected to an acoustic startle session.  On protocol days 9-14, rats received 3 
once-daily injections of Amph that escalated from 1-8mg/kg.  On the last day of 
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Amph treatment, rats were tested for acoustic startle response and on protocol 
day 20 in a drug-free state.  Rats were pre-tested on protocol day 25 then 
conditioned with Meth or saline on protocol days 28-33.  On protocol day 36, rats 
were tested for place preference.  B)  PPI Test 1 (protocol day 5).  Rats 
demonstrated a significant decrease in %PPI when given a 30min pretreatment 
of Amph (8mg/kg, i.p., day 14, PPI Test 2) compared to a saline (1ml/kg, i.p.) 
pretreatment at 71 and 77dB (two-way rmANOVA, with post hoc Newman Keuls 
test, *p<0.05, **p<0.01).   C) CPP Test (protocol day 36).  Rats demonstrated a 
significant preference for the Meth-paired chamber after conditioning (unpaired 
t-test, ##p<0.01).  D)  There was a significant correlation between amount of 
time spent on the Meth-paired compartment during the CPP Test and the %PPI 
Amph effect score (Pearson Correlation, p<0.05, r2=0.3451).  E)  There was no 
correlation between the development of motor sensitization as assessed by a ratio 
of horizontal activity on the first over the last injection of Meth and the %PPI 
Amph Effect Score (Pearson correlation, p>0.05, r2=0.001).  Sal = saline, 1ml/kg, 
i.p.; Amph = amphetamine, 1-8 mg/kg, i.p.; Meth= methamphetamine, 1mg/kg, 
i.p. 
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Figure 23.  Isolation rearing produced sensorimotor gating and 
associative learning deficits following Meth conditioning.   
A)  Timeline of behavior/treatment protocol.  After 8 weeks of isolation or social 
rearing (protocol days 1-56), all rats were tested for acoustic startle response 
30min following a saline pretreatment (1ml/kg, i.p.; protocol days 56 and 59).  
On days 70, 78, and 82, rats were tested for startle 30min after an Amph (0.1, 1 
and 1mg/kg, i.p., respectively) pretreatment.  Rats were tested for initial 
preference on protocol day 83, conditioned with Meth (1mg/kg, i.p.) on protocol 
days 90, 92, and 94, and saline (1ml/kg, i.p.) on protocol days 92, 93, and 95.  
Rats were subsequently tested for preference on protocol day 98 (CPP Test 1).  
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Rats were tested for acoustic startle response after a saline (1ml/kg) 
administration on day 99 (PPI Test 7).    B) Social reared rats demonstrated a 
significant preference for the Meth-paired CPP chamber after conditioning 
compared to the CPP pre-test (unpaired t-test, #p<0.05).  C) Isolation reared 
rats did not demonstrate a preference for the Meth-paired environment in a 
drug-free state on CPP Test 1.  D)  After Meth conditioning, isolation reared rats 
demonstrated a significant deficit in %PPI compared to social reared rats at the 
71 and 77dB prepulse intensity (two-way rmANOVA with post hoc Newman Keuls 
test, *p<0.05).  Sal = saline, 1ml/kg, i.p.; Amph = amphetamine, 0.1-1mg/kg, i.p.; 
Meth= methamphetamine, 1mg/kg, i.p. 
182 
 
 
Figure 24.  Isolation reared rats demonstrated enhanced 
hyperactivity and associative learning in response to Meth 
administration.     
A)  Timeline of behavior/treatment protocol; days 1-99 are similar to that 
described in Fig. 3.  On protocol day 106, all rats were given a Meth injection 
(1mg/kg, i.p.) on the Meth-paired chamber and motor activity was monitored 
(Motor Test).  Finally, rats were tested for state-dependent CPP (CPP Test 2; 
protocol day 139) immediately following an injection of Meth (1mg/kg, i.p.).  B)  
Isolation reared rats demonstrated an increase in total distance traveled (cm) at 
5, 30 and 35min post-Meth (1.0mg/kg, i.p.) injection (two-way rmANOVA with 
post hoc Newman Keuls test, *p<0.05, **p<0.01) compared to social reared rats.  
Both social C) and isolation D) reared rats demonstrated a significant preference 
for the Meth-paired compartment post- compared to pre-conditioning when 
given an injection of Meth (1.0mg/kg, i.p.) immediately before CPP Test 2 
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(unpaired t-test, ##p<0.01). Sal = saline 1ml/kg, i.p.; Meth = methamphetamine, 
1mg/kg, i.p. 
184 
 
 
 
Figure 25.  Activation of mGluR5 enhances development and 
expression of Meth-induced CPP in isolation reared rats without an 
effect on subsequent sensorimotor gating deficits.   
A)  Timeline of behavior/treatment protocol.  Rats were reared in isolation for 8 
weeks and subsequently tested for sensorimotor gating deficits on protocol days 
56 and 59 (PPI Tests 1 and 2).  Rats were pre-tested on protocol day 60 in a drug-
free state.  During conditioning, rats were given a 20min pre-treatment with 
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CDPPB (3mg/kg, s.c.; n=11) or its vehicle (1ml/kg, s.c.; n=11) prior to Meth 
(1mg/kg, i.p.) on days 63, 65, and 67, or saline (1ml/kg, i.p.) on days 64, 66, and 
68.  Rats were tested for Meth-induced preference on day 71 in a (CPP Test 1) in a 
drug-free state and sensorimotor gating deficits on day 72 (PPI Test 3) 30min 
after a saline (1ml/kg, i.p.) injection.  Rats were given an injection of Meth 
1mg/kg and immediately placed in the Meth-paired chamber as in conditioning 
on the Motor Test (day 79).  Rats administered CDPPB (3mg/kg, s.c.) prior to 
conditioning were given vehicle (1ml/kg, s.c.) and rats that had a pre-
conditioning treatment of vehicle (1ml/kg, s.c.) were injected with CDPPB 
(3mg/kg, s.c.) prior to CPP Test 2 on protocol day 85.  B)  CPP (protocol days 71 
and 85).  Rats administered CDPPB during conditioning demonstrated greater 
amount of time spent on the Meth-paired chamber compared to rats given pre-
conditioning vehicle.  Rats administered CDPPB prior to CPP Test 2 spent more 
time on the Meth-paired side on this test day compared to CPP Test 1.  Rats 
administered CDPPB prior to conditioning demonstrated an increase in time 
spent in the Meth-paired side on compared to rats that were administered 
CDPPB prior CPP Test 2 on this test day (two-way rmANOVA with post hoc 
Newman Keuls test, *p<0.05, **p<0.01).  C)  There was no difference between 
rats given CDPPB or vehicle prior to conditioning on %PPI in the acoustic startle 
response session on day 72 (PPI Test 3) (two-way rmANOVA with post hoc 
Newman Keuls test, p>0.05). 
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CHAPTER VIII 
GENERAL DISCUSSION 
 
The overall goal of this dissertation project was to expand our knowledge 
of the role of the mGluR5 system in Meth addiction and in the co-morbidity of 
schizophrenia and Meth substance use disorder.  Towards that end, we 
characterized the function and expression of mGluR5 following both short 
(Chapters III and V) and extended (Chapters IV and V) periods of withdrawal 
after repeated Meth administration.  We determined that mGluR5 was necessary 
for the maintenance of Meth-induced place preference (Chapter IV) and that 
mGluR5 expression was differentially regulated by Meth in various reward-
related brain regions (Chapters V and VI).  We found that sensorimotor gating 
deficits associated with schizophrenia were negatively correlated with Meth-
induced associative learning in both pharmacological and developmental rat 
models of schizophrenia (Chapter VII).  Both models also showed hyperactive 
motor responses to Meth compared with controls (i.e., social rats; Chapter VII).  
Finally, we determined that activating mGluR5 augmented the development and 
expression of Meth-induced CPP in a developmental model of schizophrenia 
(Chapter VII).  These novel findings contribute to our understanding of the 
dynamics of mGluR5 system in multiple phases of Meth addiction and reward 
mediated behaviors, and in the co-morbid stimulant-abusing schizophrenia 
patient.   
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Phases of Meth addiction 
The addiction phenomenon is a complex and dynamic process.  The 
neurobiology of this process is dictated by many factors, including the nature of 
the abused drug, the dose and frequency of exposure, the drug experience of the 
individual, and the involvement of associated behaviors.  For purposes of this 
dissertation project, we adapted a commonly used set of time-related descriptors 
or phases to categorize our investigations as follows: induction, 
acquisition/development, maintenance, and expression.  The induction phase 
simply refers to the initial administration of Meth and the behavioral response.  
The consequences of this initial or acute administration may persist long after 
Meth is administered.  We have assessed two behaviors which occur subsequent 
to the repeated treatment of Meth, CPP and motor sensitization.  During 
acquisition, Meth is repeatedly paired with a context and the rewarding 
properties of Meth then become associated with these environmental cues.  
Repeated Meth treatment also results in a progressive enhancement in motor 
activity and we will refer to the phase between the first and last repeated 
treatment as the development of motor sensitization.   Neuronal adaptations that 
are induced and acquired/developed are then maintained after Meth is no longer 
administered.  Behaviors are then expressed under the appropriate conditions 
where Meth or Meth-related cues are present.  Each of these phases provides 
valuable information as to how neuronal adaptations occur throughout the 
addiction process. 
 
188 
 
 
Induction  
The initial Meth administration serves as a stimulus that induces 
behavioral and neurotransmission responses.  The consequences of this stimulus 
can persist beyond the lifetime of the stimulus itself, and with repeated exposures 
these consequences can summate.  For example, a single treatment with 
psychostimulants including cocaine, amphetamine, and Meth increases motor 
function and, with repeated intermittent administration, e.g., once daily, these 
responses are enhanced or „sensitized‟.  We are interested in the mGluR5 
neurobiology that is associated with development of sensitization, and so we 
studied outcomes measured during the induction period and soon after 
sensitization had been achieved.  To study effects during induction, we have 
assessed changes in Meth-induced behaviors and the mGluR5 system within the 
inter-dosing interval used in our behavioral paradigms.   
When rats are given an acute injection of Meth, motor activity is increased 
compared to saline treated animals.  This hyperactivity was observed in normal 
rats and was reduced with the mGluR5 NAM, MTEP (Chapter VI).  Our 
laboratory also shows that a single administration of Meth can induce CPP that 
can persist and be expressed 3 days later (Herrold et al. 2009).  Meth therefore, 
serves as a strong stimulus which induces neuronal and behavioral changes that 
persist after the drug is withdrawn from the system.  
Hyperactivity in response to stimulants is a common feature of 
schizophrenia.  Our results agree with this clinical assessment as both repeated, 
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escalating Amph treated as well as isolation reared rats displayed increased 
motor activity to an initial Meth injection compared to social reared control 
animals.  The implication of these data in the model of co-morbidity, 
schizophrenia and Meth addiction will be discussed later. 
To fully understand how the mGluR5 system may adapt within the inter-
dosing interval used in our behavioral paradigms, we assessed mGluR5 surface 
expression levels 24hrs after Meth administration.  This assessment tells us if 
basal levels of glutamate receptors are changed as a result of drug injection.  We 
determined that mGluR5 receptors were unchanged 24hr after a single Meth 
injection, but down-regulation of these receptors with mGluR5 NAM treatment 
prior to Meth administration reduced the acute hyperactive response to Meth 
(Chapter VI).  Thus, while the function of mGluR5 is necessary for the induction 
of Meth behavior, changes in protein levels of these receptors are not.  Shaffer 
and colleagues report that mGluR5 protein levels are increased in the membrane 
fraction of mPFC tissue 1hr after acute Amph (5mg/kg).  However, these changes 
are transient and mGluR5 protein levels are normalized by 5hrs post-Amph 
treatment (Shaffer et al. 2010).   It is therefore possible that mGluR5 levels 
assessed in the current study would have been initially up-regulated, had tissue 
been assessed at an earlier time-point.  To determine if the acute Meth treatment 
employed in our study truly replicated the findings of Shaffer and colleagues, rats 
must be sacrificed and mGluR5 surface expression assessed 5hrs following Meth 
(1mg/kg) administration. 
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Acquisition/Development   
With repeated treatment, the context associated with Meth becomes 
significant or salient to the individual.  We are interested in the neuronal 
adaptations that occur during this salience attribution, i.e., how the association 
between the reward of Meth and the Meth context is acquired.  Meth-induced 
motor hyperactivity can also progressively enhance with repeated administration 
such that the activity induced by the last Meth administration is larger than 
activity induced by the first, i.e., development of motor sensitization.  The 
administration of the mGluR5 NAM, MTEP, prior to repeated Meth 
administration blunted the development of Meth-induced motor sensitization, a 
novel finding of the current dissertation project (Chapter VI).  The findings from 
the current studies with CPP and motor sensitization align with the established 
role of mGluR5 in the acquisition phase of other addiction models.   It is known 
that mGluR5 regulates the development of Meth-induced CPP (Miyatake et al. 
2005) and the acquisition of Meth self-administration (Osborne and Olive 2008).  
Furthermore, mGluR5 knock-out mice fail to develop cocaine-induced motor 
sensitization.  So it is clear that mGluR5 is involved in the development of motor 
sensitization and this action is not stimulant-specific.   We extended this work to 
ascertain if the role of mGluR5 in Meth-induced behaviors in rat was altered in 
models of schizophrenia.  In the isolation rearing model, where initial deficits in 
Meth-induced CPP were found, the administration of the mGluR5 PAM, CDPPB, 
enhanced task acquisition (Chapter VII).  Showing that the agonist can promote 
other forms of learning, CDPPB also facilitates the acquisition of extinction 
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learning in cocaine CPP treated rats (Gass and Olive 2009).  Further discussion 
of these data in co-morbidity models will follow. 
 
 
Anatomy and cell biology of induction / acquisition behaviors 
The acquisition process of associative learning is thought to involve the 
transfer of sensory information from the cortex to the NAc, VP and the 
hippocampus via glutamatergic afferents (Christie et al. 1985;Fuller et al. 
1987;Sesack et al. 1989).  All of these regions also receive dopaminergic input 
from the VTA and project to motor output regions regulating activity levels.  
When Meth is administered, extracellular glutamate concentration levels increase 
in the mPFC and dopamine increases in the NAc (Shoblock et al. 2003).    
Activation of mGluR5 and dopamine D1 receptors results in an array of 
transduction cascades which can converge to enhance common secondary and 
tertiary messengers such as intracellular calcium (Abe et al. 1992;Surmeier et al. 
1995) and the phosphorylation of cAMP response element binding protein 
(CREB) (Dudman et al. 2003;Mao et al. 2007;Roberson et al. 1999;Voulalas et al. 
2005).  For example, mGluR5 activation results in phosphoinositide hydrolysis 
and subsequent activation of phospholipase C (PLC) and protein kinase C (PKC) 
(Abe et al. 1992;Joly et al. 1995), which ultimately can increase intracellular 
calcium.  Activity of PLC and PKC both regulate the development of CPP (Aujla 
and Beninger 2003;Cervo et al. 1997;Narita et al. 2004).  Activation cAMP-
dependent protein kinase (PKA) via dopamine D1 receptor activation leads to 
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enhance calcium influx through cAMP-dependent protein kinase (PKA) 
phosphorylation of ionotropic NMDA receptors (Das et al. 1997).  This D1R 
process plays a role in the acquisition of stimulant-induced associative learning 
(Beninger and Gerdjikov 2004;Gerdjikov et al. 2007).  Activation of both D1 and 
mGluR5 can increase cAMP-response element binding protein (CREB) (Dudman 
et al. 2003;Mao et al. 2007;Roberson et al. 1999;Voulalas et al. 2005).  CREB 
phosphorylation can increase protein synthesis and enhance cellular indices of 
memory, e.g., long term potentiation (LTP) (Bourtchuladze et al. 1994).  In the 
NAc and hippocampus, mGluR5 is necessary for LTP (Bikbaev et al. 
2008;Schotanus and Chergui 2008).  High frequency stimulation induced LTP in 
NAc slice preparations is dependent upon mGluR5 and dopamine D1 receptors 
(Schotanus and Chergui 2008).  Induction of LTP in the NAc and dentate gyrus 
subfield of the hippocampus is inhibited by mGluR5 blockade (Bikbaev et al. 
2008;Schotanus and Chergui 2008); both regions are important for the 
induction of stimulant-induced CPP.   Bikbaev and colleagues also revealed that 
in vivo (i.c.v.) treatments of the mGluR5 NAM, MPEP, inhibit acquisition of 
spatial/working and reference memory in rats, and reduce LTP in ex vivo 
hippocampal slices (Bikbaev et al. 2008).  Our data and the literature, concur 
with the idea that Meth administration indirectly enhances glutamate 
transmission, and via mGluR5 activation in limbic brain regions, promotes the 
association between the rewarding properties of drugs and the context in which 
they are administered. 
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Maintenance 
After the acquisition of stimulant-induced associative learning, the 
stimulant-related memories are maintained for protracted periods.  Memory 
maintenance is a dynamic process.  This dissertation project contributed to the 
understanding the role of mGluR5 in the maintenance of Meth-context 
associations.  We found that mGluR5 was necessary for the long-term (Chapter 
IV), but not short-term (Chapter III) maintenance of Meth-induced CPP.  There 
are two likely explanations for these findings.  First, the mGluR5 system has 
adapted and perhaps up-regulated over the two week withdrawal from Meth 
conditioning.  Second, the memory of Meth-associations has become more 
vulnerable to deterioration over time.  We included a vehicle control to account 
for the second factor, and we have biochemical evidence to support that an up-
regulation in reward related brain regions occurred 14 days after repeated Meth 
administration.     
Our behavioral and biochemical findings converge upon an important role 
for mGluR5 in the VP in the maintenance of stimulant-mediated behaviors.  We 
found that 14 days after a sensitizing treatment regimen of Meth, the mGluR5 S/I 
ratio was up-regulated in the VP without a change in surface.  This change in the 
ratio was likely due to a modest decrease within the intracellular pool (Chapter 
VI).  When mGluRs are removed from the membrane surface they are generally 
either desensitized and rapidly recycled back to the membrane surface, slowly 
recycled and kept within the endosome of the cell or trafficked to the lysosome 
and degraded (Dhami and Ferguson 2006).  Therefore in the current study, 
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mGluR5 levels are sustained within the membrane surface of VP cells, while the 
intracellular mGluR5 proteins are removed or degraded.  VP neurons appear to 
be adapting to the changing glutamate environment to maintain surface levels of 
mGluR5; yet, surface levels are not scaled up.  Interestingly, administration of 
mGluR5 NAMs blunt Meth-induced CPP at the same withdrawal period that the 
mGluR5 S/I ratio was up-regulated in the VP.  Though levels of the surface 
mGluR5 component were unaltered, this does not preclude changes in the 
function of mGluR5 in the VP at the level of downstream signaling mechanisms, 
for example.  Our laboratory has demonstrated that ionotropic glutamate 
receptors in the VP are necessary for the expression of morphine-induced CPP 
and motor sensitization (Dallimore et al. 2006), and the work in the current 
dissertation project suggests that mGluR5 in the VP may be critical for the 
expression of Meth-induced CPP and motor sensitization as well.  In Amph-
sensitized rats, VP neurons increase in firing during the presentation of an 
Amph-associated cue (Tindell et al. 2005).   These converging data suggest that 
modulation of VP neuronal activity by mGluR5 may play an important role in the 
maintenance and subsequent expression of stimulant-induced associative 
learning.  Exciting future studies with intra-VP injections of an mGluR5 NAM 
would verify the necessity of mGluR5 during long-term maintenance to express 
Meth-induced CPP.   
 Pre-clinical electrophysiological and biochemical experiments (for review, 
see (Kalivas and Hu 2006)) and human brain imaging studies (Ernst and Chang 
2008) suggest that the PFC becomes hypoactive during extended withdrawal 
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from stimulants.  Our data provide one mechanism by which this may occur 
following repeated Meth administration.  We found that 14 days after repeated 
Meth treatment, surface to intracellular ratio levels of the GluR2 AMPA receptor 
subunit were increased.  This increase corresponded with a decrease in the 
STEP61 protein, while GluR1 AMPA receptor subunits remained unchanged 
(Chapter VI).  We determined that the alterations in GluR2 and STEP61 levels 
were a result of mGluR5 activation during repeated Meth administration 
(Chapter VI).  These findings demonstrate that though mGluR5 surface 
expression levels were not changed after an initial Meth injection, the activity of 
these receptors during induction of Meth-induced sensitization likely influences 
persistent molecular events resulting in alterations in ionotropic glutamate 
receptor distribution.  An increase in the surface expression of GluR2 AMPA 
receptor subunit without an alteration in the GluR1 subunit would lead to a 
decrease in calcium permeability and inward rectification of mPFC neurons, 
known characteristics of GluR2 subunits (Buldakova et al. 1999).  Levels of GluR1 
and GluR2 mRNA and protein are expressed throughout the layers of the cerebral 
cortex(Martin et al. 1993;Sato et al. 1993).  However, GluR2 levels are generally, 
modestly higher than GluR1 in the cortex (Sato et al. 1993).  Therefore, an 
increase in the S/I ratio of GluR2 alone would not change overall excitability.  
GluR2 receptors In conclusion, after 14 days from Meth conditioning, mPFC 
neurons are likely in a calcium-impermeable state that is regulated by mGluR5. 
 
Expression and biochemical response to Meth-related cues 
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After Meth-associated memories have been acquired and maintained, they 
can be expressed under the appropriate conditions, such as the presentation of 
salient contextual cues previously paired with the rewarding properties of Meth. 
Activity of mGluR5 necessary for the expression of Amph-induced CPP (Herzig et 
al. 2005) and cue as well as Meth-induced expression of Meth-seeking behavior 
(Gass et al. 2009).  In the current dissertation project, we also demonstrated that 
augmenting mGluR5 signaling enhanced expression of Meth-induced CPP in 
isolation reared rats (Chapter VII, further discussed in following sections).  
Therefore, mGluR5 protein surface expression levels were assessed 24hr after 
Meth-induced CPP was expressed.  We determined that mGluR5 surface to 
intracellular ratio was decreased in the mPFC of Meth-conditioned rats.  This 
outcome may reflect internalization of receptors 24hr after CPP expression 
during short-term withdrawal (Chapter V).  Upon exposure to stimulant-
associated cues, extracellular glutamate levels in the mPFC are increased 
(Hotsenpiller et al. 2001;Hotsenpiller and Wolf 2002).  Cellular activation also 
occurs in limbic structures subsequent to drug-associated cues, measured by 
increases in the immediate early gene fos expression (Brown et al. 1992;Rhodes 
et al. 2005).  With prolonged agonist exposure and cellular activation, the 
mGluR5 system must adapt, and these receptors are phosphorylated and 
desensitized via PKC (Gereau and Heinemann 1998;Lee et al. 2008).  Therefore, 
the internalization of mGluR5 shown after short-term withdrawal and 
subsequent to drug-related cue re-exposure is likely reflective of cellular 
homeostasis. 
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Activation of mGluR5 enhanced Meth addiction behaviors associated with 
negative symptoms in schizophrenia-like rats 
The addiction behaviors assessed in the current dissertation project, i.e., 
motor sensitization and CPP, were chosen since they  may measure positive and 
negative symptoms of schizophrenia, respectively.  We found that activation of 
mGluR5 through the use of the mGluR5 PAM, CDPPB facilitated CPP but not 
motor sensitization behaviors (at least at the dose tested).  Therefore, mGluR5 
may be involved in the negative symptoms of schizophrenia such as anhedonia, 
cognitive fragmentation and working memory deficits they may lead to addiction 
vulnerability in schizophrenia patients.   
Our isolation rearing co-morbid model revealed that mGluR5 activation 
can enhance the acquisition and expression of Meth-induced associative learning 
in schizophrenia-like rodents, which show an initial deficit in this behavior 
(current study Chapter VII and (Le et al. 2002;Wongwitdecha and Marsden 
1995)).  A common characteristic of schizophrenia is hypofrontality.  The results 
of the current dissertation support the proposition that mGluR5 is involved in 
these dynamics that contribute to the ability of schizophrenia-like rodents to 
acquire stimulant-induced associative learning.  The mPFC is a critical brain 
region for the induction of stimulant-mediated behaviors, and the isolation 
rearing model used in this project is characterized by decreased levels of mGluR5 
in the mPFC (Melendez et al. 2004) as well as reduced mPFC volume (Day-
Wilson et al. 2006).  There is clinical evidence to support the role of the mPFC in 
198 
 
anhedonia experienced by schizophrenia patients.  Recently, it was shown that 
metabolic activity in the mPFC is negatively correlated with self reports of 
anhedonia in schizophrenia patients (Harvey et al. 2010;Park et al. 2009).  
Therefore, by increasing mGluR5 function in the mPFC via CDPPB 
administration, the ability to experience Meth-induced reward may be increased 
in isolation-reared rodents.  There is also pre-clinical data that support the value 
of enhancing mGluR5 for treating anhedonia; administration of CDPPB increases 
sucrose consumption in animals that show a deficit in this behavior induced by 
the NMDA channel blocker, MK-801 (Vardigan et al. 2010).  Our findings are 
congruent with the pre-clinical and clinical literature suggesting that 
schizophrenia-like individuals have decreased capacity to experience or respond 
to reward, and we furthered these concepts to demonstrate that mGluR5 activity 
is important for this phenomenon. 
Though isolation reared rats did not express Meth-induced CPP in a drug-
free state, the addition of the Meth cue resulted in a positive preference for the 
Meth-paired context (Chapter VII).  These data demonstrate that while 
schizophrenia-like rats may be less sensitive to the rewarding properties of Meth 
or perhaps less able to make an association between Meth and the context in 
which it was administered, they are capable of making the association when in 
the same physiological state as the conditioning period.   Meth increases 
extracellular glutamate overflow in the mPFC (Shoblock et al. 2003).  Cues 
previously paired with Meth also increase mPFC glutamate and this is enhanced 
when Meth is given during cue exposure (Qi et al. 2009).  Thus, increased mPFC 
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glutamate may have contributed to the ability of Meth administration during CPP 
test to promote place preference in the current study.   
The CPP procedure involves components of reward as well as associative 
learning.  Another negative symptom, along with anhedonia, central to mPFC 
abnormalities of schizophrenia which may contribute to the deficit in Meth CPP 
is working memory deficits (Goldman-Rakic and Selemon 1997).  Moreover, 
working and recognition memory deficits show improvement with by mGluR5 
PAMs such as CDPPB (Uslaner et al. 2009).  Our data also demonstrate, for the 
first time, that though schizophrenia-like rodents demonstrate initial deficits in 
Meth-induced CPP, this behavior was acquired and then was expressed when 
„salient signaling‟ was amplified.  That is, when the drug-cue, Meth, is 
administered prior to the CPP test, all of the signals present during the 
acquisition phase are present and under these conditions, the isolation reared 
rats were capable of expressing CPP.  CDPPB co-administered with Meth during 
conditioning, enhances mGluR5 signaling, and this strengthened the acquisition 
of Meth-induced associative learning so that preference was expressed by 
isolation reared rats in a drug-free state.  Therefore, the glutamate system may 
contribute to the state-dependency of Meth-induced CPP in isolation reared rats 
and enhances the neuronal signaling important for associative learning. 
 
Critical discussion of co-mobidity behavioral models 
Though repeated, escalating Amph administration and isolation rearing 
are two very different means of inducing a schizophrenia-like brain state and 
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sensorimotor gating deficits, we demonstrate that in both pharmacological and 
developmental models of schizophrenia, sensorimotor gating deficits associated 
with schizophrenia were negatively related to Meth-induced associative learning.  
The isolation reared rats and those subjected to repeated, escalating Amph 
treatments showed PPI deficits.  These behavioral responses to Meth are 
consistent with deficits in sensory processing and cognitive fragmentation in 
schizophrenia patients.  Thus, PPI deficits may serve as a predictor for stimulant-
mediated dysregulation.  And so doing, PPI deficits may provide a means of 
screening for potential vulnerability to substance use disorders as well as 
schizophrenia itself.  We also found that Amph- and isolation rearing-induced 
deficits in PPI are related with an enhancement in Meth-induced hyperactivity.  
Our findings are supported by the literature that indicates schizophrenia-like 
rodents show an enhanced response to stimulant-induced motor sensitization 
(Berg and Chambers 2008;Chambers and Taylor 2004) but a deficit in stimulant-
induced associative learning (Le et al. 2002;Wongwitdecha and Marsden 1995).  
Another developmental rodent models of schizophrenia, which implements 
neonatal hippocampal lesions (NVHL) is also characterized by an increase in 
drug-taking behavior measured in self-administration paradigms (Brady et al. 
2008;Chambers and Self 2002).  Though not directly correlated with stimulant 
seeking or taking behavior, NVHL rats show PPI deficits (Lipska et al. 1995).   
These data call into question what aspects of addiction are modeled by CPP, 
motor sensitization, and self administration and how these addictive behaviors 
manifest and contribute to substance use disorders in the c0-morbid 
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schizophrenia patient.  The addiction model of CPP utilizes reward and 
associative learning mechanisms, both of which relate to negative symptoms of 
schizophrenia.  Therefore, it is logical that our data demonstrate a negative 
correlation between sensorimotor gating deficits and Meth-induced place 
preference.  The self-administration completed in the laboratories of Chambers 
and O‟Donnell stress that schizophrenia-like rodents are motivated to perform an 
operant task for a stimulant reinforcer (Brady et al. 2008;Chambers and Self 
2002).  The use of a progressive ratio schedule for Meth self-administration 
nicely demonstrates that schizophrenia-like rats are even motivated to work 
harder than control animals to receive Meth reinforcement (Brady et al. 2008).  
The acute effects of Amph (e.g., euphoria, hyper-vigilance) appear to “sensitize” 
with repeated exposure and can result in psychotic state that is akin to the 
positive symptoms of schizophrenia (Angrist et al. 1980;Strakowski et al. 1996).  
Thus, it is also logical that with both models of schizophrenia used in the current 
project, the motor responses to Meth were greater than (i.e., sensitized) that 
observed in controls (i.e., social).  Therefore, we have determined that deficits in 
sensorimotor gating induced by two very different means (i.e., repeated, 
escalating Amph and isolation rearing), produce a phenotype that negatively 
correlate to the rewarding and positively correlate to the motor effects of Meth.   
There are many hypotheses as to why schizophrenia patients take illicit 
substances.    One of which is that schizophrenia patients are “self medicating”, 
perhaps due to a reduced capacity to feel reward, or anhedonia (Khantzian 1997).  
Another hypothesis is that schizophrenia patients are more vulnerable to the 
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rewarding effects of abused substances (Krystal et al. 1999;Tseng et al. 2009).  
These two hypotheses may go hand-in-hand: that is, negative symptoms may 
predict as well as play a causal role in stimulant use.  Both working memory and 
anhedonia occur and predict substance abuse likelihood in schizophrenia 
patients (Potvin et al. 2008a;Potvin et al. 2008b).  Therefore, it may be 
hypothesized that schizophrenia patients must take more stimulants in order to 
experience their rewarding or reinforcing effects.  Our studies also demonstrate 
that the mGluR5 system may be critical in fine tuning the signaling necessary to 
amplify the effects of stimulants in schizophrenia-like rats.  Therefore, 
modulation of mGluR5 may be a potential therapeutic target not only for Meth 
addiction but also Meth addiction in the co-morbid schizophrenia patient. 
In conclusion, the current dissertation project makes an important 
contribution to the current understanding of mGluR5 function and expression in 
the maintenance of Meth behaviors.  Furthermore, these data and their 
interpretation elucidate a role of mGluR5 in modulating rewarding signaling in 
Meth abuse, schizophrenia co-morbidity.  
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